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  Abstract  
 
A low and highly variable bioavailability is  often the main  reason for  the failure of the 
development  of  a  drug  intended  for  oral  delivery.  Focusing  on  absorption  instead  of 
bioavailability from oral administration enables the identification and understanding of key 
causes of low and erratic absorption to improve drug performance in early development.  
 
In the work carried out as part of this thesis, the in silico estimation of drug absorption (fa*fg) 
was  carried  out.  The  use  of  a  population  pharmacokinetic  approach  was  proposed,  as 
implemented in NONMEM, to estimate fa*fg and variability from phase I clinical studies 
(AstraZeneca database). This work enabled the identification of the rate limiting step in oral 
drug  absorption,  and  allowed  for  comparisons  of  fa*fg  and  inter-subject  variability  for 
different drug formulations.  
 
Solubility/dissolution and permeability were investigated in vitro in terms of their variability 
for two model drugs – dipyridamole and furosemide. Physiological parameters such as bile 
salt  concentrations  and  pH  were  simulated  in  vitro  to  understand  their  effects  on  the 
absorption process. Dipyridamole saturated solubility and dissolution are pH and bile salt 
dependent. However, when both dissolution and permeability were tested simultaneously, it 
was found that pH plays an important factor in the permeation of dipyridamole rather than 
bile salt concentration. This can explain to some extent the variability between individuals in 
the absorption of dipyridamole. Furosemide solubility experiments showed that pH, buffer 
capacity  and,  to  a  lesser  extent,  bile  salt  concentration  affect  its  saturated  solubility. 
Surprisingly, almost complete drug release was observed under all simulated conditions with 
a  clinical  dose.  Similarly,  the  permeation  of  furosemide  did  not  differ  under  different 
conditions.  It  was  suggested  that  with  this  clinical  dose,  other  physiological  parameters 
contribute to variability in furosemide absorption, such as gastric emptying time.  
 
Moreover, the efficacy of three formulations (solid dispersion, Self Micro Emulsifying Drug 
Delivery systems and nano-particles) in increasing solubility\ dissolution in vitro and in vivo 
in the rat model was compared.  Lack of IVIVC was observed. It was suggested that the 
missing  link  is  the  human  absorption  estimation  that  can  be  resolved  by  the  proposed 
population pharmacokinetics approach presented herein.   
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1.1   Overview 
Oral  drug  delivery  is  the  preferred  route  of  drug  administration.  However,  it  is  a  multi-
factorial process and the performance of any dosage form is the result of complex interplay 
between the drug, formulation and GI (gastrointestinal) physiology. Often the variability in 
gut  physiology  is  underestimated,  with  only  one  or  two  variables  being  considered  in 
formulation  design  and  drug  targeting  (McConnell  et  al.,  2008a).  Therefore,  formulation 
development  research  is  required  to  take  into  account  the  very  variable  nature  of  the 
gastrointestinal tract to achieve dosage form optimisation.  
 
The work in this thesis focuses on drug absorption and inter-subject variability. The in silco, 
in vitro and in vivo approaches commonly used in drug development have been investigated 
herein in relation to gastrointestinal physiology to identify the factors which contribute to low 
and erratic oral absorption.  
 
The sections below provide an overview of the physiological processes in the GI tract and 
their influence on drug absorption and inter-subject variability in relation to the measurement 
of absorption and bioavailability. 
 Inter-subject variability in oral drug absorption  
 
- 3 - 
 
1.2   Bioavailability and Absorption  
 
The  terms  absorption  (fa)  and  bioavailability  (F)  are  often  used  interchangeably  (Chiou, 
2001). Oral bioavailability is primarily a function of oral absorption and first pass hepatic 
elimination which represents the fraction of a dose administered that reaches the systemic 
circulation  (Figure  1.1).  fa  is  the  fraction  of  a  dose  entering  the  cellular  space  of  the 
enterocytes from the gut lumen (the drug may not be released from the formulation and 
remain in solid form, the drug may also be lost by decomposition in the gut lumen, or it may 
become soluble in the gut lumen but fail to permeate through the gut wall). The elimination 
phase  is  represented  by  fh  (the  fraction  of  drug  entering  the  liver  that  escapes  first  pass 
hepatic metabolism and biliary secretion, thus entering the systemic circulation) and fg (the 
fraction of drug entering the enterocytes  that escapes  first  pass  gut  wall metabolism and 
enters  the  portal  vein)  (Huang  et  al.,  2009).  Therefore,  low  oral  bioavailability  may  be 
attributed to poor absorption and/or extensive first pass elimination (Equation 1.1).  
 
   
Equation 1.1: Oral bioavailability 
 
 
 
Figure 1.1: Events in the gastrointestinal tract following administration of an oral dosage form (Dressman and Reppas, 
2000). 
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1.3  Bioavailability and Inter-subject Variability  
 
An  important  problem  identified  during  drug  development  and  therapy  is  inter-subject 
variability. The result is that a standard dosage regimen of a drug may prove therapeutic in 
some  patients,  ineffective  in  others,  and  toxic  in  others.  The  need  to  adjust  the  dosage 
regimen of a drug for an individual patient is evident, and this need is clearly greatest for 
drugs that have a narrow therapeutic window, that exhibit a steep concentration-response 
curve, and that are critical to drug therapy.  
 
Hellrigel et al. (1996) examined the relationship between absolute oral bioavailability and 
inter-subject variability. Their results clearly showed a significant relationship between the 
absolute bioavailability of an oral dosage form and its inter-subject coefficient of variation 
(CV).  Drugs  with  low  bioavailability  will  have  greater  inter-subject  variability  in 
bioavailability,  and  vice  versa  (Figure  1.2).  These  results  have  a  significant  clinical 
implication and could have an impact on how bioavailability and bioequivalence studies are 
designed and interpreted. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
Figure 1.2: Relationship between absolute bioavailability (F) and inter-subject variability (CV) in absolute bioavailability 
(Hellrigel et al. 1996). Inter-subject variability in oral drug absorption  
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All the components of bioavailability (fa, fg and fh) are sensitive to inter-subject difference 
(Jamei et al., 2009a). The factors which contribute to inter-subject variability in fa are the 
formulation aspects (disintegration and particle size), physicochemical attributes of the drug 
(dissolution  and  solubility)  and  variation  in  GI  physiology  which  is  represented  by  pH, 
stomach emptying time, and transit time varying with  age, gender, and diseases.  Factors 
include food, alcohol, or concomitant medications that may also affect the dissolution of the 
drug or GI function (Figure 1.3). fg is sensitive to the abundance and the regional distribution 
of drug metabolizing enzymes which could be influenced by genetics and diet. Variation in 
blood flow to the gut, and disease states can also add variability in oral drug absorption. 
Efflux pump, i.e. P-glycoprotein (P-gp), as well as influx and efflux by other transporters 
may be subject to inter-subject variations affecting transporters abundance and/or activity. 
The final element that determines inter-subject variability in bioavailability is the first pass 
metabolism of the drugs by the liver (fh). Hepatic clearance of drugs which are inefficiently 
extracted from the blood is sensitive to changes in the activity of drug metabolizing enzymes 
in the liver. Environmental substance or toxins as well as genetic makeup (polymorphism) 
contributes  to  inter-subject  differences  in  drug  metabolism.  Other  factors  affecting  inter-
subject variability in hepatic clearance are related to age, ethnic groups and gender. Another 
aspect of variability is the intra-subject variability, any of the factors mentioned before is 
additionally  subjected  to  intra-subject  variability.  In  particular,  intra-subject  variability  in 
absorption is affected by diurnal factors, changes in blood flow, body position, and volume of 
fluid and food intake.  Inter-subject variability in oral drug absorption  
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1.4   The Requirement for Good Prediction of Gastrointestinal 
Absorption 
 
Focusing on fa instead of bioavailability, enables the identification and understanding of the 
key causes of low absorption and consequently of inter-subject variability in absorption. The 
first step will be to obtain a preliminary account of the extent of oral absorption (fa) and 
variability instead of bioavailability (F). Requirement for this is that accurate methods for 
prediction  or  estimation  of  the  gastrointestinal  fraction  absorbed  (fa),  are  available  and 
applied. Further on, the factors that determine GI absorption and inter-subject variability need 
to be well understood and considered. Finally, investigating different formulation approaches 
to increase absorption and reduce inter-subject variability is required. Potential benefits of 
high absorption are less inter-subject variation in systemic exposure, smaller dosage forms 
and lower material costs. Thus, it is desirable to find candidate drugs with sufficiently high 
absorption. 
 
 
Figure 1.3: Factors contributing to inter-subject variability in oral absorption  Inter-subject variability in oral drug absorption  
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1.5   Physiological Factors Affecting Drug Absorption  
 
Each  compartment  of  the  GI  tract  features  distinctive  physiological  and  morphological 
characteristics  capable  of  influencing  drug  pharmacokinetics  (Table  1.1).  Key  challenges 
typically faced by drugs on oral administration are: the dynamic luminal conditions (changes 
in  pH  along  the  gut,  gastrointestinal  fluids  composition  and  microbiota  rich  colon),  the 
complex gut wall (enzymes and transporters) and highly variable gastric emptying time and 
gut motility (Pocock et al., 2013). 
 
Table 1.1: Characterisation of different parts of the GI tract (Washington et al. 2001) 
Region   Length (m)  Surface 
area (m
2) 
pH  Residence 
time 
Microorganism  
Oesophagus  0.3  0.02  6.8  <30 seconds  Unknown 
Stomach  0.2  0.2  1.8-2.5  1-5 hours  ≤10ﾲ 
Duodenum  0.3  0.02  5-6.5  <5 minutes  ≤10ﾲ 
Jejunum  3  100  6.9  1-2 hours  ≤10ﾲ 
Ileum  4  100  7.6  2-3 hours  ≤10⁷ 
colon  1.5  3  5.5-7.8  15-48 hours  ≤10ﾹﾹ 
1.5.1  Gastrointestinal Fluids Volume and Composition  
 
Gastrointestinal fluid is complex dynamic and fluctuating and essential for disintegration, 
dispersion, solubility/dissolution of drugs. Like other GI parameters, the volume of liquids in 
various compartments can vary within and between individuals. It is affected by the amount 
of  liquid  ingested,  the  volume  of  gastric  and  pancreatic  secretion,  gastric  emptying  rate, 
intestinal transit time, as well as uptake and efflux of liquids along the GI membrane.  
 
Post mortem studies in humans have shown the presence of fluids in the stomach and the 
small intestine are 118mL and 212mL, respectively (Gotch et al., 1957; McConnell et al., 
2008a). Cummings et al. (1990) measured the large intestine fluid which was 187mL mean 
value. The fluidity of the caecum and ascending colon is slowly reduced as the water is 
reabsorbed. The reduction in the water content means that there is less mixing in the bulk 
phase and therefore less access to the mucosal surface, along with less water available for 
drug dissolution. Gas bubbles present in the colon also will reduce contact of the drug with 
the mucosa (Johnson and Gee, 1981). These values represent the total water including that 
bound to GI mass and therefore may not be a very relevant factor in drug dissolution.  Inter-subject variability in oral drug absorption  
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Schiller  et  al.  (2005)  investigated  the  GI  transit  of  sequentially  administered  capsules  in 
relation to  the free water along the intestinal  lumen by magnetic resonance imaging and 
found that fluid is not homogeneously distributed along the gut, which likely contributes to 
the inter-subject variability of drug absorption (Table 1.2).  
 
Table 1.2: Water sensitive magnetic resonance imaging (MRI) in 12 healthy volunteers (Schiller et al. 2005) 
  Fasted  Fed (1 hour  before imaging) 
  Mean (mL)  Median (mL)  Mean (mL)  Median (mL) 
Stomach  45  47  686  701 
Small intestine  105  83  54  39 
Large intestine  13  8  11  18 
 
The composition of the GI fluids varies according to the stimulus and the secretion rate. The 
gastric juice is a mixture of water, hydrochloric acid, electrolytes and organic substance. The 
main electrolytes in gastric secretion are: H
+, Cl
- , K
+, Na
+, Mg
2+, and Ca
2+ (Hirschowitz, 
1961). The composition of the fluids in the upper small intestine includes chyme from the 
stomach, as well as secretions from the liver, the pancreas, and the wall of the small intestine. 
Composition is affected by fluid compartmentalisation, mixing patterns, absorption of fluid 
into the intestinal wall, and transit down the intestinal tract. Secretions from the pancreas 
include bicarbonate as well as proteases, amylases, and lipases. The liver secretes bile which 
contains bile salts, phospholipids, bicarbonate, cholesterol, bile pigments and organic waste. 
The  wall  of  the  small  intestine  secretes  mineral  ions  such  as  bicarbonate,  sodium  and 
chloride, as well as water. Lindahl et al. (1997) chemically characterised the upper GI tract 
fluids in the fasted state. It was concluded that the chemical characteristics of the GI fluids 
not only varied between individuals, but also showed a pronounced day to day variation in 
the same individual, which might be crucial for the overall rate and extent of drug absorption. 
As food intake triggers many of the secretions in the small intestine, the composition of fed 
state intestinal fluid can vary greatly from fasted state (Kalantzi et al., 2006). Inter-subject variability in oral drug absorption  
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1.5.2  Gastrointestinal pH 
1.5.2.1  Gastric pH 
 
The  fasting  gastric  pH  has  been  studied  in  depth.  Using  a  pH  sensitive  radiotelemetry 
capsule, the records measured for gastric pH were highly acidic (range 1.0-2.5) (Dressman et 
al.,  1990;  Evans  et  al.,  1988;  Fallingborg  et  al.,  1990).  Dressman  et  al.  (1990)  have 
investigated the changes in pH due to the buffering effect of food. The authors found that 
when a meal was administered the gastric pH climbed temporarily from 1.7 in fasted state  to 
average peak value of 6.7, then declined gradually back to the fasted state value over a period 
of less than two hours (Figure 1.4). In addition, it was proven that the pH is not uniform in 
the stomach, due to  the differences  in  the distribution  of parietal cells, and the different 
patterns of motility in various regions of the stomach (McLauchlan et al., 1989). 
 
 
Figure 1.4: Approximation of a typical pH profile in the stomach. The letter “M” denotes food intake (Dressman et al. 1990) 
 
In the same article, considerable differences in the pH between subjects were reported in the 
fed and fasted state. Gastric pH is sensitive to increasing age, pathological conditions and 
drug induced changes. Although the majority of elderly people exhibit gastric pH profiles 
similar  to  younger  people,  10-20%  of  the  elderly  population  exhibit  either  diminished 
(hypochlorhydria) or no gastric  acid  secretion (achlorhydria), leading to  basal  gastric pH 
values >5.0 (Holt et al., 1989; Sievers, 1966). Inter-subject variability in oral drug absorption  
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1.5.2.2 Intestinal and Colon pH 
 
The range of intestinal pH profiles were investigated widely in a representative group of 
normal subjects. The mean pH in the proximal small intestine lies within the range 5.5-7.0, 
gradually increasing by about 1 pH unit to 6.5-7.5 in the distal. There was a sharp fall in pH 
to  a  mean  of  6.4  (range  5.5-7)  as  the  capsule  passed  into  the  caecum.  pH  then  rose 
progressively from the right to the left colon with a final mean value of 7.0 (Evans et al., 
1988; Fallingborg et al., 1989; Fallingborg et al., 1990; Nugent et al., 2001). 
 
The duodenal pH is directly influenced by a meal. In the fed state, the small intestine pH first 
decreases in response to a meal with the arrival of acidic chyme from the stomach but later 
the fasted state pH is re-established as a result of pancreatic bicarbonate secretion. Dressman 
et al. (1990) measured the median fasting duodenal pH as 6.1. During the meal, a brief period 
of elevated duodenal pH was observed, as the median pH value was 6.3. The pH in the 
postprandial phase in the duodenum is considerably lower than in the fasted state around 5.4 
(Hörter and Dressman, 2001). 
 
One of the most important messages from studies is that the pH shows huge inter-subject 
variability between people, and an outstanding example of this is demonstrated in the pH 
profiles measured by Fallingborg et al. (1989) in 39 healthy individuals in which there can be 
over two pH units difference at the same site. Similar results were recorded by Annaert et al. 
(2010) (Figure 1.5). In addition to inter-subject variability, there are also potentially marked 
differences  within  individuals  on  different  occasions;  previous  work  showed  substantial 
differences in gastrointestinal pH profiles measured one week apart, under the same feeding 
conditions for the same subject (Ibekwe et al., 2008). 
 
Figure 1.5: Profiles of luminal pH in the duodenum as a function of collection time. Values for two age groups: 18–25 years 
and 62–72 years (Annaert et al. 2010) Inter-subject variability in oral drug absorption  
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Considering the pH changes along the GI tract and between subjects, weak acid and base 
solubility will be highly affected. It is important that poorly water-soluble weakly basic drugs 
dissolve rapidly in the stomach because dissolution of undissolved drug in the intestine may 
be too low to permit complete absorption. Moreover, weak bases will be less soluble in the 
stomach if given immediately after food intake because the gastric fluids are less acidic. 
Poorly  soluble  weak  acids  with  pKa  values  less  than  six  are  relatively  insoluble  in  the 
preprandial gastric juice and dissolution occurs first in the upper small intestine. However, in 
the case of very weak acids the variations in pH in the gastrointestinal tract are irrelevant to 
the  solubility  because  these  compounds  are  always  in  the  free  acid  form  over  the 
physiological pH range (Hörter and Dressman, 2001). 
 
1.5.3  Gastrointestinal Motility and Transit 
 
Gastric  emptying  time  and  transit  time  along  the  intestine  are  absolutely  crucial  when 
considering the dissolution rate of poorly soluble drugs, as it reflects the time available for 
dissolution. Since the stomach is an important site for the dissolution of weak bases, a shorter 
gastric emptying time will decrease the time for the weak base to dissolve, and hence less of 
the drug in solution form will transfer to the intestine. Shorter or erratic transit time in the 
intestine will also impact considerably on the dissolution rate for poorly-soluble drugs with 
small absorption windows. If the dissolution rate is low and the oral drug delivery system 
moves rapidly through the intestine, a much lower proportion of the drug will be available for 
absorption. Transit time will also affect the boundary layer thickness: the contractions which 
create the motility of the intestine and stomach also contribute to the mixing of the luminal 
contents. Consequently, in the fasted state when only short bursts produce motor activity, the 
boundary layer will be wide. However, this might be compensated for by a longer transit 
time. The contrary will happen in the fed state – that is, more contraction, increasing motility 
and mixing - hence increasing the dissolution rate.  Inter-subject variability in oral drug absorption  
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1.5.3.1 Gastric Motility  
 
Many factors affect the residence time of a solid or dissolved drug in the stomach. Thus, 
factors influencing the rate of gastric emptying may alter the rate or extent of absorption of 
most  if  not  all  orally  administered  drugs.  The  most  important  factors  include  stomach 
fullness, frequency of feeding, and the composition of the chyme in stomach and intestine or 
even the anticipation of food (Olsson and Holmgren, 2001).  
 
The gastric emptying of tablets, pellets and liquids is variable whereas solutions empty from 
the stomach quite rapidly and are not greatly affected by the digestive state of the individual. 
There  are  conflicting  reports  as  for  the  emptying  time  of  solid  dosage  forms  from  the 
stomach. Kaniwa et al. (1988) found that small pellets with the size below 1mm empty from 
the stomach more quickly than large pellets and tablets. However, Clarke et al. (1993) found 
that pellets of two size 0.5 and 4.75mm have the same gastric emptying rate. Newton (2010) 
showed that the issue of how pellets empty from the stomach is not well supported by the 
pharmaceutical literature and claims that pellets less than 2mm will empty from the stomach 
as if they were liquids in the fed state, can be contradicted easily by examining the study 
protocol and/or the analysis of the data.  
 
Many  tools  have  been  developed  in  order  to  characterise  the  inter-  and  intra-subject 
variability in gastric emptying. Intra-subject variation of drug absorption rates appeared to be 
due to variations in gastric emptying rates (Levy and Hollister, 1965). Petring and Flachs 
(1990)  tried  to  determine  the  extent  of  inter-  and  intra-subject  variability  in  the  gastric 
emptying of semisolids and liquids. The results showed that the intra-subject variability was 
not statistically significant for any absorption parameters, (this may be due to the use of a 
small  semi-solid  test  meal)  while  the  inter-subject  variability  was  significant  for  all 
parameters.  Inter-subject variability in oral drug absorption  
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1.5.3.2 Small Intestine Transit Time  
 
The small intestine transit time of dosage forms is almost invariably quoted at 3–4 h, and a 
meta-analysis of transit data in the small intestine showed no difference between tablets, 
pellets and liquids (Davis et al., 1986). In other measurements of the small intestine transit 
time, it was found that the  small intestinal transit was 8h, and colonic transit time was 17.5h 
(median values) (Fallingborg et al., 1989). However, those are mean values from pooled data 
with different methodologies. It is, therefore, safe to assume that the actual values ranged 
from 0.5 to ∼9.5 h. Figure 1.6 demonstrates the high inter-subject variability in the Davis 
study. It can be noted that individual small transit values appeared quite variable and the 
range is quite large. 
 
Figure 1.6: Small intestine transit of pharmaceutical dosage forms. Mean ± SEM (Davis et al. 1986). 
 
Fadda et al. (2009a) examined how the timing of tablet and food administration can affect the 
small intestine transit time. The results are shown in Table 1.3. The small intestinal transit 
times of tablets after the fasted and fed dosing regimen were similar while with the pre-fed 
(when tablet was administered 30 min prior to a meal) dose, small intestinal transit time was 
significantly shorter than in the fasted or fed state. This can influence drug bioavailability. 
The explanation of this phenomenon is the increasing peristaltic activity of the small intestine 
in response to the intake of a meal.  
 
Table 1.3: Transit time of non-disintegrated tablet in fasted and different fed states (Fadda et al. 2009) 
  Small intestine transit time (min) 
Fast  Fed  Pre-fed 
Median  204  210  141 
Range   167-521  198-226  115-188 
 
 Inter-subject variability in oral drug absorption  
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1.5.3.3 Colon Transit Time 
 
Whole bowel transit time is generally between 24 and 36 hours in healthy individuals, but 
values ranging from 0.4 to 5 days have been reported in the literature (Abrahamsson et al., 
1988; Arhan et al., 1981). Eating and morning awakening appear to be the major stimuli in 
eliciting colonic motility. Transit through the large bowel is highly influenced by the pattern 
of daily activity. The highest calorie intake in the western world occurs in the evening and 
colonic motility decrease at night. Dietary fibre, in the form of bran and wholemeal bread, 
fruit and vegetables, increases faecal weight by acting as a substrate for colonic bacterial 
metabolism.  This increased faecal  bulk  is  associated with  a reduced colonic transit time, 
although the mechanism is uncertain (Cummings et al., 1978). Irregular motility and lack of 
bile salts in the colon can affect the solubility and dissolution of some compound. 
 
To conclude, there is high inter-subject variability of motility along the GI tract. Figure 1.7 
demonstrates this. There is no doubt that when analysing data, one should exercise caution in 
interpreting the mean value as a definite value. 
 
 
Figure 1.7: Regional GI transit times of a non disintegrating capsule in 39 subjects (GRT=gastric residence time, SITT= 
small intestine time, CTT= colonic transit time) (Fallingborg et al. 1989). Inter-subject variability in oral drug absorption  
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1.5.4  Gut Metabolism and Transporters  
 
The  mucosal  enzymes  and  transporters  are  very  important  and  manipulate  drug 
bioavailability. The enzymes (e.g. CYP3A), metabolise the substance crossing the mucosa, 
whereas  efflux  transporters (e.g.  P-gp) transfer  the drug back into the  lumen, and influx 
transporters (e.g. PEPT1) which can enhance absorption. 
 
Lin and Lu (2001) indicated that the intestinal mucosa is the most important extra-hepatic site 
of drug biotransformation. Hence, potential exists for significant pre-systemic metabolism 
and  as  a  result  enhanced  reduction  in  bioavailability  as  the  drug  passes,  consecutively, 
through the small intestine and liver. In the small intestine as well as in the liver, CYP3A is 
the most abundant P450 subfamily expressed, with an average specific content representing 
50-70% of spectrally determined P450 content (Paine et al., 1997; Watkins et al., 1987). Like 
hepatic CYP3A, enteric CYP3A is localised within the mature absorptive columnar epithelial 
cells (enterocytes) that largely compose the mucosal lining (Kolars et al., 1994).  
 
Total P450 content in GI mucosa microsomal fraction varies with anatomical region. Even 
within the small intestine, proximal mucosal P450 content is generally higher than the P450 
content of more distal mucosa. Transition from ileal to colonic mucosa again results in a 
further drop in total P450 content (Waziers et al., 1990; Zhang et al., 1999). Not only might 
CYP3A reduce the oral bioavailability, but it may also be a major source of inter-subject 
variability in blood level and drug response as a consequence of variable constitutive enzyme 
expression and drug-drug interaction (Paine et al., 1997). 
 
P-gp acts as part of a detoxification and excretion pathway in the gastrointestinal tract. P-gp 
shows  extremely  broad  substrate  specificity  with  a  tendency  towards  lipophilic,  cationic 
compounds (Chan et al., 2004). Intestinal P-gp is localised to the villus tip enterocytes, which 
is the main site of absorption for orally administered drugs (DeVita et al., 1991). It has been 
found that P-gp not only limits drug absorption by efflux but also increases the access of drug 
to metabolism by mucosal enzymes through repeated cycles of absorption and efflux (Benet 
et al., 2004). Inter-subject variability in oral drug absorption  
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1.6  Solubility/Dissolution and Permeability  
 
The  limiting  steps  of  oral  absorption  can  be  categorised  into  three  types:  permeability, 
dissolution rate and solubility (Figure 1.8). The oral absorption is ‘dissolution rate limited’ if 
the permeation rate is much larger than the dissolution rate; the dissolved drug instantly 
disappears from the intestinal fluid. In the case of ‘permeability limited’ the permeation is 
slow and dissolution is fast. The dissolved amount accumulates in the intestinal fluid. The 
third classification is the case where the concentration of the drug in the intestine reaches the 
maximum solubility in GI fluids. Therefore, the solid drug can no longer dissolve into the 
intestinal fluids and the oral absorption is ‘solubility limited’ (Sugano et al., 2007).  
 
 
 
Figure 1.8: Bucket presentation of oral absorption. (A) Dissolution rate limited absorption. (B) Permeability limited 
absorption. (C) Solubility limited absorption (Sugano et al. 2007). Inter-subject variability in oral drug absorption  
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1.6.1  Dissolution  
 
The  dissolution  of  a  drug  is  a  prerequisite  for  it  be  absorbed.  Important  factors  which 
influence  the  kinetics  of  drug  dissolution  can  be  identified  through  modification  of  the 
Noyes-Whitney equation (Equation 1.2): 
 
  
Equation 1.2: Modified Noyes-Whitney equation  (Hörter and Dressman, 2001) 
 
Where DR is the dissolution rate, A is the surface area available for dissolution, D is the 
diffusion coefficient of the drug, h is the thickness of the boundary layer adjacent to the 
dissolving  drug  surface,  CS is  the  saturation  solubility  of  the  drug,  Xd is  the  amount  of 
dissolved drug and V is the volume of dissolution media (Hörter and Dressman, 2001).  
 
An important factor determining the dissolution rate is the particle size of the drug. The 
dissolution rate is directly proportional to the surface area of the drug, which increases with 
the  decrease  in  particle  size.  However,  decreasing  particle  size  might  also  become  a 
limitation  when  the  wetting  capacity  of  the  buffer  is  very  poor,  resulting  in  particulate 
agglomeration (Solvang and Finholt, 1970). 
 
The contact angle at the liquid-solid interface can give estimation of the buffers’ wetting 
capacity: when the angle is high, the wetting properties of the buffer are poor. There are 
several factors that can decrease the angle and hence increase wet-ability; among them the 
native surfactant in the gastric and intestinal fluids. Bile salt concentration in the fasted state 
in the small intestine can vary between 1 to 6mM. Differences in bile salts concentration 
between individuals can also affect the contact angle, thus increasing or decreasing the fluid 
wetting capacity (Bakatselou et al., 1991). 
 
According  to  the  Noyes-Whitney  equation,  dissolution  rate  is  also  affected  by  drug 
diffusivity  (D).  The  Stokes  -Einstein  equation  (Equation  1.3)  states  that  diffusivity  is 
inversely dependent on the fluid viscosity (ƞ):  
 
Equation 1.3: The stokes- Einstein equation Inter-subject variability in oral drug absorption  
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Viscosity (ƞ) of the GI fluids may vary between individuals as the function of food intake and 
secretion to the gastrointestinal luminal. The food effect is highly dependent on the food 
components and the volume of co-administered fluids. Furthermore, the diffusion coefficient 
is reduced by micellar solubilisation (Hörter and Dressman, 2001). 
1.6.2  Permeability  
 
Overall permeability can be considered as the sum of passive (diffusion driven) and active 
(transporter mediated) processes. The latter can affect both influx and efflux of a drug (i.e. P-
glycoprotein).  Molecular  properties  relevant  to  intestinal  absorption  include  lipophilicity, 
molecular size and charge, and hydrogen bonding, and importantly, most of these properties 
are also intrinsically dependent on one another. 
 
Depending on the mechanism of transport, the drug flux through the intestinal mucosa (J) can 
be described with the following equations (Equation 1.4 and Equation 1.5): 
 
 
Equation 1.4: Drug flux for passive transport 
 
   
Equation 1.5: Drug flux for carrier mediated transport 
 
Where Pw is the effective membrane permeability coefficient, Cw is the drug concentration, 
Jmax  is  the  maximum  drug  flux  through  the  membrane  and  KM  is  the  Michaelis–Menten 
constant (Dressman and Lennernaes, 2000). 
 
Any  drug  molecule  that  successfully  overcomes  the  various  biological  membranes  and 
reaches  its  site of action should feature  a balance between its  hydrophilic and lipophilic 
properties.  According  to  Fick’s  first  law  of  diffusion,  passive  drug  transport  across  a 
membrane  is  proportional  to  the  membrane-water  partition  coefficient.  Since  membrane-
water partition coefficients are not readily available, partition coefficient between water and 
an organic solvent such as octanol are normally used. The octanol- water partition coefficient 
(P) is a physical property used extensively to describe a chemical’s lipophilic or hydrophilic 
properties. It is the ratio of unionized compound in mutually saturated octanol and water. 
Since  P  values  may  range  over  several  orders  of  magnitude,  the  logarithm  (log  P)  is 
commonly used for convenience (Smith et al., 1975). Partition coefficients that are measured Inter-subject variability in oral drug absorption  
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at  a  given  pH  are  known  as  distribution  coefficients  (D),  defined  as  the  ratio  of  the 
concentration of compound in  the organic phase to the concentration of both ionised and 
unionised species in the aqueous phase at a given pH (Scherrer and Howard, 1977). 
 
The  lipophilicity  of  a  drug  is  the  most-used  physicochemical  property  to  predict  its 
permeation in biological systems. Molecules diffuse across the membrane in proportion to 
their concentration gradient  across the membrane.  and in  proportion  to their lipophilicity 
(Cao et al., 2008). However, molecular size is yet another factor affecting drug permeability 
through  the  membrane,  most  conveniently  defined  by  use  of  molecular  weight  (MW). 
However, this may not be sufficient, because MW, as such, contains no information about the 
actual three-dimensional (3D) shape of the molecules. 
 
Another parameter used to describe permeation is hydrogen bonding. Ordered lipid layers 
provide a finite amount of hydrogen bonding groups. These groups, the majority of which are 
hydrogen bond acceptors, are located exclusively in the head group region of the lipids. In 
order to partition into the hydrocarbon region of the bilayer, the solute must be sufficiently 
lipophilic to overcome the energy losses that occur in breaking the hydrogen bonds with 
water or the lipid head groups. This step can thus present a considerable energy barrier for 
solutes, which exhibit strong hydrogen bonding (donor) tendencies. Accordingly, biological 
permeation can be expected to markedly depend on the hydrogen bonding capacity of the 
solute (Conradi et al., 1991; Diamond and Wright, 1969; Tayar et al., 1991). Inter-subject variability in oral drug absorption  
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1.7  Prediction of Absorption 
 
In  a  recent  publication  by  Musther  et  al.  (2014),  an  extensive  analysis  of  the  published 
literature data of human and animal (mouse, rat, dog and non-human primates) bioavailability 
was  conducted.  A  database  of  184  compounds  was  assembled.  Linear  regression  for  the 
reported  compounds  indicated  no  strong  or  predictive  correlations  to  human  data  for  all 
species, individually and combined. 
1.7.1  Animals and Absorption in Human  
 
Chiou and Barve (1998) investigated the correlation between fa values in rats and humans 
(Figure 1.9). The extent of absorption which was reported in the literature or estimated by 
them was  based on studies using radio-labelled  compounds or based on pharmacokinetic 
methods. The authors found high correlation (R
2=0.97) between fa values in rats and humans 
for 64 test substances.  
 
Figure 1.9: Correlation of fraction absorbed in humans VS rats for 64 drugs (right) and for 24 drugs with less than 90% 
absorption (left) (Chiou and Barve, 1998). 
 
In a similar experiment, Zhao et al. (2003) collected data of 241 human, oral absorption from 
the literature. They identified a standard deviation of 11% between human and rat absorption. 
It was suggested that the absorption in rats could be used as an alternative method to human 
absorption in pre-clinical oral absorption studies.  
 
In addition, Chiou et al. (2000) conducted a retrospective evaluation using dogs as an animal 
model to study fa of 43 drugs in humans (Figure 1.10). The overall correlation was relatively 
poor (R
2=0.51) as compared to the earlier rat vs. human study. This suggests that caution 
must be exercised in the interpretation of data from dogs to humans, and may be related to 
“leakier” tight junctions found in dog jejunum.  Inter-subject variability in oral drug absorption  
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Figure 1.10: Correlation between fraction absorbed data in human vs. dogs for 43 drugs (Chiou et al., 2000). 
 
In  a  similar  manner,  Chiou  and  Buehler  (2002)  examined  whether  monkeys  were  an 
appropriate model to predict human data for the fraction absorbed, revealing  a strong linear 
relationship between the fa data of monkeys to that of humans (R
2=0.97). 
 
Similar to the human study, a limitation of animal models is that they are unsuitable for high 
throughput screening. In addition, the absorption rate and absorption rate constant (ka) are 
expected to differ between animals and humans due to the influence of intestinal radius and 
gastric emptying time. Absorption is expected to be slower in humans than in rats and other 
laboratory animals (Fagerholm, 2007).  
1.7.2  Prediction of Absorption in Humans from Permeability Data 
 
One of the major determinants for fa is GI permeability (Peff). The Peff is defined as the speed 
(cm*s
-1) at which a molecule is transported (by passive diffusion and /or active transport) 
across a membrane, cell endothelium or epithelium.  
 
Cao et al. (2006) tested the intestinal permeability of 14 drugs and three drug-like compounds 
with  different  absorption  mechanisms  in  rat  and  human  jejunum,  determined  by  in  situ 
intestinal  perfusion.  The  authors  showed  that  there  was  no  correlation  found  in  the 
bioavailability  between  rat  and  human,  while  a  good  correlation  was  observed  between 
human and rat intestinal permeability of drugs with both carrier-mediated absorption and 
passive diffusion mechanisms (Figure 1.11). However, Fagerholm (2007) claimed that most 
of the compounds in this study were characterised by high permeability, which resulted in 
predicting  complete  fa.  The  author  suggested  that  perfusion  methods  are  not  sufficiently 
sensitive enough to measure the permeability of compounds with low or moderate Peff. The Inter-subject variability in oral drug absorption  
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limits in this method are the comparably slow screening rate, and that this model is mainly 
useful only for predicting the active uptake potential.  
 
 
Figure 1.11: Correlation of drug permeability in rat jejunum and in human jejunum. Permeability coefficients (Peff) were 
determined by in situ intestinal perfusion (Cao et al. 2006). 
 
The Caco-2 cell model is used for screening/estimation of Peff, and consequently can be used 
to predict drug transporter by different pathways across the intestinal epithelium. Arguably, 
the best correlation is obtained for drugs that are transported by the passive transcellular route 
(Artursson et al., 1996). However, as mentioned above, some of the disadvantages of this 
model  such  as  differences  in  the  composition  of  cell  membrane,  paracellular  radius  and 
transporter expression imply that the uptake characteristics of Caco-2 cells are different from 
that of the small intestine (Balimane and Chong, 2005). Lennernäs et al. (1996) indicated that 
Caco-2 monolayers can be used to predict passive drug transport in humans, while prediction 
of transport by carrier-mediated systems may require a scaling factor due to a low expression 
of carriers in this cell line.  
 
Irvine et al. (1999) compared Caco-2 Peff and human fa data for around 40 passively absorbed 
compounds,  and  found  a  poor  correlation  between  the  two  parameters.  In  addition,  they 
related MDCK Peff values and human fa values, and found that the accuracy and precision 
were similar to that of the Caco-2 cell line. In turn, Matsson et al. (2004) compared the 
widely-used  permeability  model  Caco-2  regarding  ability  to  predict  fa  after  oral 
administration in humans. The authors showed relatively good correlation between model 
estimation of Peff values and fa for 14 compounds with mainly passive absorption. However, Inter-subject variability in oral drug absorption  
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as opposed to the study of Irrvin et al. (1999), only 14 compounds were tested. Thus, it can 
be assumed that the Caco-2 model generally works well to predict complete or near complete 
fa for a highly permeable substance. 
 
Stewart  et  al.  (1995)  compared  the  intestinal  permeability  obtained  in  three  absorption 
models  for  consistency,  and  assessed  the  utility  of  the  models  in  predicting  the  fraction 
absorbed in human studies. The methods compared are the rat in situ single pass intestinal 
perfusion method, the rat everted intestinal ring method, and Caco-2 cell monolayers. The 
authors found that Caco-2 cell monolayers and rat single pass intestinal perfusion combine 
the highest correlation between the systems, and correlate well with the fraction absorbed in 
humans.  As  most  of  the  tests  were  done  using  small  organic  molecules,  however,  they 
suggested that caution was needed when extrapolating permeability data from those methods 
to complex molecule like peptidomimetics.  
 
1.7.3   PBPK Models 
 
Physiologically based pharmacokinetics models (PBPK) use the “bottom–up” approach. The 
bottom up approach is basically modelling and simulation of the ADME processes. The key 
element of this approach is the separation of information on the human body from that of the 
drug physicochemical characteristics and the study design. This ‘Bottom up’ approach allows 
easily changing the study design. Hence, the power of studies to recognise covariates can be 
investigated a priori with the aim of improved decision making (Jamei et al., 2009a). The first 
PBPK model was introduced in 1973 by Theorell et al. (1937a; 1937b) and since then, thanks 
to the better understanding of the body physiology and development of new in vitro tools to 
assess  drug  performance,  great  progress  has  been  made  in  developing  PBPK  models 
(Kostewicz et al., 2014). Inter-subject variability in oral drug absorption  
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1.7.3.1 CAT Model 
 
Few models have been developed to mimic in silico the in vivo situation in the gut. One that 
laid the base for further developments is the CAT model. This model accounts for the transit 
in  the  stomach,  duodenum,  jejunum,  and  ileum,  and  the  absorption  in  the  duodenum, 
jejunum,  and  ileum  The  assumptions  for  the  CAT  model  include:  absorption  from  the 
stomach and colon is insignificant compared with that from the small intestine; transport 
across the small intestinal membrane is passive; dissolution is instantaneous and  drug transit 
through the small intestine can be viewed as a process flowing through a series of segments, 
each described by a single compartment with linear transfer kinetics from one to next, and all 
compartments may have different volumes and flow rates, but having the same residence 
times (Figure 1.12). 
 
 
 
Figure 1.12: Schematic diagram of the CAT model with linear transit and passive absorption kinetics (Yu, 1999). 
 
Jamei  et  al.  (2004)  have  collected  measures  of  variability  for  each  of  the  physiological 
parameters relevant to the CAT model and have assessed the impact of these on the outcome 
of the modelling. This study was carried out for drugs with a wide range of permeability 
characteristics. The contribution of transit time, permeability and the radius of small intestine 
to the changes in fa were 19%, 72% and 3.4%, respectively. They concluded that although 
permeability was the most influential factor determining fa, individual parameters such as 
transit time and the radius of the small intestine were also important. The results confirmed 
the assertion that inter- and intra-variability of the parameters should be considered in any 
predictive PB modelling studies particularly when less permeable drugs are investigated.  Inter-subject variability in oral drug absorption  
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1.7.3.2 ACAT model 
 
Agoram et al. (2001) developed the ACAT model based on the CAT model, to include the 
dissolution  rate,  the  pH  dependence  of  solubility,  absorption  in  the  stomach  or  colon, 
metabolism in the gut or liver, degradation in the lumen, changes in the absorption surface 
such as transporter densities, efflux proteins densities, and other regional factors within the 
intestinal tract. Similar to the CAT model, the basic assumption of the ACAT model is that 
drug passing through the small intestine will have an equal transit time in each of the seven 
compartments. Addition of compartments corresponding to the enterocytes and surrounding 
tissues instead of treating the luminal barrier as a thin wall, add more compatibly to the real 
condition in  the GI tract.  Furthermore, the ACAT model uses the concentration  gradient 
across the apical and basolateral membranes to calculate the rate of drug transfer into and out 
of an enterocyte compartment for each GI tract lumen compartment, whereas the CAT model 
assumed drug transfer to be unidirectional – luman to central compartment. 
 
This model includes linear transfer kinetics and nonlinear metabolism/transport kinetics, six 
states of drug component (unreleased, undissolved, dissolved, degraded, metabolised, and 
absorbed), nine compartments (stomach, seven segments of small intestine, and colon), and 
three  states  of  excreted  material  (unreleased,  undissolved,  and  dissolved).  It  takes  into 
consideration  physicochemical  factors  (pKa,  solubility,  particle  size,  particle  density,  and 
permeability),  physiological  factors  (gastric  emptying,  intestinal  transit  rate,  first-pass 
metabolism, and luminal transport), and dosage factors (dosage form and dose) in predicting 
oral drug absorption (Figure 1.13). 
 
Figure 1.13: The schematic diagram of the ACAT model developed by Agoram et al. (2001) Inter-subject variability in oral drug absorption  
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The  commercially  available  software,  GastroPlus™,  was  developed  based  on  the  ACAT 
mode. This software has undergone several improvements with respect to its capability in 
predicting oral absorption of a variety of drugs in comparison to the original ACAT model. In 
addition  to  its  use  for  predicting  oral  drug  absorption  in  the  GI  tract,  whole-body 
physiologically  based  pharmacokinetic  and  combined  pharmacokinetic  and 
pharmacodynamic models have been constructed within Gastroplus™ for predicting whole-
body  pharmacokinetic  and  pharmacodynamic  characteristics  in  humans  (De  Buck  et  al., 
2007; Tubic et al., 2006). 
 
The  advantage  of  this  software  is  that  the  combination  of  in  vitro,  in  vivo  or  in  silco 
parameters  of  the  compound  can  be  used  to  estimate  drug  performance.  Moreover, 
investigation of different formulations (immediate release formulations, controlled release 
formulations  or  other  forms  of  delayed  release)  based  on  the  drugs  physicochemical 
properties  e.g.,  drug  aqueous  solubility–pH  relationship,  permeability,  particle  size 
distribution  and  formulation  type  can  be  carried  out.  Another  important  aspect  of  this 
software is that physiological parameters like GI transit time, pH, absorptive surface area, 
bile salt concentrations in different regions of the gut, pore size and density, compartment 
dimensions  and  fluid  content  are  built  into  the  model  and  can  be  modified  to  adjust  to 
different population characteristics. 
 
1.7.3.3 ADAM Model 
 
Similar to the ACAT model, the ADAM model was developed based on the CAT model, and 
it is a compartmental transit model. It divides the GI tract into nine anatomically defined 
segments from the stomach through the intestine to the colon. Drug absorption from each 
segment is described as a function of release from the formulation, dissolution, precipitation, 
luminal degradation, permeability, metabolism, transport and transit from one segment to 
another. Furthermore, the ADAM model also considers the heterogeneity of the GI tract such 
as heterogeneous distribution of enterocytic blood flow and enzymes in the gut wall. Food 
effects such as the impact of changes in gastric emptying, splanchnic blood flow, and luminal 
pH  are  also  taken  into  consideration  and  simulated.  This  model  was  incorporated  in  a 
software called SimCyp population based ADAM simulator  
 Inter-subject variability in oral drug absorption  
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As in the previous model, some assumptions have been made. First, it is assumed that the 
absorption  from  the  stomach  is  insignificant  compared  to  that  from  the  small  intestine. 
Second, the movement of liquid and solid drug through each segment of the GI tract may be 
described by first order kinetics. Third, it is also assumed that drug metabolism in the colon is 
negligible. 
 
One main advantage of the ADAM model as incorporated in the SimCyp simulator is that it 
is  capable  of  capturing  the  likely  inter-subject  variability  in  oral  bioavailability  as  it 
conditioned by age, sex, race, genetics and disease of the patient, and by the intake of food. 
Jamei et al. (2009b) investigated inter-subject variability in the bioavailability of four drugs 
covering a wide range of permeabilities. The predicted median values of fa and their inter-
subject  variability  were  calculated  and  observed  (mean)  and  predicted  (mean  and  range) 
values were compared. While predicted and observed mean values were similar for the three 
most permeable compounds, there was a greater discrepancy for the drug which is the least 
permeable. This was associated with a greater predicted variability in the value of fa of that 
drug.  Therefore,  they  indicated  that  inconsistency  between  point  predictions  of  fa  and 
observed values from small clinical studies may be expected to the extent that the latter may 
not capture the full extent of inter- and intra-subject variability. 
 
SimCyp simulator has been developed enormously since it was first introduced.  It includes 
the  population  mean  and  inter  subject  variability  of  regional  luminal  pH  and  bile  salt 
concentrations in the fasted and fed states and enables to assess  the solubility and dissolution 
rate via a bile micelle solubilisation and a diffusion layer (Jamei et al., 2009a). Different 
populations with different physiology that might affect the drug performance in vivo were 
incorporated as part of the simulator, for example, obesity and renal impairment disease, 
paediatric, Japanese and Chinese ethnic populations. The interplay of basal luminal fluid, 
additional fluid taken with dose, biological fluid secretion rates, and fluid absorption rate in 
the  fasted  or  fed  state  were  modelled  in  time-dependent  fluid  volume  dynamics  model. 
Gastric emptying, intestinal transit times and their inter subject variability are incorporated 
for  the  fasted  and  fed  states.  Gut  wall  passive  and  active  permeability  (Peff,  man)  can  be 
predicted  from  in  vitro  permeability  measurements  (Caco-2,  etc.)  or  using  QSAR-type 
models; regional Peff  differences can be specified. SimCyp can also be used to  establish 
physiologically based (PB) in vitro–in vivo correlations (PB-IVIVCs). 
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Thesis overview  
 
The work presented in this thesis explored different methods to estimate fa and inter-subject 
variability  in  humans.  It  has  been  proposed  to  use  the  well  stirred  model  to  estimate 
absorption using population pharmacokinetics approach (Chapter 2). In addition, different in 
vitro (Chapter 3) and in vivo (Chapter 4) techniques were utilised in this research to identify 
the key causes for high inter-subject variability in oral drug absorption.  
 
In Chapter 2, an attempt is made to establish a data set of fa and inter-subject variability of 
different compounds. Calculations of fa for individuals were carried out based on data from 
clinical trials with radiolabeled compounds in plasma and urine, clinical trials with urine data 
alone,  as  well  as  calculations  based  on  the  well  stirred  model.  Furthermore,  correlation 
analysis of physicochemical properties of the compounds was carried out to identify the key 
causes  of  low  and  erratic  absorption.  In  the  second  part,  phase  I  clinical  trials  of  four 
compounds from the AstraZeneca database were utilised to estimate absorption (fa*fg) and 
inter-subject  variability.  The  well  stirred  model  was  implemented  in  the  population 
pharmacokinetic  approach  (NONMEM  software)  to  identify  the  rate-limiting  step  in  oral 
drug absorption, and to estimate the food effect on absorption.  
 
Chapter 3  focuses on identifying the key  causes  for high inter-subject variability  of two 
model drugs: dipyridamole and furosemide. (AstraZeneca compounds were not available for 
further investigation in vitro, therefore drugs with high reported inter-subject variability were 
identified.) Compounds were investigated in vitro for solubility, dissolution and permeation, 
the  primary  processes  governing  oral  drug  absorption.  In  the  first  section,  the  regional 
solubility of the two drugs was tested in pooled gastric and jejunum aspirated fluids from 
healthy  volunteers.  In  addition,  the  solubility  was  measured  in  ileostomy  fluids  from  10 
individual UC subjects. The ileostomy fluids were characterised with respect to pH, buffer 
capacity, osmolality and surface tension. Correlation analysis with solubility measurements 
was  then  carried  out  to  investigate  the  underlying  causes  for  variability  in  solubility. 
Simulated  intestinal  fluids  were  used  to  investigate  the  effect  of  bile  salt  on  the  drug 
solubility. In the second part, the effect of bile salt and pH on the dissolution of these drugs 
was investigated and finally the dissolution and permeation were investigated simultaneously 
using the dissolution/permeation system developed by Kataoka et al. (2012). Inter-subject variability in oral drug absorption  
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In  Chapter  4,  different  formulation  approaches  (solid  dispersion,  self-emulsifying  drug 
delivery  system  and  nano  particles),  for  increasing  drug  solubility/dissolution  and  hence 
absorption, were compared. The formulation performances were evaluated in vitro and in 
vivo in rat models to establish ‘in vivo in vitro correlation’ (IVIVC).   
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Chapter 2 -   Estimation of Oral Drug 
Absorption and Inter-Subject Variability in 
Humans  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
 
- 31 - 
 
2.1  Chapter Overview  
 
A preliminary account of the extent of oral absorption (fa) and inter-subject variability instead 
of the overall bioavailability is required to investigate the absorption process. It is challenging 
to  calculate  fa  due  to  the  lack  of  published  pharmacokinetic  data  from  humans  in  the 
literature. Therefore, in some studies, manipulations have been made in order to assess fa. 
Zhao et al. (2001) chose the fa data for modelling based on one of the following methods: 1) 
fa was obtained from bioavailability values after oral administration. If the bioavailability was 
low, fa should be equal to or higher than the values of bioavailability 2) fa was obtained from 
cumulative urinary excretion of drug-related material following oral administration. If the 
urinary excretion was low (<80%) and it could not be proved that urinary excretion of the 
absorbed drug was the main route or nearly all the drug was recovered in urine and faeces, fa 
should  be  equal  to  or  higher  than  the  percentage  of  urinary  excretion  of  the  drug.  3) 
Intravenous administration showed that nearly the entire drug was excreted in urine or that 
excretion in bile was small; however, the drug was not completely recovered in urine and 
faeces. Thus, fa should be between the percentage of excretion in urine and faeces (100% 
excreted in faeces). 
 
In another study, Takano et al. (2006) used the relative bioavailability of solid dosage form 
and  a  solution  orally  administered  in  the  fasted  state.  Assuming  linear  kinetics  of  drug 
metabolism  in  both  administrations,  lipophilic  drugs  administered  as  a  solution  could  be 
completely absorbed due to their high permeability. Therefore, the relative bioavailability 
solid/solution is almost equal to fa solid in the fasted state. Another manipulation for calculating fa 
is the use of relative bioavailability of solid dosage form orally administered in the fasted and 
fed states. The greater concentration of bile salts and lecithin in the fed state can enhance the 
solubility of lipophilic drugs. Therefore, the relative bioavailability fasted/fed of these drugs can 
be  regarded  roughly  as  the  fa  of  a  solid  dosage  form  in  the  fasted  state,  assuming  high 
permeability to the intestinal wall and linear kinetics metabolism. Moreover, Jamei et al. 
(2009a) have indicated that estimating fg and fa from ordinary clinical data is not possible and 
many reports in the literature erroneously refer to the composite function of fg*fa as if it 
represents only fa. Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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After reviewing the literature, with the knowledge gained, up to date, it seems that there is no 
reliable representative dataset of fa and its associated inter-subject variability. A dataset that 
includes  information  on  fa  inter-subject  variability  will  allow  scientists  to  investigate  the 
mechanism behind the variability of fa by correlating variability to different drug properties. 
In the first section of this chapter, data for fa estimation were collected to establish reliable 
dataset  of  fa  based  on  published  clinical  trials  in  healthy  subjects.  Where  possible, 
individual’s fa values were calculated and a correlation analysis was carried out between fa, 
inter-subjects variability and the drug physicochemical properties (permeability and solubility 
properties). In this research, due to the lack of ability to estimate fg with the available data 
herein (plasma concentration vs. time), fg is assumed to be equal to 1. Therefore, whenever 
the concept absorption is mentioned, it refers to the fraction absorbed and the fraction that 
escapes gut wall metabolism (fa*fg). 
 
When  describing  inter-subject  variability,  it  is  desirable  to  include  as  many  subjects  as 
possible to identify possible trends and variations in population. Population pharmacokinetics 
(as  implemented  in  NONMEM)  is  a  useful  and  readily  available  tool  to  analyse 
pharmacokinetics of datasets. NONMEM is usually used to  estimate pharmacokinetics of 
drugs  from  clinical  data  by  compartmental  analysis.  Most  of  the  focus  is  on  drug 
bioavailability and not fa.  In the second section of this chapter, the well stirred model was 
incorporated in NONMEM software to estimate fa*fg and gain a better understanding on its 
associated inter-subject variability using the dataset of healthy subjects from phase 1 clinical 
studies of different formulations. Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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2.2  Estimation of fa and Inter-Subject Variability from Published 
Clinical Trial Data  
2.2.1  Introduction  
2.2.1.1 Estimation of fa from In Vivo Data in Humans 
 
There are few methods to estimate fa from in vivo plasma concentration vs. time profile in 
humans.  First,  a  mass  balance  study  of  radio-labelled  compounds  where  in  this  method, 
intravenous (IV) and oral labelled of a similar dose are given and the fa is estimated by an 
accurate determination of the ratio AUC in plasma of the total radio-labelling compound 
administration. However, radio-labelled studies are not routinely carried out. Another non-
invasive method is by determination of the percentage of the parent compound if excreted 
intact  (or  metabolites)  in  urine  following  oral  and  IV  administration  of  similar  doses 
(Equation 2.1). This model assumes a significant fraction of the dose must be excreted in 
urine for this method to be accurate and the metabolism profile in the oral dose should be 
similar to the IV administration.  
 
   
Equation 2.1: Fraction absorbed obtained from urinary data 
 
The well stirred model of hepatic drug clearance was established by Rowland et al. (1973) 
and Wilkinson and Shand (1975). This model allows calculating the hepatic drug clearance 
based on whole blood drug concentration as a function of hepatic blood flow, the free fraction 
of drug in the blood and the intrinsic metabolic clearance in the liver based on unbound drug 
concentration. This model treats the liver as a single well stirred compartment and all the 
three aqueous spaces within the liver (blood, interstitial space and intracellular space) are 
well mixed; in addition the distribution equilibrium is achieved so rapidly that the drug in the 
emergent  venous  blood  is  in  equilibrium  with  that  in  the  liver.  That  means  that  drug 
distribution into the liver is  perfusion-limited  with  no diffusion delay and that no active 
transport systems are involved (Pond and Tozer, 1984).  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
 
- 34 - 
 
The total bioavailability is a product of an orally administered drug that is metabolised in the 
GI tract, the intestinal wall and the liver (Equation 2.2).  
   
Equation 2.2: Oral bioavailability adapted from Pond and Tozer (1984) 
 
Eh is the hepatic extraction ratio, i.e. the fraction of drug entering the liver that is eliminated 
by the organ. The hepatic extraction ratio depends on blood flow (Qh), protein binding (fu) 
blood  to  plasma  ration  (Cb/p)  and  clearance  intrinsic.  Correction  for  blood  to  plasma 
concentration  was  made  based  on  the  publication  from  Yang  et  al.  (2007).  Further  on, 
correction for renal elimination is considered for compounds which were eliminated intact in 
urine. Whether or not a drug undergoes extensive first pass, elimination can be anticipated 
from plasma data when the following parameters are known: the ratio of blood to plasma 
concentration (Cb/p); plasma clearance (Clp); the fraction of the drug in the body that was 
excreted unchanged in the urine (fe) and liver blood flow (Qh).Therefore, by taking all these 
parameters to one equation, fa can be estimated based on the Equation 2.3. 
 
Equation 2.3: Calculation of F based on the well stirred model by Yang et al. (2007)  
 
2.2.2  Objectives 
 
  To calculate fa based on human clinical trials published in the literature.  
  To establish dataset of fa and its inter-subject variability from the scientific literature.  
  To identify the factors causing high inter-subject variability using correlation analysis to 
the compounds physicochemical properties.  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
 
- 35 - 
 
2.2.3  Methods 
2.2.3.1 Estimation of fa in Humans from Pharmacokinetic Data 
 
In  this  study,  three  methods  which  were  described  in  the  introduction  were  utilised  to 
estimate fa from human clinical trial studies: 
1) Radio-labelled compounds in plasma or urine after IV and oral administration. 
2) Urine excretion data following oral and IV administration (Equation 2.1). 
3) The well stirred model (Equation 2.3).  
Bioavailability data presented in Table 2.1 were calculated based on AUC ratio of IV and oral 
administration (reported in the publications). Data for all other parameters were collected 
from different clinical trials; Eh and fa were calculated for each subject. 
2.2.3.2 Critical Review of Clinical Trials 
 
The scientific literature related to clinical trials in humans was examined using the following 
search  engines:  Web  of  knowledge,  PubMed,  ScienceDirect,  Wiley  InterScience, 
SpringerLink and Google Scholar. The key words used were either/or a combination of the 
following  with  the  drug  name:  absolute  bioavailability,  bioavailability,  pharmacokinetics 
parameters,  intravenous  and  oral  administration,  radiolabelled  data,  blood  to  plasma 
concentration and hepatic extraction ratio.   
 
More than 400 clinical trials were reviewed, and the criteria used for screening:  
1.  The study was conducted in normal volunteers or in patients with normal kidney and 
liver function.  
2.  Mean absolute bioavailability (calculated from AUC) was provided.  
3.  In the case where few articles were found for the same compounds, the lowest dose 
given was chosen (to eliminate transporters saturation process).  
4.  In the absence of IV data in a radiolabel test, the minimum extent of absorption was 
estimated given that sufficient sampling time was allowed. 
5.  Where faeces data were not available, the pattern of parent drug and metabolite after 
IV and oral administration was compared; indicating absorption from the GI tract is 
complete.  
6.  Individual’s  values  of  plasma  clearance,  absolute  bioavailability  based  on  AUC 
calculation were presented. Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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7.  Since most of the published clinical trials do not include data regarding the blood to 
plasma concentration ratio, a separate search for these values was conducted and the 
mean value was used. 
8.  The mean value of 1.5 L/h of hepatic flow was included (based on the publication 
from Bradley et al. (1945)). 
 
In addition, the physicochemical properties of the compounds (molecular weight, HBD, PSA, 
measured logP and intrinsic solubility) were adopted from the publication by Benet et al. 
(2008). 
 
2.2.3.3 Describing Variability  
 
One  measure  of  variability  is  variance.  It  is  defined  as  the  sum  of  the  squares  of  the 
deviations of observations; variance does not allow a ready comparison of variability across 
sets of observations of different magnitude, or of different dimensions. The coefficient of 
variation,  the  square  root  of  variance  (the  standard  deviation)  normalized  to  the  mean, 
overcomes this problem. The terms high and low variability refer to distributions that have 
high and low coefficients of variation, respectively. Typically, a coefficient of variation of a 
pharmacokinetic parameter of 10% or less is considered low, 25% is moderate, and above 
40% is high (Rowland and Tozer, 2011).  
 
Calculations for the coefficient of variation for bioavailability, hepatic excretion ratio and 
fraction absorbed were carried out according to Equation 2.4 using Excel: 
 
 Equation 2.4: Coefficient of variation. Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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2.2.4  Results & Discussion 
2.2.4.1 fa Estimations from Published Clinical Trials in Healthy Subjects  
 
In  this  investigation,  more  than  400  published  clinical  trials  for  different  drugs  were 
reviewed. However, only 22 articles contained the required information to estimate fa based 
on the well stirred model (Table 2.1-calculations were made based on the well stirred model). 
Most  of  the  clinical  trials  which  were  reviewed  did  not  include  IV  administration  or 
individual values of plasma clearance or bioavailability. Moreover, parameters such as the 
blood to plasma concentration ratio or individuals liver blood flow are not routinely measured 
and reported. Another 20 publications were utilised to estimate fa based on the measurements 
of radio-labelled compounds in plasma/urine or based on the assumption that the compound 
is mainly eliminated in urine (Table 2.2- calculations were made based on methods 1 and 2 
described in Section 2.2.3.1).  
 
In this investigation, some of the individuals fa calculations based on the well stirred model 
were not realistic (more than 100% or negative values were attained-marked as (*) in Table 
2.1). Possible explanation to the discrepancy in the calculations is the use of mean values of 
hepatic liver blood flow and blood to plasma concentration ratio. As individuals liver blood 
flow is not measured routinely in clinical trials, the mean value of 1500 mL/min was chosen 
based on the publication from Bradley et al. (1945). Liver blood flow values can be diverse 
due  to  population  variability  (Price  et  al.,  2003)  and  affect  liver  elimination.  Therefore, 
individuals calculations based on the mean liver blood flow might yield misleading results. 
Moreover, the use of mean Cb/p values might introduce another error in the individuals’ fa 
estimations. Cb/p can vary from 0.5-2 for a drug like molecule, in addition blood to plasma 
concentration ratio is usually measured in vitro by spiking the drug in blood samples and not 
always blood samples are directly taken from the individuals who participate in the study. 
The  error  is  expected  to  be  more  significant  for  drugs  with  high  hepatic  clearance.  A 
simulation made by Yang et al. (2007) revealed that the error in fh is likely within +0.2 units 
(for Cb/p span from 0.7-2), provided that the hepatic clearance values are not greater than 25% 
of the liver blood flow. 
 
When omeprazole fa was calculated based on the well stirred model for each individual, a 
value of more than 100% was obtained for some individuals. However, when only the mean 
value was considered in all parameters, it gave 100% absorption which fits the radio-labelled Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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data reported in the same publication. Similar results were obtained for felodopine (mean 
fa=85%). Another example is the labetalol blood/plasma ratio where mean value was reported 
as 1.36, and ranges between 1.05 to 1.62 (Lalonde et al., 1990). There is no doubt that this 
range can significantly affect the individual’s calculations.  
 
Other explanations for the discrepancy in the calculation; first, an assumption of negligible 
gut wall metabolism was made to simplify the calculation due to scarcely published fg data. It 
might  be  that  the  assumption  of  negligible  fg  is  not  valid  for  some  compounds  in  this 
investigation and therefore introduces another error in fa estimation. Second, Nomier et al. 
(2008) describe an approach utilizing oral/intravenous pharmacokinetic data to estimate oral 
absorption from animal studies. The author suggested that compounds with Eh higher than 0.5 
and low F, might suffer from low success of prediction due to the impact of experimental 
variability which might  be the case herein. Third, another assumption of the well  stirred 
model is that the pharmacokinetics is within the linear range for both PO and IV doses. 
However, it is likely that some drugs exhibit nonlinear pharmacokinetics. It was found that 
many  of  the  highly  hepatic  extracted  drugs  show  dose  dependent  and  time  dependent 
bioavailability. The nonlinearity is  most probably due to  saturation of  metabolism  at  the 
higher plasma concentration (Pond and Tozer, 1984). Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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Table 2.1: Bioavailability, fafg and hepatic excretion ratio (calculated from PK data) and inter-subject variability (CV%).  
((*)values exceeding 100% absorption or negative values)  
   Compound  Number of 
participants / 
Doses(IV/Oral) 
F 
(%) 
CV 
(%) 
Eh 
(%) 
CV  
(%) 
fafg  
(%) 
CV 
(%) 
1  Ciclosporine 
(Hebert et al., 1992) 
N=6 
IV=3mg/kg 
Oral=10 mg/kg   
25.0  38.1  23.2  16.1  32.8  39.8 
  Ciclosporine 
(Gomez et al., 1995) 
N=5 
IV=2 mg/kg  
Oral=8 mg/kg   
22.4  21.3  33.7  26.1  34.7  28.7 
2  Diltiazem  
(Kolle et al., 1983) 
N=6 
IV=20 mg 
tablet= 120mg   
32.6  30.8  53.1  15.3  72.3  35.3 
  Diltiazem  
(Kolle et al., 1983) 
N=6 
IV= 20mg  
Solution=120mg 
43.8  22.3  53.0  15.3  83.8  19.6 
3  Omeprazole 
(Regårdh et al., 1990) 
N=9 
IV=10 mg/kg  
Oral=20 mg/kg   
53.6  61.5  60.9  54.7  259.3* 
105 
(mean 
value) 
97.8* 
4  Felodipine (Edgar 
et al., 1985) 
N=8 
IV=2.5 mg/kg  
Oral=27.5 
mg/kg   
16.2  37.5  80.7  18.9  57.5* 
85 
(mean 
value 
200.1* 
5  Verapamil 
(Freedman et al., 1981) 
N=6 
IV=15 mg  
Oral=80 mg  
23.7  42.8  61.1  13.0  60.6  47.5 
6  Flumazenil 
(Janssen et al., 1989) 
N=8 
IV=2 mg 
Oral=30 mg  
27.8  21.5  74.6  6.7  103.5  1.2 
7  Valproic acid 
(Perucca et al., 1978) 
N=8 
IV=800 mg 
Oral=800 mg   
99.5  9.8  3.0  11.6  102.6  9.9 
8  Labetalol  
(McNeil et al., 1979) 
N=6 
IV=100 mg  
Oral=100 mg  
38.3  67.9  59.4  35.3  160.5*  124.8* 
9  Methadone 
(Meresaar et al., 1981) 
N=8 
IV=10 mg 
Oral=10 mg  
79.1  26.6  12.9  82.1  92.3  28.6 
10  Fluvastatin 
(Lindahl et al., 1996) 
N=9 
IV=2 mg  
Oral=70 mg  
32.6  32.9  69.3  2.7  92  25.1 
11  Prazosin  
(Grannen et al., 1981) 
N=4 
IV=0.5mg/kg  
Oral=0.5 mg/kg   
63.1  20.8  13.3  35.1  73.2  24.4 
12  Erythromycin 
(Somogyi et al., 1995) 
N=4 
IV=250 mg 
Oral=300 mg  
32.0  23.9  12.9  36.2  36.6  21.5 
13  Zidovudine 
(Klecker et al., 1987) 
N=9 
IV=120 mg  
Oral=200 mg 
63.4  20.1  100.1  21.3  347.0*  165.4* 
14  Nitrofurantoin 
(Hoener and Patterson, 
1981) 
N=6 
IV=50 mg 
Oral=50 mg 
86.3  14.5  18.8  23.9  106  13.8 
15  Haloperidol 
(Cheng et al., 1987) 
N=6 
IV=1 mg 
Oral=5 mg 
60.0  29.5  35.5  26.2  95.9  36.0 Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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  Compound  Number of 
participants / 
Doses(IV/Oral) 
F  
(%) 
CV 
(%) 
Eh 
(%) 
CV  
(%) 
fafg  
(%) 
CV 
(%) 
16  Amitriptyline 
(Schulz et al., 1983) 
N=7 
IV=40mg 
Oral=50mg   
47.7  22.9  42.9  22.3  83.2  13.1 
17  Dipyridamole 
(Mahony et al., 1982) 
N=4 
IV=20 mg  
Oral=50 mg 
42.7  30.7  9.3  40.4  47.2  30.8 
18  Midazolam 
(Allonen et al., 1981) 
N=6 
IV=0.075 mg/kg  
Oral=15 mg 
44.0  38.8  33  15.3  67  42.2 
19  Methapyrilene 
(Calandre et al., 1981) 
N=6 
IV=25 mg  
Oral=50 mg 
14.1  69.4  125.4  43.1  -118.2*  -266* 
20  Flunisolide  N=12 
IV=1 mg  
Oral =1 mg 
20.1  93.8  68.5  15.6  53.5  49.8 
21  Nifedipine 
(Kleinbloesem et al., 
1984) 
N=6 
IV=0.075 mg/kg 
Oral=20 mg 
51.3  24  29.5  16.2  72.8  24 
  Nifedipine 
(Kleinbloesem et al., 
1984) 
N=6 
IV=0.075 mg/kg 
Oral=20 mg 
51.3  24  29.5  16.2  73.3  35.1 
  Nifedipine 
(Kleinbloesem et al., 
1986) 
N=7 
IV=4.5 mg  
Oral=20 mg 
51.1  33.50  39.12  23.7  66.8  33.5 
22  Quinidine 
Sulphate 
(Greenblatt et al., 1977) 
 
N=7 
IV=150 mg  
Oral=200 mg 
79.42  18.80  13.55  31.05  92.53  13.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
 
- 41 - 
 
 
Table 2.2: fa and inter-subject variability (calculated from urine and radio-labelled data) 
 
 
 
 
  Compound  Number of 
participants / 
Doses(IV/Oral) 
fa  (%)  CV (%) 
1  Hydrochlorothiazide  
(Beermann and Groschinsky-Grind, 1977) 
N=7 
Oral=25-75 mg 
67.73  23.25 
2  Venlafaxine 
(Howell et al., 1993) 
N=11 
Oral=50 mg 
92.1  8.79 
3  Iothalamate  
(Prueksaritanont and Chiou, 1987) 
N=4 
Oral=800 mg 
1.09  45.87 
4  Ganciclovir 
(Jacobson et al., 1987) 
N=4 
Oral=20 mg/kg 
3  30.1 
5  Practolol  
(Bodem and Chidsey, 1973) 
N=7 
Oral=600 mg 
95  3.16 
6  Phenoxymethylpenicillin  
(Hellstrom et al., 1974) 
N=10 
Oral solution=22 mg 
49  20.41 
7  Vigabatrin  
(Durham et al., 1993) 
N=6 
Oral=1500 mg 
95.4  19.60 
8  Granisetron 
(Clarke et al., 1994) 
N=3 
Oral=200 mg 
97.3  0.92 
9  Ketorolac 
(Mroszczak et al., 1987) 
N=7 
IV=1.7 mg/kg 
Oral=1.7 mg/kg 
99.4  4.12 
10  Nitrendipine 
(Mikus et al., 1987) 
N=7 
IV=2 mg 
Oral=20 mg 
88.38  18.14 
11  Felodipine  
(Edgar et al., 1985) 
N=8 
IV=2.5mg/kg  
Oral=27.5mg/kg   
89.07  4.87 
12  Terbutaline 
(Borgstrom et al., 1989) 
N=7 
IV=0.25 mg  
Oral=5 mg   
73.00  11.10 
13  Bretylium  
(Anderson et al., 1980) 
N=10 
IV=100 mg  
Oral=400 mg   
25.19  40.39 
14  Mercaptoethanesulfonic acid 
(James et al., 1987) 
N=8 
Oral=800 mg   
76.05  21.20 
15  Promethazine 
(Taylor et al., 1983) 
N=7 
IV=12.5 mg  
Oral=25 mg   
83.00  37.92 
16  Salbutamol 
(Goldstein et al., 1987) 
N=7 
IV=0.4 mg  
Oral=4 mg   
96.67  13.69 
17  Mebendazole 
(Dawson et al., 1985) 
N=5 
Oral=100 mg   
100.93  9.01 
18  Metoprolol 
(Regårdh et al., 1974) 
N=5 
Oral=5mg   
96  1.56 
19  Gabapentin 
(Gidal et al., 2000) 
N=50 
Oral=600 mg   
49.3  27.59 
20  Dihydroergotamine 
(Bobik et al., 1981) 
N=6 
IV=0.01 mg/kg  
Oral=0.6 mg/kg   
96.38  2.99 Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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2.2.4.2 fa and Inter-Subject Variability  
 
After excluding negative or exceeding 100% absorption values (marked (*) in Table 2.1), fa 
values  of  38  drugs  were  correlated  against  the  inter-subject  variability  (CV%).  The 
correlation of R
2 =0.41 was obtained (Figure 2.1). The higher correlation (R
2 = 0.63) was 
obtained when  only  fa  estimated  based  on the  radiolabel/urine data  were included in  the 
analysis  (Figure  2.2).  Bioavailability  was  plotted  against  inter-subject  variability  in 
bioavailability for this dataset and a correlation of 0.39 was found (Figure 2.3). For the drugs 
where fa was calculated based on the well stirred model, hepatic excretion ratio (Eh) was 
correlated to the inter-subject variability in bioavailability (Figure 2.4), the R
2 was 0.15. The 
lack of correlation may indicate that for these compounds the factor which contributes to 
inter-subject variability in bioavailability is not only the elimination (first pass effect) but also 
the absorption process. It is important to note that since an individual’s plasma clearance was 
normalised by mean liver blood flow and mean blood to plasma ratio, some aspects of inter- 
subjects variability in elimination (i.e. changes between individuals liver blood flow) are not 
considered in this calculation. Therefore, some of the inter-subject variability shown herein 
might be still related to elimination. In general, it is possible to conclude that there is a 
general trend where low absorption can be associated with high inter-subjects variability in 
absorption considering the small dataset sample size and the limitations in this study. 
 
Figure 2.1: fa vs. inter-subject variability (CV %) Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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Figure 2.2: fa vs. inter-subject variability (CV %) showed as two dataset based on different estimations methods of fa.  
 
 
Figure 2.3: Bioavailability vs. inter-subject variability in bioavailability (CV %).  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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Figure 2.4: Hepatic excretion ratio vs. inter-subject variability in bioavailability (CV%)  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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2.2.4.3 Correlation of Physicochemical Properties to fa and Inter-Subject Variability  
 
It has been recognized that drug solubility/dissolution and gastrointestinal permeability are 
the fundamental parameters controlling the rate and extent of drug absorption (Amidon et al., 
1995). To identify the factors that might affect absorption and inter-subject variability in this 
dataset, a correlation analysis was carried out between different physicochemical properties, 
fa and inter-subject variability. The intrinsic solubility in water at 37˚C was utilised as  a 
measure for solubility for the convenient comparison of all compounds, since measurements 
in simulated fluid media are limited and pH might also have an effect on weak acid/base 
solubility.  Polar  surface  area  (PSA-  square  Angstroms)  and  a  count  of  the  number  of 
hydrogen bond donors (HBD) present in a compound molecule are used to describe passive 
human  Peff  (Winiwarter  et  al.,  2003).  Moreover,  when  no  active  transport  processes  are 
involved,  it  is  expected  that  lipid/water  partition  coefficients  will  correlate  with  drug 
permeability. Further on, Takagi et al. (2006) evaluated the correlation of measured LogP and 
calculated LogP with human jejunal permeability, and showed a correlation in two thirds of 
the  time.  Since  it  is  difficult  to  compare  permeability  results  from  different  published 
experiments and in vivo human jejunal permeability data is limited, PSA, HBD and measured 
LogP were chosen as an indication for permeability.  
 
When plotting the intrinsic solubility and the measured LogP against fa or fa inter-subject 
variability, no correlation was observed (Figure 2.5). It might be related to the fact that these 
physicochemical  factors  might  not  reflect  loyalty  to  the  situation  in  vivo.  As  mentioned 
measured LogP tends to describe better the passive diffusion permeation and the intrinsic 
solubility is a simplification of the real solubility in vivo which depends on pH and bile salts 
composition among other factors that affect solubility in the GI tract. However, when fa was 
plotted against HBD and PSA, a relative trend was observed associated with high absorption 
and low HBD and PSA properties. Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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Figure 2.5: Correlations analysis between the inter-subject variability (CV%) of fa, fa and different physicochemical 
properties  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
 
- 47 - 
 
fa inter-subject variability was plotted against the compounds BCS classification (Figure 2.6). 
Although one would expect that the drugs classified as BCS I will present lower inter-subject 
variability  compared  to  compounds  classified  as  BCS  II,  III,  or  IV,  similar  inter-subject 
variability  was  observed  among  all  classifications.  A  possible  explanation  to  the  high 
variability  found  for  some  BCS  I  compounds  might  be  related  to  the  fact  that  the  BCS 
classification  definition  is  based  on  the  extent  of  permeability  and  does  not  take  into 
consideration the rate of permeation through the membrane which might be important even 
for some highly permeable compounds. A more statistical explanation might be related to the 
number of subjects that were included in the analysis. In order to understand variability, a 
large number of subjects are required to identify trends. This study’s limitations included 
relatively low number of subjects in each clinical trial (4-10 subjects) and a limited number 
of compounds. Therefore, the ability to observe any trend is limited and any conclusion from 
this research needs to be considered in the light of these limitations.  
 
 
Figure 2.6: BCS classification vs. inter-subject variability in fa Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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2.2.5  Summary  
 
Estimation of fa and inter-subject variability were carried out based on acceptable methods 
from published clinical trials in healthy subjects. However, it can be concluded that due to 
scarce  published  data,  it  is  challenging  to  estimate  fa  from  human  in  vivo  data  alone. 
Therefore,  it  is  understandable  why  many  scientists  made  assumptions  to  simplify  fa 
estimation. An attempt to identify the factors affecting low and erratic fa was not successful 
and might be related to the quality of the chosen parameters to reflect the absorption process 
in vivo. The limitations in this study included; the use of mean values for some parameters to 
calculate individuals’ fa values, the low number of subjects involved in each clinical trial (4-
10 subjects) and the low number of compounds in the analysis (40).  
 
Based on the results found herein, it was decided to utilise larger dataset of subjects (clinical 
trials from phase 1 studies which included 30-50 subjects) to estimate fa and its’ inter-subject 
variability. A population pharmacokinetics approach (as implemented in NONMEM) was 
further employed.  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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2.3  Estimation of fa and Inter-Subject Variability Using Population 
Pharmacokinetics  
2.3.1  Introduction 
2.3.1.1 Population Pharmacokinetics (popPK) 
 
The idea of popPK models based on preclinical and available clinical data were extensively 
developed and implemented in the process of drug development. In the early stages of drug 
development,  these  models  have  been  used  as  a  significant  tool  in  selecting  promising 
compounds and identifying safe and effective doses and dose regimen. In later clinical phases 
of full development, mechanistic models have been proposed to characterize drug absorption, 
taking into account different processes in drug absorption.  The description of the variability 
in drug absorption may become more important, for evaluation of safety and efficacy and 
differentiation between formulations performance (Miller et al., 2005).  
 
2.3.1.2 NONMEM 
 
When analysing clinical pharmacokinetic data (drug plasma concentrations), it is common to 
use non-linear mixed-effect modelling, the so-called population approach. This led to the 
development  of  software  tools,  NONMEM  (NONlinear  Mixed  Effects  Modelling),  with 
further applications among the pharmaceutical and clinical pharmacology communities (Beal 
and  Sheiner,  1980).    The  advantage  of  this  modelling  approach  is  the  improvement  in 
underlying effects in drug performance which is important in understanding variability in 
population. The term population pharmacokinetics does not only refer to the mean value but 
also  takes  into  consideration  each  individual  and  his  contribution  to  the  mean  value. 
Therefore, this software can handle a large data set of subjects alongside with sparse data. 
Some of NONMEM applications are: analysis of PK data (either sparse PK data from early 
stages  of  drug  development  or  extensively  sampled  PK  data  from  phase  I  studies), 
investigation  of  pharmacokinetics-  pharmacodynamics  relationships,  use  of  explanatory 
model-based  analysis,  for  instance,  analysis  that  estimate  the  quantitative  relationship 
between  inputs  (e.g.  drug  dose  and  time,  patient  characteristics,  stage  of  disease)  and 
outcomes (e.g. biomarkers or observable clinical measures) according to some mechanistic 
views of the relationship (Pillai et al., 2005). Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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The process of finding the optimal model includes four major steps: model definition, model 
fit, model diagnostics and model evaluation. NONMEM is a tool for building mathematical 
model  of  this  underlying  process  using  several  building  blocks.  The  basic  block  is  the 
structural  model.  An  example  of  collected  data  includes  the  measurement  of  the  plasma 
concentration over time. Inferences from the data are drawn and summarized in terms of 
estimated model parameters, such as drug clearance (CL). Another important component of 
the model is variability. Therefore, parameters of the model are treated as distributions, rather 
than  single  values.  This  is  the  second  building  block  called  “random  effects  (the 
measurements “noise”). In biological data, there are two sources of random variability which 
are  quantified  in  mixed  effect  analysis:  variability  between  different  individuals  –  inter-
individual  variability  (IIV)  and  residual  variability  (RV).  Inter-individual  variability  is 
considered at the level of the model parameter and the residual variability is at the level of the 
observed data point and includes noise due to measurement error, erroneous data records, and 
changes in individual biology over time, or error due to model misspecification. Often, if the 
drug was studied on different study occasions, variability between these occasions may also 
be quantified (inter-occasion variability IOV).  
 
The known, observable properties of individuals (covariates i.e. age, weight and etc...) that 
cause the descriptors to vary across the population are the fixed effects whereas the random 
effects  cannot  be  predicted  in  advance.  Modelling  population  pharmacokinetics  as 
implemented in NONMEM allows scientists to recognize the sources of variability, such as 
inter-subject, intra-subject, and inter-occasion and it can be used to explain variability by 
identifying factors of demographic, pathophysiologic, environmental, or drug-related origin 
that may influence the pharmacokinetic behaviour of a drug. Moreover, it can quantitatively 
estimate the magnitude of the unexplained part of the variability in the patient population 
(Ette and Williams, 2004). 
 
One of the more difficult tasks for a modeller is to find an appropriate structural description 
of  drug  absorption,  as  the  population  pharmacokinetic  modelling  approach  should  be 
executed while taking into account the physicochemical properties of a drug, the physiology 
of the subject and the variability of all the different mechanisms of absorption. The traditional 
models used to describe the absorption process are simple and include a parameter describing 
the absorption rate (first or zero order absorption rate constant), bioavailability and usually a 
lag time parameter characterizing any potential absorption delay. Some of the limitations in Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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developing  an  absorption  model  are  the  design  and  execution  of  studies  that  will  allow 
precise  characterization  of  drug  absorption.  Given  the  importance  of  characterizing 
absorption, more effort should be expended on developing these models. 
 
Due to the limitations in estimating fa and its inter-subject variability in the previous section, 
it has been decided to explore AstraZeneca (AZ) compounds database to identify different 
compounds  with  several  phase  1  clinical  studies  to  calculate  fa  utilising  the  population 
pharmacokinetics  approach.  The  population  approach  allows  the  determination  of  the 
magnitude of inter-subject (individuals) variability and can handle large numbers of subjects 
than  presented  in  one  single  phase  1  study.  The  well-stirred  model  was  implemented  in 
NONMEM  to  estimate  fa*fg  (absorption)  instead  of  bioavailability.  The  population 
pharmacokinetics of 4 AZ compounds with different reported bio-availabilities was tested by 
the simultaneous fitting of data from different drug formulations, including oral solution, 
immediate-release  (IR)  formulations,  extended-release  (ER)  and  prolonged  release  (PR) 
formulations.  
 
The purpose of this investigation was to obtain an accurate estimation of fa*fg from plasma 
concentration vs. time data and therefore only parameters that characterise first pass and renal 
elimination were included in the model building (i.e. liver blood flow, blood to plasma ratio 
and renal clearance). Moreover, within this study, fa*fg was estimated without incorporating 
in vitro permeability data of gut wall metabolism; therefore, whenever the concept absorption 
is  mentioned,  it  refers  to  the  fraction  absorbed  and  the  fraction  that  escaped  gut  wall 
metabolism. 
 
2.3.2  Objectives 
 
•  To develop a population pharmacokinetic model to estimate fa*fg and inter-subject 
variability (NONMEM). 
•   To  estimate  fa*fg  of  different  compounds  to  understand  formulation  effect  on 
absorption and inter-subject variability. 
•  To  investigate  the  rate  limiting  step  in  absorption  by  comparison  fa*fg  from  oral 
solution and solid dosage forms administrations. 
•   To estimate fa*fg to investigate food effect on absorption and inter-subject variability. Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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2.3.3  Methods 
2.3.3.1 Data  
 
Four AZ compounds with low (AZD7009), intermediate (AZD1305 and AZD0865) and high 
(AZD242)  bioavailability  were identified from the AstraZeneca  compounds database. All 
datasets were phase 1 studies performed in healthy volunteers, conducted in accordance with 
the  Declaration  of  Helsinki,  which  were  compliant  with  the  International  Conference  on 
Harmonisation (ICH)/Good Clinical Practice (GCP) and regulatory requirements, and also 
the  AstraZeneca  policy  on  Bioethics.  Compound  selection  was  based  on  availability  of 
intravenous data and differing physicochemical and pharmacokinetic properties. Compound 
physicochemical  properties  and  pharmacokinetic  parameters  based  on  non-compartmental 
analysis are specified in Table 2.3 and Table 2.4 (Data on files from AstraZeneca). 
 
In addition to the intravenous data, clinical trials which investigated different formulations 
under different conditions were incorporated in the analysis and fa*fg was estimated for the 
oral  solution  and  different  formulation.  The  clinical  trials,  administered  doses  and 
formulations’ description are detailed in Appendix 1. 
 
Table 2.3: Compounds pharmacokinetics parameters based on the non-compartmental analysis (Data on files from 
AstraZeneca). 
Properties  AZD0865  AZD242  AZD7009  AZD1305 
Bioavailability (%) 
± SD (CV%) 
57.1±12.2 
(22.2%) 
103±4 
(4.4%) 
15.5±4 
(25.8%) 
32±10 
(30%) 
Plasma Clearance 
(L/h)  
3.8  0.16  213  34-57 
Renal clearance 
(L/h) 
0.11  0.03  12  5.4 
Distribution 
volume  (L) 
27  9  19.7  152-344 
Blood to plasma 
ratio 
0.625  0.7  1  0.93 Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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Table 2.4: Compounds physicochemical properties Data on files from AstraZeneca). 
  AZD0865  AZD242  AZD7009  AZD1305 
MW 
(g/mol) 
366.4  408.5  446.5  434.5 
Solubility   Solubility in 
water (pH=8), 
FaSSIF (pH=6.5), 
SGF (pH=1.7) 
and human 
intestinal fluids 
(pH=6.9), are 
0.003, 0.006, 3.05 
and 0.005 mg/mL 
respectively. Salt 
solubility in water 
is approx. 0.35 
mg/mL.  
Ranged from 
0.02 mg/ml at pH 
2.5 to 86 mg/ml 
at pH 7.2. 
0.2, 9 and 50 
mg/mL in water 
(pH=9.8), 
phosphate buffer 
(pH= 7.7) and 
0.1M HCl 
(pH=1.2) 
respectively. 
3.1, 3.1 and 0.56 
mg/mL at pH 9, 7 
and 5, respectively 
 
pka  6.1  3.7  9.7  9.9 
Partition 
coefficient  
log KD  
4.2  2.8  3  2.5 
.  
 
2.3.3.2  Model Building  
 
Population  pharmacokinetic model building was undertaken using NONMEM  VII  (V-12, 
Icon plc). Individuals’ plasma concentration vs. time profiles, from different clinical trials of 
the same formulation were pooled to form a single dataset, with mass units expressed in 
nanomoles. The covariates available for all datasets were age, height, weight and body mass 
index  (BMI).  Raw  plots  of  plasma  drug  concentration  vs.  time  were  generated  using  R 
software (Version R-3.1.1, available on http://www.r-project.org/) and inspected for possible 
trends in the structural models. Disposition of each compound was determined by modelling 
the  intravenous  data  alone.  One-,  two-,  three-  and  four-compartment  models  with  linear 
intrinsic hepatic clearance (CLi) were tested. The  IV data were analysed with  first-order 
conditional  estimation  (FOCE)  plus  interaction  (between  inter-individual  and  residual 
variability). For the IV data analysis, the ADVAN7 TRANS1 subroutine in NONMEM was 
used. Once an adequate structural model was identified, the disposition parameters were then 
fixed,  based  on  the  assumption  that  the  disposition  parameters  would  remain  unchanged 
when the oral dose is administered. Additional (e.g. oral) data from each formulation were 
pooled with the intravenous data, and the absorption model was developed.  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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For  the  fa*fg  estimation  the  following  equations  were  included  in  NONMEM  coding 
(presented in Appendix 1).Within NONMEM hepatic clearance was calculated based on the 
intrinsic  clearance.  The  following  equations  were  included  in  NONMEM  coding.  Liver 
volume (LV) is associated to the subject weight as indicated by Price et al. (2003)):  
 
 
Equation 2.5: Liver volume based on publication from Price et al. (2003) normalised by weight  
 
Liver blood flow (Qh) in males in was reported as 50.4 L/h the blood/plasma ratio was used to 
take into account the total blood to total plasma drug concentration ratio (BPR) (Equation 
2.6): 
 
Equation 2.6:  Liver blood flow  
 
Calculation of clearance hepatic was based on the intrinsic clearance (CLi), and liver blood 
flow (Equation 2.7)  
 
Equation 2.7: Clearance hepatic calculation based on intrinsic clearance 
 
Allometric weight scaling was added to renal clearance fixed effects a priori, standardized to 
a body weight of 70 kg according to the following relationships Equation 2.8 (Holford, 
1996). 
 
 
 
 
Equation 2.8: Renal clearance normalised by weight  
 
The entrohepatic circulation (ER) was calculated based on the intrinsic hepatic clearance 
(CLi) and liver blood flow (FQ) (Equation 2.9) and was further utilised to estimate fa*fg 
based on bioavailability (F1) NONMEM estimation  (Equation 2.10): 
 
Equation 2.9: Entrohepatic circulation 
 
 
Equation 2.10: Calculation of fa*fg based on the well stirred model  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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For this NONMEM analysis, the ADVAN5 TRANS1 subroutine was used. Inter individual 
variability for different PK parameters was estimated using an exponential model (log normal 
model), except for the fa*fg, where a Logit transformation was used to ensure the individual 
estimate  remained  between  0  and  1  and  to  reduce  potential  numerical  instability  during 
computation. Inter individual variability was added in a step-wise fashion, firstly to clearance 
and volume parameters, and then to absorption parameters. Proportional and mixed additive 
models were tested for residual error. 
 
A  Lag-time or a discrete number of transit compartments were utilised in the absorption 
model,  to  mimic  more  closely  the  in  vivo  absorption  process.  Transit  compartments  for 
administration of the solid dosage formulations were used to mimic a delay in absorption 
onset and a gradual increase in absorption rate in a more physiological manner while lag time 
offered a good fit in the case of oral solution administration. Drug transfer from the final 
transit compartment to the central compartment occurred through an absorption compartment, 
from which the drug was absorbed according to the first-order rate constant ka. The optimal 
number of transit compartments (n) was estimated and chosen based on the lowest OFV 
(objective function value) (Figure 2.7). 
 
 
 
Figure 2.7: Structural model used in NONMEM.  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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2.3.3.3 Pharmacokinetic Model Evaluation  
 
Model selection was  achieved by observing successful  convergence,  use of the objective 
function value (OFV- an objective function value is the sum of squared deviations between 
the predictions and the observations. In NONMEM, the objective function is -2 times the log 
of  the  likelihood.  A  difference  in  objective  function  value  of  3.84  is  considered  to  be 
significant  at  p<0.05  with  one  degree  of  freedom,  based  on  chi  squared  distribution); 
successful covariance step (estimations of RSE values), by examination of relative standard 
error values and goodness-of-fit plots (prediction vs. observations, and plots of residuals vs. 
population  prediction  and  time).  Xpose  (Version  4.0)  and  R  based  model  building  aid 
(Version  3.1.1)  were  used  for  the  graphical  goodness-of-fit-analysis.  A  visual  predictive 
check (VPC’s) was employed to characterize the model’s simulation properties. The final 
model was used to simulate 1000 new datasets, based on the design of the original dataset. 
For each of the original data points, a 95% prediction interval was obtained by extracting the 
2.5% and 97.5% percentiles of their simulated distributions. These were then plotted against 
the observations using PsN (Version 3.5.3) and Xpose (version 4.0). The software tool Perl-
speaks-NONMEM was used to run a nonparametric bootstrap of 200 iterations to provide 
unbiased estimates of the standard errors and the 95% confidence intervals of the estimated 
parameters.  
 
2.3.3.4 CV Calculations  
 
Simulations of the model using R software in 1000 subjects were carried out to estimate 
variance from the model, the square root of the variance being the standard deviation. The 
coefficient of variation (CV%) was then calculated by dividing the standard deviation in the 
mean value. Moreover, the nonparametric test, bootstrap, was used to confirm the 5-95% CI 
(confident interval).  The terms high and low variability refer to distributions that have high 
and  low  coefficients  of  variation,  respectively.  Typically,  a  coefficient  of  variation  of  a 
pharmacokinetic parameter of 10% or less is considered low, 25% is moderate, and above 
40% is high (Rowland and Tozer, 2011). Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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2.3.4  Results & Discussion  
 
In this investigation, the well stirred model was successfully implemented in NONMEM to 
focus on the drug absorption, and not the overall bioavailability. The advantage of using 
pooled data in NONMEM enabled the estimation of population variability in absorption. The 
disposition  parameters  (The  intrinsic  clearance  (CLi),  volume  of  distribution  (V)  of  the 
central compartments and similar parameters for the peripheral compartments are presented 
in  Table  2.5).  fa*fg,  the  absorption  rate  constant  (ka),  lag  time  or  transit  time  were  also 
estimated (Table 2.6, Table 2.7, Table 2.8 and Table 2.9). 
 
The  best  fit  for  the  disposition  model  for  all  four  compounds  was  achieved  with  three 
compartment disposition model. For AZD0865, AZD242, AZD1305 and AZD7009, the OFV 
decreased by 51, 35, 79 and 167 units respectively, when moving from a two compartment 
model analysis to a three compartment fit. A successful covariance step was obtained for all 
structural models.  When a four compartment model was assessed for all compounds, either 
the covariance step was unsuccessful, or the OFV increased, which can both indicate model 
misspecification. Reasonable goodness-to-fit  plots  were achieved where  the lack of trend 
indicates  that  the  structural  model  adequately  described  the  data  at  all-time  points.  The 
goodness-to-fit plots and VPC’s plots are presented in Appendix 1.  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
 
- 58 - 
 
Table 2.5: Disposition parameter based on IV administration 
 
 
 
Table 2.6 : fa*fg   and ka estimations of AZD0865 formulations 
 
   Model 
Parameter  
AZD0865  AZD242  AZD1305  AZD7009 
Fixed effects (θ) 
(% RSE) 
Intrinsic CL 
(L/h) 
3.99 (7%)  0.16 (10%)  55.7 (9%)  282 (41%) 
Volume (L)  8.59 (10%)  4.09 (9%)  45.3 (26%)  19.7 (27%) 
Q1(L/h)  28.9 (18%)  0.436 (36%)  9.89 (26%)  132 (14%) 
V1 (L)  9.35 (10%)  5.09 (13%)  99.9 (11%)  123 (9%) 
Q2(L/h)  0.437 (18%)  0.543 (25%)  204 (11%)  19.3 (7%) 
V2 (L)  9.65 (35%)  1.54 (27%)  128 (5%)  236 (5%) 
Inter-individual 
variability (Ω)  
(% RSE) 
Intrinsic CL 
(L/h) 
21.4% (24%)  26.2% (27%)  29.3% (24%)  102% (41%) 
Volume (L)  27.3% (27%)  21.4% (22%)  77.7% (33%)  56.4% (19%) 
Q1(L/h)  37.7% (39%)  13.4% (33%)  54.9% (33%)  37.7% (22%) 
V1 (L)   26.2% (29%)  8.9% (25%)  25% (33%)  22.3% (25%) 
Q2(L/h)  45.1% (23%)  29.4% (26%)  11% (55%)  0 FIXED 
V2 (L)  71.1% (16%)     42.3% (6%)  0 FIXED  0 FIXED 
Residual error 
(Σ) (% RSE) 
 
Variance 
 
 0.0066 (8%)  0.00244 (24%)  0.0226 (6%)  0.0185 (8%) 
Additive  105 (18%)  1.6 (134%)  0  0 
  Model 
Parameter 
Oral 
solution 
IR tablet in 
the base 
form 
IR tablet in 
the salt form 
IR tablet in 
the base 
form 
IR tablet in 
the salt form 
Fixed effects (θ) 
(% RSE) 
Normal gastric pH  Elevated gastric  pH 
ka (h
-1)  2.59 (7%)  3.24 (21%)  2.49 (9%)  0.624 (14%)  2.53 (18%) 
fa*fg  (%)  60.8 (15%)  58.2 (40%)  68 (10%)  16 (8%)  29 (12%) 
Lag time/ 
KTR (min) 
0.198 (2%)  38.3 (10%)  23.1 (7%) 
 
14.7 (12%)  42.4 (12%) 
Inter-individual 
variability (Ω)  
(% RSE) 
ka (%)  21.2% (13%)  49.1% (33%)  85.7% (11%)  36.5% (32%)  65.8%  
(23%) 
fa*fg  (%)  40.2% (14%)  34.8% (30%)  42.8% (17%)  45.7% (23%)  36.6% (23%) 
Lag time/ 
KTR (%) 
13.9% (15%)  35.6% (18%)  58.1% (13%)  0 FIX  39% (30%) 
Residual error 
(Σ) (% RSE) 
 
Variance  0.018 (2%)  0.001 (15%)  0.062 (8%)  0.01 FIX  0.001 (48%) 
Additive  60.4 (9%)  88.6 (26%)  949 (24%)  25000 (7%)  28200 (9%) Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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Table 2.7: fa*fg   and ka estimations of AZD242 formulations 
  Parameter  Oral solution 
Fixed effects  
(θ) (% RSE) 
ka (h
-1)  10 (34%) 
fa*fg  (%)  98.5 (29%) 
Lag time/ KTR (min)  0.179 (12%) 
Inter-individual 
variability (Ω) (% 
RSE) 
ka (%)  59.7% (35%) 
fa*fg  (%)  30.8% (45%) 
Lag time/ KTR (%)  11.4% (78%) 
Residual error (Σ) 
(% RSE) 
Variance 
 
0.0112 (5%) 
Additive  2.69 (25%) 
 
 
 
 
Table 2.8: fa*fg   and ka estimations of AZD1305 formulations 
  Model 
Parameter 
Oral solution 
fast 
Oral 
solution fast 
Oral solution 
fed 
ER 
formulation 
fast 
ER 
formulation 
fed 
Fixed effects (θ) 
(% RSE) 
ka (h
-1)  1.42(12%)  1.6 (8%)  0.965 (6%)  0.165 (10%)  0.278 (15%) 
fa*fg  (%)  63 (35%)  60 (43%)  77 (24%)  71.3(30%)  71.1 (28%) 
Lag time/ 
KTR 
(min) 
0.15 (1%)  0.24 (4%)  0.22 (4%)  0.46 (10%)  0.43 (12%) 
Inter-individual 
variability (Ω)  
(% RSE) 
ka (%)  60% (13%)  51.2% (9%)  38.1% (18%)  41.3% (23%)  60.5% (20%) 
fa*fg  (%)  102% (16%)  90.8% (15%)  122.5% (19%)  101.5% (23%)  100.5% (24%) 
Lag time/ 
KTR (%) 
0 FIX  26.2% (17%)  28.5% (20%)  51.9% (15%)  53.8% (17%) 
Residual error 
(Σ) (% RSE) 
 
Variance  0.062 (2%)  0.0174 (5%)  0.0179 (5%)  0.093 (4%)  0.123 (4%) 
 
 
 
 
Table 2.9: fa*fg   and ka estimations of AZD7009 formulations 
  Model Parameter  Oral solution   PR tablet 
Fixed effects  
(θ) (% RSE) 
ka (h
-1)  1.6 (10%)  0.0452 (7%) 
fa*fg  (%)  33 (20%)  60 (92%) 
Lag time/ KTR (min)  0.157 (1%)  4.95 (15%) 
Inter-individual 
variability  
(Ω) (% RSE) 
ka (%)  60.2% (15%)  60.7% (9%) 
fa*fg  (%)  64.8% (21%)  0 FIXED 
Lag time/ KTR (%)  0 FIX  157.5% (12%) 
Residual error  
(Σ) (% RSE) 
Variance  0.101 (3%)  0.118 (2%) 
ka (h
-1)  46.3 (8%)  0 Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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Lag-time estimation was carried out for the oral solution data, and appeared to improve the fit 
for all oral solution formulations (decrease of 911, 702, 462 and 407 units in the OFV for 
AZD0865, AZD242, AZD1305, AZD7009, respectively). For AZD0865, two different IR 
tablets were given as the base form and the salt form of the drug. For the IR tablet in the base 
form and in the salt form, it was found that the 13 and 8 transit compartments improved the 
model  fit.  The  same  formulations  were  administered  with  elevated  gastric  pH  after  IV 
administration of 80mg omeprazole. For these data sets, 4 and 10 transit compartments for 
the base and the salt form in elevated gastric pH gave the best model fit. The food effect for 
AZD1305 pharmacokinetics was investigated when an oral solution and an ER formulation 
were given. 2 compartments and 1 compartment transit increased the model fit by a decrease 
in  OFV  for  ER  tablet  under  fasted  and  fed  conditions.  The  addition  of  one  transit 
compartment for AZD7009 PR formulation yielded a decrease in OFV compared to the lag 
time. 
 
 The goodness of fit plots all solid dosage formulation presented in Appendix 1. It can be 
seen that for some compounds (AZD242 and AZD0865) there is a trend in the CWERS plots 
vs. time in late time points (after 24h). This might be attributed to the long elimination phase 
of the drug due to the very low clearance of the drug. However, since the focus of this 
research is in the absorption phase alone, the model fit was reasonably accepted (when data 
points after 24h were ignored a reasonable goodness of fit was accepted).  
 
The visual predictive check for all compounds presented in Appendix 1, indicates that the 
final model was able to simulate data with a similar distribution to the observed data. The 
VPC is showing the median, 5
th, 50
th and 95
th s of the observations lie within the 95% CI of 
model simulation. 
 
The software tool Perl-speaks-NONMEM was used to run a nonparametric bootstrap of 200 
iterations  to  provide  unbiased  estimates  of  the  standard  errors  and  the  95%  confidence 
intervals of the estimated parameters. The median and 5-95% CI values are presented in 
Table 2.10.  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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Table 2.10: Bootstraps results for fa*fg    
Compound     fa*fg (%)  Bootstrap - 
fa*fg 
(%)median  
Bootstrap  
5-95% CI 
AZD0865 
Normal gastric 
pH 
Oral solution   60.8%  61%  57.9-65.2% 
IR tablet in the 
base form 
58%  57.5%  51.4-65% 
IR tablet in the 
salt form 
73%  68%  65-70% 
Elevated 
gastric pH 
IR tablet in the 
base form 
15.7%  15.7%  12.5-20.8% 
IR tablet in the 
salt form 
28.5%  28.1%  23.7-32.4% 
AZD242  Oral solution   99%  100%  92-100% 
AZD1305  Oral solution 
fasted state 
60%  60.9%  52-67% 
Oral solution 
fed  state 
77%  77%  69-85% 
ER fasted state  71%  73%  60-84% 
ER fed state  71%  68%  61-76% 
AZD7009  Oral solution   33%  33.5%  27.3-39.7% 
PR tablet  57%  53%  48-60% 
 
 
 
 
Table 2.11: CV% estimations for fa*fg   based on simulations for AZD compounds  
Compound   Formulation   CV% Based on 
simulations 
AZD0865   
Normal gastric   pH 
Oral solution   15% 
IR tablet in the base form  14.2% 
IR tablet in the salt form  13.5% 
AZD0865   
Elevated  gastric pH 
IR tablet in the base form  38% 
  IR tablet in the salt form  25% 
AZD242  Oral solution   9% 
AZD1305  Oral solution fasted state  33% 
Oral solution fed  state  28% 
ER fasted state  30% 
ER fed state  27% 
AZD7009  Oral solution   39.3% 
PR tablet  N/A 
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AZD242 
 
AZD242 was chosen as a control drug based on the assumption of 100% absorption and low 
inter-subject variability, to confirm that the fa*fg  values generated by NONMEM with the 
fitted “well-stirred” model equations are valid. The absorption rate constant was high for oral 
solution, indicating fast absorption. 100% absorption was estimated for the oral solution with 
short lag time. With regards to variability, NONMEM assessed relatively low inter-subject 
variability  (9%).  This  emphasises  the  fact  that  high  absorption  is  associated  with  low 
variability. 
AZD0865 
 
AZD0865 is a weak base with a pka of 6.5. Based on the in vitro studies,  it is expected that 
AZD0865 solubility would be highly dependent on the gastrointestinal pH, and therefore 
drug  precipitation  might  occur  as  a  consequence  of  the  pH  increase  from  acidic  in  the 
stomach (especially in the fasted state) to near-neutral in the small intestine (Carlert et al., 
2010).  
 
The oral solution bioavailability was reported to be 55%. Based on the results of the fa*fg 
estimation for the oral solution, fh is around 90%, indicating low hepatic extraction; therefore, 
the relatively low bioavailability can be attributed to absorption (60%). A relatively low inter-
subject variability for the oral solution of 15% was estimated (CV %). Absorption decreased 
slightly when the drug was administered as the base form, and increased as the salt form. For 
all formulations the fa*fg    inter-subject variability was similar.  When the drug was given 
after administration of omeprazole for both IR formulations, a significant decrease in the 
absorption was observed (15% and 30% for the base and the salt form, respectively- Figure 
2.8). In addition, an increase in inter-subject variability was observed.  
 
To identify the rate limiting step in absorption there is a need to compare the oral solution to 
the solid dosage form formulation. In the case of AZD0865, fa*fg from the base form did not 
differ from the oral solution. At first, it would appear that permeability is the rate-limiting 
step, given that the solution and solid dosage form in the base form gave similar fa*fg   values. 
However, an increase in fa*fg  for the salt tablet was observed. Therefore, it can be assumed 
that the absorption is solubility/dissolution rate-limiting. Salt formation is the first and the 
most common approach to increase drug solubility in the pharmaceutical industry (Kawabata Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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et al., 2011; Korn and Balbach, 2014)). In the case of AZD0865, mesylate as a crystalline 
powder was developed to overcome the solubility issue. In addition, the permeability data 
from in vitro studies in Caco-2 cells (AstraZeneca data on file) indicate that AZD0865 is a 
highly permeable drug.  
 
Considering the dose and the high solubility of the drug in the gastric fluids, it is reasonable 
to  assume  that  for  all  dosage  forms,  a  complete  dissolution  in  the  stomach  occurred. 
However, with stomach emptying, the drug from either solution or tablets can precipitate, and 
low dissolution occurs in the small intestine. It seems that the salt  IR tablet managed to 
minimize this effect, and yielded a super-saturated state for a longer period of time to allow 
higher absorption. To emphasise that, fa*fg of the IR tablet in the base form decreased by 
more than half under elevated gastric pH.  A lower decrease was attained for the salt form, 
with twice the extent of fa*fg compared to the base form. This indicates that gastric pH plays 
an important role in drug absorption. A median gastric pH of 5.8 was expected based on a 
study with the same omeprazole regimen (Röhss et al., 2007). At elevated gastric pH, the 
AZD0865 solubility in the gastric fluid is low, and almost all the drug would be emptied into 
the  duodenum  from  the  stomach  in  the  undissolved  form.  Both  the  rate  and  extent  of 
absorption are therefore limited by intestinal drug dissolution.  
 
 A separation of the fraction that escapes gut wall metabolism (fg) from the fraction absorbed 
(fa) was not made in this investigation. However, based on clinical studies where AZD0865 
was  administered  with  grapefruit  juice,  and  which  did  not  seem  to  affect  the 
pharmacokinetics of AZD0865, this indicates that metabolism by CYP 3A4/3A5 in the gut is 
of minor importance for the pharmacokinetics of AZD0865.  
 
The inter-subject variability estimated herein was similar for all formulations around 15%, 
and increased under elevated gastric pH conditions. The increase in solubility of the drug 
using the salt formation did not affect the inter-subject variability. It might be attributed to the 
slight increase in absorption (only 10%) when the drug was administered in the salt form. In 
the  case  of  elevated  gastric  pH,  the  differences  in  gastric  pH  due  to  omeprazole 
administration can explain the increase in variability. 
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Figure 2.8: fa*fg values of AZD0865 
 
AZD7009 
 
AZD7009 is a weak base (pka=9.7), and as such its solubility in aqueous solutions is pH 
dependent, and increases with a decrease in pH. The oral bioavailability is 16%; Cmax varied 
between 16-62% in the single dose- escalating study. 
 
The absorption rate was faster in the case of the solution compared to the PR formulation (3.2 
and 0.04 h
-1) respectively, with higher inter-subject variability in the solution absorption rate 
than in the solid dosage form. The solution lag time was shorter compared to the transit time 
for the PR tablet with high inter-subject variability in transit time for the PR formulation. 
Low fa*fg was estimated for the oral solution with high inter-subject variability whereas the 
fa*fg  for  the  PR  tablet  increased  to  60%  (Figure  2.9).  The  low  fa*fg  after  oral  solution 
administration (30%) indicates fh is around 50%. Therefore,   the low bioavailability (16%) in 
the  case  of  the  solution  dosage  form  can  be  attributed  to  both  absorption  and  hepatic 
elimination. Solubility or dissolution should not be the rate-limiting step for this compound, 
as its pka is higher than the gastrointestinal pH range. The increase in  fa*fg   for the PR 
formulation might indicate a possible stability issue for the drug in the upper part of the 
gastrointestinal tract. Allowing for a low dissolution rate in the upper part of the gut will Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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enable more of the drug to reach the lower parts of the gut, thus prolonging absorption. 
However, no in vitro stability data were found to support this hypothesis.  
 
The fact that in the upper part of the gut the drug might be more susceptible to gut wall 
metabolism can be ruled out based on clinical trial data that showed that no effect on drug 
pharmacokinetics when co-administered with the P-gp inhibitor verapamil (AstraZeneca data 
files).  
 
Figure 2.9: fa*fg values for AZD7009 Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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AZD1305 
 
AZD1305 is a base with pka of 9.9. The solubility is pH-dependent, and increases at pH 
below 9.9. The permeability data from in vitro studies in Caco-2 cells (AstraZeneca data on 
file) indicate that AZD1305 is a highly-permeable drug. The absolute bioavailability for the 
oral solution and the ER formulation ranged from 31 to 50% and 22 to 61%, respectively.  
 
The  ka  value  for  the  oral  solution  was  relatively  high  compared  to  the  ER  formulation, 
indicating  a  slow  release  of  the  drug  from  the  tablet  matrix  in  the  GI  tract,  and  slow 
absorption. It can be seen that the inter-subject variability in the rate of absorption was higher 
in the case of the solid dosage forms as compared to the solution, which might be attributed 
to  the  differences  in  the  disintegration  and  dissolution  of  the  drug  resulting  from  the 
difference between individual GI physiology. The oral solution fa*fg   in the fasted state was 
estimated as 60% and increased in the fed state (77%). Comparing the ER formulation and 
the solution in the fasted state, it can be seen that absorption increased by 10%. In addition, 
no food effect was observed for the ER formulation (71% vs. 68% under fast and fed states 
respectively) (Figure 2.10). Interestingly, inter-subject variability was high for both the oral 
solution and the ER tablet under the fasted and fed states (greater than 30%). 
 
The physiology of the gastrointestinal tract changes in the fed state, and may consequently 
affect drug absorption. The remarkable changes in the stomach under the fed state notably 
include a rise in gastric pH thanks to buffering and dilution effects, along with an increase in 
the gastric fluid volume and a decrease in gastric emptying time. In the small intestine, an 
increase in bile salt concentration, decrease in fluid volumes and in some cases inhibition of 
CYP enzymes and efflux transporters are expected (Varum et al., 2013). Since AZD1305 is a 
free base with pka of 9.9, it would be expected to have high solubility in the gastric fluids, 
and its solubility should not decrease significantly in the administered clinical dose in the 
intestine in the fed or the fasted state. However, degradation of the drug in low pH conditions 
might explain the increased absorption under fed state. In vitro studies have shown support 
for this hypothesis (Sigfridsson et al., 2012).  In the fed state, both the elevated gastric pH 
and the low retention time in the stomach might contribute to the drug stability, and therefore 
more drug arriving to the small intestine that is available for absorption. In addition, it might 
be that an increase in bile salt concentration and gastric fluid volumes might have a positive 
food effect on the drug absorption under fed conditions. The food effect vanished when the Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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extended release formulation was given under both fed and fasted states. Thanks to a slower 
dissolution in the stomach, less of the drug is deemed susceptible to degradation in the acidic 
conditions of the stomach, and more available to be absorbed in the small intestine.  
 
High inter-subject variability can be attributed to the absorption process for all formulations 
(CV=35%).  Although  a  positive  food  effect  caused  an  increase  in  fa*fg  in  the  fed  state, 
formulating  the  drug  as  an  extended-release  tablet  did  not  improve  the  inter-subject 
variability  either  in  the  fasted  or  fed  states.  It  might  be  that  the  drug  stability  differs 
significantly between individuals, even in the lower parts of the GI tract, due to differences in 
the pH in the small intestine.  
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2.3.5  Summary  
 
The well stirred model was successfully implemented in NONMEM to estimate population 
absorption.  Estimations  of  fa*fg  and  inter-  subject  variability  were  obtained  for  4  AZ 
compounds  with  different  formulations.  The  salt  form  of  AZD0865  increased  the  drug 
absorption  indicating  absorption  is  solubility/dissolution  limited,  as  the  drug  possibly 
precipitated to a significant extent in the small intestine. Due to the drug’s basic nature, low 
absorption was estimated under elevated gastric pH. Inter-subjects variability in absorption 
was relatively low for AZD0865. The PR tablet of AZD7009 increased the absorption in vivo. 
The food effect on AZD1305 absorption disappeared when the extended-release formulation 
was administered, indicating that in the absence of food the oral solution is less stable in the 
lower  stomach  pH.  Obtaining  an  accurate  estimation  of  absorption  and  variability  in 
absorption from phase 1 clinical trial will enable scientist to understand better the absorption 
process and evaluate formulation performance with combination of in vitro data. In addition, 
understanding inter-subject variability in early stages of drug development will help scientists 
to plan and interpret phase 2 and 3 clinical trials.  
 
As has been described, PBPK models are readily available to estimate fa, and most of them 
rely on in vitro data. Therefore, a prerequisite for the absorption estimation is reliable in vitro 
methods. These PBPK models can be incorporated in population approaches (as has been 
done in the SimCyp simulator and GastroPlus). For the purpose of this investigation and for 
simplification reasons, only parameters that characterise elimination were included in the 
model building (i.e. liver blood flow, blood to plasma ratio and renal clearance). Further work 
will  include  adding  physicochemical  (i.e.  measurements  of  solubility,  dissolution  and 
permeability) and physiological parameters (i.e. gastric emptying time and transit time) to the 
model to mimic closely the situation in vivo.  Estimation of Oral Drug Absorption and Inter-subject Variability in Humans 
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2.4  Chapter Conclusions 
 
Focusing on fa*fg instead of the overall bioavailability  enabled a better understanding of 
possible loss of drug in the GI tract and accordingly developing suitable formulations to 
increase absorption in early stages of drug development. Therefore, an accurate estimation of 
fa*fg is an essential key in this investigation. In the first section, different methods to estimate 
fa*fg  from  human  clinical  trials  were  utilized.  However,  due  to  the  lack  of  published 
individuals’  pharmacokinetics  values,  in  addition  to  the  small  number  of  subjects  who 
participated in the published clinical trials, it was not possible to yield a reliable large dataset 
of  fa  and  inter-subject  variability.  Considering  these  limitations,  fa*fg  and  inter-subject 
variability for 38 compounds were estimated. A moderate correlation was obtained between 
fa*fg and inter-subject variability. In addition, the physiochemical parameters chosen in this 
study did not yield a significant correlation to the low and erratic absorption. Based on these 
conclusions, phase 1 clinical trials for 4 compounds with different formulations were utilized 
to estimate fa*fg in the second section. In addition, utilizing the population pharmacokinetics 
approach (NONMEM) enabled to estimate the inter-subject variability in a relatively large set 
of  data  (30-50  subjects).  In  this  section,  the  population  pharmacokinetic  model  was 
successfully developed to estimate fa*fg and inter-subject variability. Due to the complexity 
and multiple factors affecting drug absorption in the GI tract, there is a need to further verify 
these results  in  vitro.  In the next  chapter, different  in  vitro experiments were utilized to 
investigate the important factors in causing high inter-subject variability in absorption. Since 
the compounds investigated in this chapter were not available for further experiments, two 
model  drugs  (dipyridamole  and  furosemide)  with  high  inter-subject  variability  in 
bioavailability  (attributed  to  absorption)  were  investigated  to  understand  the  mechanism 
causing variability. 
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3.1  Chapter Overview  
 
The biopharmaceutics drug classification scheme (BCS) for correlating in vitro drug product 
dissolution  and  in  vivo bioavailability  was  developed  based  on  the  recognition  that  drug 
solubility/dissolution  and  gastrointestinal  permeability  are  fundamental  parameters 
controlling  the  rate  and  extent  of  drug  absorption  (Amidon  et  al.,  1995).  Based  on  this 
assumption, it is important to consider the inter-subject variability in solubility, dissolution 
and permeability and which factors contribute to inter-subject variability in absorption.  
 
In situ measurements  of drug  concentration in  the gastrointestinal  fluids  are hindered by 
numerous ethical and practical concerns regarding a healthy subject’s safety. Therefore, a 
more practical approach to estimating drug solubility, dissolution and permeability in the GI 
tract  is  to  use  different  in  vitro  methodologies  (Dressman  et  al.,  2007).  In  the  previous 
chapter,  absorption  and  inter-subject  variability  were  estimated  in  humans  from  drug 
concentration in plasma and hypothesis based on in vitro data was drawn to underline the 
reasons for low and erratic absorption. To our knowledge, there is no single in vitro system 
that composes the complexity of the GI tract to investigate all variable parameters that can 
influence absorption variability in the GI tract. Understanding the mechanism for absorption 
variability in the early stage of drug development by using in vitro systems will assist in 
designing formulations to increase absorption and decrease inter-subject variability.  
 
In this chapter, due to the complexity of the GI tract environment and lack of one in vitro 
model to estimate all GI parameters simultaneously, solubility, dissolution and permeability 
were assessed separately as for which parameters in the GI tract might affect drug absorption. 
In  the  first  section,  solubility  was  tested  in  real  human  fluids  and  simulated  fluids. 
Characterisation of these fluids enables the underlining of the parameters in the GI tract that 
contribute to changes between individuals. Parameters that showed significant correlation to 
variability (i.e. bile salt and pH) in the drug’s solubility were further investigated with regards 
to dissolution and permeability. In the second part, the extent and dissolution rate of these 
drugs  were  investigated  using  simulated  intestinal  fluids,  in  particular,  under  different 
conditions  of pH and bile salt concentration.  Based on the understanding that it is  often 
difficult to extrapolate from in vitro dissolution data alone on the in vivo absorption, adding 
permeability data will add a deeper understanding of the absorption process and inter-subject 
variability. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Due to difficulties obtaining the API’s and the formulations of the compounds investigated in 
chapter  2,  a  literature  research  for  well  formulated  compounds  with  highly  variable 
bioavailability  in  humans  was  carried  out.    Two  compounds  that  were  commercially 
marketed were chosen. Dipyridamole (BCS II) is a poorly soluble weak base with pKa =6.4 
(Williams et al., 1981). Its bioavailability is 52%, and varies significantly between subjects in 
the range of 20- 70% (Rajah et al., 1977; Tyce et al., 1979). Furosemide, a weak acid with 
pKa =3.8, is reported to be a poorly soluble and permeable drug and the FDA classified it as 
a BCS IV drug (Granero et al., 2010). Furosemide mean bioavailability was reported to be 
about 60%; however, its bioavailability is highly variable and erratic, with values ranging 
from 12% up to 100% (Hammarlund et al., 1984; Kelly et al., 1974; Ponto and Schoenwald, 
1990). Since neither drug is extensively metabolized in humans, it is reasonable to assume 
that bioavailability is a good indicator to absorption. Therefore, the inter-subject variability in 
bioavailability  might  be  attributed  to  the  absorption  process  rather  than  the  elimination 
process.  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.2  Inter – subject Variability in Gastrointestinal Drug Solubility 
3.2.1  Introduction  
 
As  described  in  the  previous  chapter,  gastrointestinal  fluid  is  complex,  dynamic  and 
fluctuating. Solubility in the GI contents is determined by its crystalline/amorphous form, 
drug lipophilicity, solubilisation by native surfactants and co-ingested food stuffs, pH, buffer 
capacity and viscosity. In addition to the composition of the fluids, the total fluid volume is 
an important factor which influences the solubility of drugs.  
 
Many publications have characterised chemically the fluids available for drug dissolution in 
the  upper  GI  tract  in  humans,  and  examined  variations  regarding  the  physicochemical 
properties  of  these  fluids.  Important  considerations  like,  osmolality,  surface  tension 
(Dressman et al., 1998), buffer species and ionic composition (Fadda and Basit, 2005), and 
gastric, pancreatic and microbial enzymes (Sousa et al., 2008), and bile salts (Holm et al., 
2013) in the luminal fluid may significantly influence drug solubility/dissolution and hence 
absorption.  The  composition  and  characteristic  of  the  fluid  from  the  human  GI  tract  is 
summarised in Table 3.1.  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Table 3.1: Characteristic of fluids aspirated from the human GI tract 
    Gastric  
fluids 
Jejunal 
fluids 
Ileal 
fluids 
Colonic 
fluids  
pH   fast state  1.23-7.36
a  6.8  7.4  6.8 
fed state  6.4-7
a       
Buffer capacity (mmol*L
-1 
*∆ pH
-1) 
fast state  7-18
a  2-13
c  6.4  37.7 
fed state  14-28
a  13-30
c     
Pepsin (mg/mL)  fast state  0.11-0.22
a       
fed state  0.26-0.58
a       
Osmolality (mOsm*kg
-1)  fast state  98-140
a  271    224 
fed state  217-559
a       
Surface tension (mN*m
-1)  fast state  41.9-45.7
a  28 -26
d    33 
fed state  30-31
a  27-37
d     
Bile salts (mM)  fast state  0.2-0.8
b  2.9    0.6 
fed state  5-18
a 
 
   
 
 (Kalantzi et al. 2006) 
a; (Holm et al., 2013)
b;(Moreno et al., 2006; Persson et al., 2005)
c (Clarysse et al., 2009a; Persson et 
al., 2005)
d; (Fadda et al., 2010a)
e;(Diakidou et al., 2009) 
f; (Lindahl et al., 1997)
g;  
 
The solubility of weak acids and bases depends on their ionization constants, ka and the pH of 
the dissolution medium (Bhattachar et al., 2006), and as such, the pH of the GI fluids remains 
one of the most important influences on the saturation solubility of ionisable drugs. This pH 
also varies  widely with location in the gastrointestinal tract, and even there are complex 
variations in pH between the fed and fasted state (Hörter and Dressman, 2001). Yet another 
parameter that affects the solubility and dissolution rate is the buffer capacity of the GI fluid, 
particularly for ionisable drugs. The buffer capacity of human gastric aspirates was reported 
to  be  14  mmol/L/pH  30  minutes  post-ingestion  of  a  liquid  meal,  increasing  to 
28 mmol/L/pH  210  minutes  post-meal  ingestion.  The  buffer  capacity  of  the  duodenal 
aspirates  varied  between  18  and  30  mmol/L/pH  during  30  to  210  minutes  post-meal 
ingestion (Kalantzi et al., 2006). Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Bile salts in the intestine also have a considerable impact on the solubility of lipophilic drugs. 
The solubility is further influenced by inter-subject variability in bile salt concentration; such 
variability is also magnified in the fed state. Holm et al. (2013) reported that under fasted 
conditions,  bile  salt  concentration  ranges  from  2  to  6.4mM  and    in  the  fed  state,  the 
concentration varies significantly with reported values ranging from 0.5 to 37mM. In the 
fasted  state,  bile  salt  concentration  is  mainly  affected  by  the  basal  secretion  of  each 
individual, whereas in the fed state, food intake and its composition can markedly affect bile 
salt levels in the gut. Surface tension also affects drug dissolution through its influence on 
wetting,  with  higher  surface  tension  values  leading  to  decreased  wetting.  Furthermore, 
variations in gut osmolality can affect drug release from different formulations and excipient 
performance, with osmolality values range from 124-278mOsm/kg and 250-367mOsm/kg in 
the fed state in the upper small intestine.  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
 
- 76 - 
 
In this work, ileostomy fluids from 10 subjects with ulcerative colitis (UC) of the colon were 
characterized in terms of pH, buffer capacity, osmolality and surface tension, and solubility 
measurements were also made. For comparison, and to understand the regional differences in 
the solubility of dipyridamole and furosemide along the GI tract, solubility experiments were 
carried out in pooled gastric and intestinal fluids from healthy volunteers, and in simulated GI 
fluids  
 
Studies are consistently published on attempts to mimic the GI fluids in vitro in order to 
characterise drug solubility, dissolution and permeability. However, most of these approaches 
aim to mimic the average person. To extend our knowledge of possible factors that might 
cause variability in drug solubility, the effects of bile salt concentration and pH were studied 
by use of simulated intestinal fluids. Different solutions of FaSSIF buffers were prepared to 
predict how the intestinal solubility of furosemide and dipyridamole varies within the normal 
range of bile salt and pH in the human small intestine. 
 
3.2.2  Objectives 
 
  To determine the solubility of dipyridamole and furosemide along the GI tract in 
gastric, intestinal pooled fluids and from ileostomy fluids.  
  To characterise 10 individual ileostomy ulcerative colitis (UC) patients’ fluids with 
regards to osmolality, buffer capacity, surface tension and pH.  
  To investigate the effect of bile salt concentration and pH on drug solubility using 
simulated intestinal fluids. 
  To identify and mechanistically understand the key causes of inter-subject variability 
in solubility of dipyridamole and furosemide. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.2.3  Materials  
 
Dipyridamole  (D9766)  and  furosemide  (F4381)  were  obtained  from  Sigma  Aldrich 
Chemicals  (Poole,  UK).  SIF  powder  was  purchased  from  Biorelevent.com.  All  salts  to 
prepare  the  buffers  were  of  analytical  grade  and  purchased  from  VWR  Chemicals  Ltd. 
(Poole, UK). Solvents used in HPLC were: HPLC water, acetonitrile and phosphoric acid. All 
were of HPLC grade and purchased from Fisher Scientific (Loughborough, UK).  
3.2.4  Methods  
3.2.4.1 Human Fluids 
 
Healthy pooled gastric and intestinal fluids were supplied by AstraZeneca, Sweden. Gastric 
and intestinal fluids were aspirated from healthy volunteers via an oral intubation tube (Loc-
I-Gut, synectics Medical, Sweden (Bønløkke et al., 1997). The fluids were collected, pooled 
and stored in -80˚C until analysis.  
 
Ileostomy fluids were supplied from the Singleton Hospital in Swansea. Fluids were collected 
from stoma bags in patients who were undergoing a routine change of their stoma bag, or 
who were undergoing surgery for stoma reversal. Ileostomy fluids were collected from 10 
different patients.  End ileostomy is usually constructed as a permanent stoma for patients 
with  ulcerative  colitis  or  Crohn’s  disease.  The  terminal  ileum  is  brought  through  the 
abdominal wall in the right iliac fossa area. This is usually the outcome of proctocolectomy 
(Keighley and Williams, 1999). The samples were not pooled, and therefore each sample 
corresponds to one patient. Patients were not fasting and their diet was not controlled.  
 
3.2.4.2 Sample Preparation 
 
The GI fluids were centrifuged with Centrifuge 5415D (Eppendorf AG, 22331 Hamburg, 
Germany)  at  16,110xg  RCF  (relative  centrifugal  force,  equivalent  to  13200rpm)  for  20 
minutes. The supernatant obtained were kept in a freezer (-80˚C) until analysed. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.2.4.3 Osmolality Measurement 
 
Osmolality was determined with a Digital Micro-Osmometer (Type 5R), (Hermann Roebling 
Messtechnik,  Berlin,  Germany).  The  operating  principle  of  this  instrument  is  based  on 
freezing point depression.  Samples were thawed to room temperature before measurements 
were taken, and a volume of 100µL was used for each measurement.  
 
3.2.4.4 Surface Tension Measurement 
 
Surface tension was measured with a Delta 8 Tensiometer (Kibron Inc) controlled by Delta-8 
manager software (version 3.8). The measurement was performed using DynePlates (96-well 
plate designed for tensiometer) with a 50µL sample in each well. 
 
3.2.4.5 Buffer Capacity and pH Measurement 
 
Buffer capacity was  measured by using a pH  meter (HI99161) equipped with  an FC202 
electrode, designed for viscous and semi-solid materials (Hannah Instruments, Bedfordshire, 
UK). Buffer capacity was measured at a pH change of 0.5 and 1.0 units. This was performed 
by the aliquots addition of accurate amounts of HCl (intestinal fluids) to a 300µL sample to 
achieve  the  desired  pH  change.  Buffer  capacity  was  then  calculated  using  Equation  3.1. 
Buffer  capacity  measurement  was  only  performed  in  one  direction  due  to  the  limited 
availability of gastrointestinal fluids and time.  
 
 
Equation 3.1: Buffer capacity calculation 
 
In equation 1, Δ AB is the small increment in mol/L of the amount of acid or base added to 
produce a pH change of Δ pH in the buffer. Equation 1 was further modified (Equation 3.2) 
to account for smaller volumes (300L) of the sample in contrast to 100mL in conventional 
measurements, which was then used for the calculation of the buffer capacity. 
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Equation 3.2: Modified equation for buffer capacity calculations  
 
M acid/base and V acid/base are the molarity and volume of the acid/base added to the V (mL) of 
the sample to produce a pH change of Δ pH in the sample.  
 
3.2.4.6 Simulated intestinal fluids Preparation 
 
Two  important  variables  in  the  composition  of  intestinal  fluids  that  might  affect  drug 
solubility were simulated in vitro, bile salt concentration and pH. Total bile salt concentration 
in  aspirated  fluids  from  the  fasted  duodenum  and  jejunum  ranged  from  0.6  to  5.5mM 
(Kalantzi et al., 2006; Lindahl et al., 1997; Moreno et al., 2006).  With respect to pH, the 
range in the duodenum and jejunum was found to be around 5.5-7.4 (Evans et al., 1988; 
Fallingborg et al., 1989; Kalantzi et al., 2006; Lindahl et al., 1997; Pedersen et al., 2000b). 
These  conditions  were  simulated  in  vitro  using  FaSSIF-V1.  FaSSIF-V1  was  prepared 
according to the recipe from Dressman et al. (1998) (Table 3.5). pH was adjusted in the range 
of 5.5-7, and the bile salt concentration ranged from 1 to 6mM.  
 
3.2.4.7 Solubility Measurements  
Solubility measurements were performed in simulated intestinal fluids, healthy GI fluids and 
ileostomy  human  fluids.  An  excess  of  the  drug  was  added  to  micro  centrifuge  tubes 
(Eppendorf AG, Hamburg, Germany) containing 200µL of fluid. The samples were placed in 
a shaking bath, maintained at 170 shakes per minute at 37C for 24 hours. After 24 hours, the 
samples were centrifuged (4472 rcf /5000rpm) at a temperature of 40 C  using a Centrifuge 
5804R (Eppendorf AG, 22331 Hamburg, Germany) for 10 minutes at 37C (a temperature set 
point  of  40C  was  used  to  maintain  the  required  temperature  in  the  micro  tubes  during 
centrifugation). The supernatant was transferred to a centrifuge filter tube (cellulose acetate 
membrane, pore size 0.22μm, sterile Corning® Costar® Spin-X®) and then centrifuged at 
5000rcf  (Eppendorf  AG,  Hamburg,  Germany)  for  20  minutes  at  37C  (40C  set  point). 
Aliquots of the filtrate (50L) were removed and diluted with the mobile phase. The amount 
of  drug  dissolved  in  the  sample  was  assayed  and  determined  by  using  HPLC-UV 
/fluorescence, as described in the following section. Calibration curves and blank samples for Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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the drugs were prepared. Spiking the different media with known concentrations of drugs 
showed recovery between 92-100%. The same samples were also analysed after only 5 hours 
of incubation and similar concentrations were measured compared to 24 hours’ incubation. 
Thus, it is possible to exclude degradation in biological fluids or binding to the filters. 
 
3.2.4.8 High Performance Liquid Chromatography (HPLC) for Assaying Drug 
Solubility  
Drug  concentrations  were  determined  by  reverse-phase  HPLC  analysis  with  UV  and 
fluorescence  detection.  The  equipment  consisted  of  an  integrated  HP  1200  Series  HPLC 
system comprising an HP1200 autosampler, an HP 1200 pump and an HP 1200 multiple 
wavelength detector system, a Vis-UV spectrophotometric detector and fluorescence detector 
(Agilent  Technologies,  West  Lothian,  UK).  The  detector  was  interfaced  with  a  pv  with 
PC/Chrom + software (H&A Scientific Inc, Greenville,NC, USA). Separation of furosemide 
was achieved with C-18 column, Hypersil Gold 150*4.6 mm 3 µm (Fisher Scientific) at 
40˚C. The mobile phase used for analysis consisted of 25:75% (V/V), acetonitrile and 0.05M 
phosphate buffer adjusted pH to 2.5. The flow rate was 1mL/min, the injection volume was 
20µL, and the detection wavelength for vis-UV was 238nm. For fluorescence excitation and 
emission, the wavelengths were set to 233 and 389nm respectively. The drug retention time 
was 12.5 min. Separation of dipyridamole was achieved with c-18 column, Atalntis, 150*4.6 
mm, 5µm (Waters) at 40˚C. The mobile phase used for analysis consisted of 40:60 %  (V/V), 
acetonitrile and 0.1% TFA in water. The flow rate was 1ml/min and the injection volume was 
20µL;  the  detection  wavelength  for  vis-UV  was  285nm,  and  for  fluorescence  detection, 
excitation and emission the wavelengths were set to 295 and 485 respectively. The drug 
retention time was 6.4 min. Calibration curves were prepared in the corresponding mobile 
phase as saturated drug solutions were subjected to 20 fold dilution. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.2.4.9 Statistical Analysis  
 
All solubility data presented and fluid measurements herein are the mean value of triplicate 
experiments.  The coefficient of variation (CV%) was calculated by dividing the standard 
deviation in the mean value. The terms high and low variability refer to distributions that 
have high and low coefficients of variation, respectively. Typically, a coefficient of variation 
of a pharmacokinetic parameter of 10% or less is considered low, 25% is moderate, and 
above 40% is high (Rowland and Tozer, 2011).  
 
Correlation analysis was carried out using Excel. Standard multiple regression using SPSS 
statistics software 22.0.0 (SPSS Inc., Chicago, IL) was conducted to assess the feasibility of 
predicting  the  solubility  of  furosemide  in  ileostomy  fluids  from  the  following  variables: 
buffer capacity and pH. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.2.5  Results & Discussion  
 
In this study, dipyridamole solubility in pooled gastric and intestinal fluids was 9.3mg/mL 
and  0.016mg/mL  respectively.  Furosemide  solubility  in  pooled  gastric  fluids  was 
0.003mg/mL, while in pooled intestinal fluids increased to 2.9mg/mL. Solubility data for 
dipyridamole and furosemide in different individuals are graphically presented in Figure 3.1 
and Figure 3.2 respectively. The mean solubility of dipyridamole was 0.043mg/mL (range 4-
69µg/mL).  The  furosemide  solubility  mean  value  in  the  ileostomy  fluids  was  1.7mg/mL 
(range 0.2-5.3mg/mL).  High variability between subjects in the solubility of both drugs was 
observed with CV values of 88% and 63% for furosemide and dipyridamole accordingly. It 
can be seen that solubility of both compounds in FaSSif were slightly different compared to 
the solubility in human intestinal fluids and ileostomy fluids (Table 3.2). 
 
 
Table 3.2: Solubility in human intestinal fluids and ileostomy fluids (mean ± SD) 
  Dipyridamole (mg/mL)  Furosemide (mg/mL) 
Gastric pooled fluids  9.3 ± 0.04  0.003±0.0006 
Intestinal pooled fluids  0.016 ± 0.0001  2.9±0.05 
Ileostomy fluids  0.043 ± 0.023  1.8±1.6 
Simulated intestinal fluids 
FaSSIF  
0.028 ± 0.001  1±0.01 Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Figure 3.1: Dipyridamole solubility in ileostomy fluids from 10 individual 
 
 
 
 
 
 
Figure 3.2: Furosemide solubility in ileostomy fluids from 10 individuals 
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pH, buffer capacity, surface tension and osmolality were later measured in 10 individual 
ileostomy fluids (individuals, mean, SD and CV% values presented in Table 3.3). In this 
study, the  mean value  of surface tension  in  ileum  fluids  was  42.9±6mN/m  (range 34-49 
mN/m, CV=14%) Osmolality mean value was found to be 398 ±81mOsmol/kg (range 328-
619mOsmol/kg  CV=20%).  The  mean  value  of  buffer  capacity  and  pH  was  18.3± 
11mM/L/∆pH (range 5.6-45mM/L/∆pH CV=60%) and 6.7±0.91 (range 6.16-7.88, CV=14%), 
respectively.  Buffer  capacity  in  ileostomy  fluids  was  reported  to  range  between  11-
54mM/L/∆pH with a mean value of 22.4mM/L/∆pH.  pH in ileostomy fluids ranged from 
5.8-8 with a mean value of 7.1 which is in agreement with the data presented herein (Fadda et 
al., 2010a). 
Table 3.3: Characterisation of ileostomy fluids (mean ±SD and CV as measure to variability)  
Subject 
no. 
Surface Tension 
(mN/m) 
Osmolality 
(mOsmol/kg) 
Buffer Capacity 
(mM/L/∆pH) 
pH 
1  36.5  368.0  6.62  6.16 
2  43.3  433.7  12.54  5.65 
3  49.5  357.3  17.16  7.54 
4  48.3  349.3  14.98  7.88 
5  48.3  434.7  14.15  6.85 
6  49.2  328.0  5.62  7.88 
7  39.6  370.0  13.71  6.08 
8  37.4  363.3  17.85  5.37 
9  49  351.7  20.57  7.68 
10  35  619.0  32.44  7.65 
Mean ± 
SD 
43±6  398.5±81  15.9±7.2   6.7±0.9 
CV (%)  14  20.3  45.5  13.5 
 
To identify the factors which contribute to the inter- subject variability in solubility of the 
two drugs, poorly soluble, weak acid and base, correlation analysis was carried out and the 
results presented as R square values in Table 3.4. Dipyridamole solubility in ileostomy fluids 
was significantly correlated with the pH changes within individuals giving R squares value of 
0.79.  No  correlation  was  found  between  dipyridamole  solubility  to  the  buffer  capacity, 
osmolality and surface tension in ileostomy fluids. Furosemide solubility in ileostomy fluids 
was relatively well correlated with pH changes of individuals and buffer capacity (R
2 = 0.58 
and 0.56 respectively). Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Table 3.4 : Correlation analysis (R
2 values) 
  Dipyridamole solubility   Furosemide solubility  
pH   0.79  0.58 
Buffer Capacity  0.079  0.56 
Osmolality   0.034  0.23 
Surface Tension  0.2  0.03 
 
pH correlations to dipyridamole and furosemide solubility in ileostomy fluids were confirmed  
using  simulated  intestinal  fluids,  where  the  correlation  of  R
2=0.82  and  0.63  between 
solubility and pH changes for dipyridamole and furosemide respectively were found (Figure 
3.3  and  ).  To  further  understand  how  bile  salts  concentration  affects  dipyridamole  and 
furosemide solubility, solubility measurements were made under different conditions of bile 
salts concentration in simulated intestinal fluids. For dipyridamole, correlation of R
2= 0.94 in 
the range of 1-6mM bile salt was obtained (Figure 3.5). Furosemide solubility in simulated 
intestinal  fluids  increased  slightly  when  bile  salt  concentration  increased  with  solubility 
ranging from 1 to 1.5mg/ml (Figure 3.6). The buffer capacity of these fluids was measured, 
and a correlation of 0.64 was attained to furosemide solubility. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Figure 3.3: Dipyridamole solubility as function of pH in simulated intestinal fluids 
 
 
Figure 3.4: Furosemide solubility as function of pH in simulated intestinal fluids Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Figure 3.5 : Dipyridamole solubility as function of bile salt concentartion in simulated intestinal fluids 
 
 
Figure 3.6: Furosemide solubility as function of bile salt concentartion in simulated intestinal fluids Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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A practical approach to estimating drug solubility in the GI tract is to aspirate fluids from the 
human GI tract and measure the solubility in these fluids ‘ex vivo’, albeit one hindered by 
numerous ethical and practical concerns regarding the safety of healthy subjects. Moreover, 
the amount of fluid  which can be aspirated is  small, and individual  samples  are usually 
pooled to produce a large volume of samples for solubility measurements. In this study, the 
solubility experiment and the measured parameters in individual subjects were carried out in 
ileostomy fluids taken from UC subjects.  These fluids are readily available, easy to collect 
and  the  volume  obtained  from  ileostomy  bags  is  sufficiently  large  to  perform  individual 
solubility measurements. Therefore, it was possible to analyse the complexity of intestinal 
fluids to further underline the factors that might affect variability between individuals in drug 
solubility. 
 
Although  many  researchers  have  investigated  the  inter-subject  variability  of  GI  fluids 
(Augustijns et al., 2013), few have correlated GI fluid variability to that of variability in 
drugs solubility (Annaert et al., 2010; Clarysse et al., 2011; Clarysse et al., 2009b; Pedersen 
et al., 2000a; Pedersen et al., 2000c). Therefore, it is desirable to obtain correlations and an 
account of the possible factors that are important for drug solubility. Most of the published 
solubility measurements and correlations were conducted in aspirated duodenal and jejunal 
fluids.  Despite the fact that dipyridamole and furosemide are commonly given in immediate 
release forms  and their main site of absorption is  the duodenum  and jejunum, as  poorly 
soluble drugs they are highly likely to reach the lower parts of the gut, namely the ileum and 
colon. Therefore, the solubility of these poorly soluble drugs in lower parts of the gut fluids is 
of  particular  relevance  and  interest,  in  particular  in  the  light  of  low  volumes  of  fluids 
availability in the lower parts of the gut.   
 
For weak bases and acids, the pH changes along the GI tract influence drug solubility. The 
solubility of furosemide (weak acid, pka 3.9) in gastric fluids is very low due to the acidic 
condition of the stomach fluids. The solubility was shown to increase in intestinal fluids as 
expected mainly due to the increase in the pH of the fluids. Furosemide solubility in pooled 
duodenum fluids was reported as 1.9 and 3.8 mg/mL by Clarysse et al. (2011) and Heikkilä et 
al. (2011). Similarly, due to the pH increase, dipyridamole solubility (weak base pka 6.4) 
decreased from the stomach to the jejunum. In previous reports, the dipyridamole solubility 
in pooled duodenum and jejunum fluids was 0.022 and 0.029 mg/mL, respectively, ( alantzi 
et  al.,  2006     derlind  et  al.,  2010)  higher  than  the  value  reported  herein.  This  can  be Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
 
- 89 - 
 
explained by pH differences as pH was measured at 6.7 in these reports and herein the pooled 
jejunum fluids pH was 7.4. 
 
Using simulated fluids as a predictor for drug solubility in vivo is a simplified method of the 
more  complex  situation  in  vivo.  In  a  recent  review  publication,  Augustijns  et  al.  (2013) 
investigated the correlation between the solubilising capacity of FaSSIF versus fasted human 
intestinal fluids. A relatively strong correlation (R
2=0.85) was observed.  A better correlation 
for  neutral  molecules  was  obtained  compared  to  ionisable  molecules.  This  indicates  that 
interplay of a few parameters of the intraluminal fluids affects the solubility of these ionized, 
lipophilic compounds. Nevertheless, it was concluded that for an initial estimation of drug 
solubility,  these  findings  show  that  FaSSIF  can  be  used  for  drug  solubility  screening  to 
predict solubility in human intestinal fluids. In this study, furosemide solubility in FaSSIF 
underestimated furosemide solubility in the upper parts of the gut, whereas dipyridamole 
solubility in FaSSIF overestimated dipyridamole solubility in the upper parts of the intestine. 
FaSSIF pH was 6.5 while pH of the pooled jejunum fluid was 7.4, and this increase in pH 
might  explain  the  increase  in  dipyridamole  solubility  and  the  decrease  in  furosemide 
solubility in FaSSIF. 
 
With regard to characterisation of the ileostomy fluids, osmolality measurements reported 
herein were higher than the normal values published in healthy subjects (124-278mOsmol/kg 
in fasted state and 250-367mOsmol/kg in the fed state). Ileal fluids from healthy subjects and 
ileostomy  fluids  differ  mainly in  their volume, with  approximately 1.5L of  fluid  passing 
through the ileo- caecal valve per day. However, the average ileostomy contents are less than 
a third of this volume (Fadda, 2007), and so we would expect ileostomy fluids to therefore be 
more  concentrated.  Furthermore,  transit  through  the  final  part  of  the  ileum  is  slower  in 
ileostomates compared to normal subjects. High retention time in the ileum generates greater 
exposure to the  bacterial flora, indirectly facilitating the generation of metabolites such as 
short chain fatty acids, thereby increasing the osmolality in ileostomy fluids compared to ileal 
fluid (Ladas et al., 1986). Vertzoni et al. (2010) characterised the ascending colon fluids from 
subjects with ulcerative colitis with regard to surface tension and osmolality. Surface tension 
was found to be around 41mN/m, with no difference between subjects in remission or in 
relapse. Osmolality was 290 and 199mOsmol/kg in subjects in remission and in relapse states 
respectively, with no significant difference, implying high variability in the fluids of these 
subjects. pH in ileum fluids from  patients was found to be around 7.3 -7.7, and no significant Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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decrease was observed compared to healthy subjects (Ewe et al., 1999). In view of the inter-
subject variability found in ileostomy fluids, it can be seen that for most of the intraluminal 
measured  parameters,  the  variability  is  intermediate  (CV˂20%).  However,  for  the  buffer 
capacity  parameter,  great  variability  was  found  between  the  individuals  (CV=60%).  As 
described,  some  of  the  factors  that  can  cause  inter-subject  variability  in  healthy  subjects 
include  food  intake,  gut  secretions,  age  and  gender.  The  severity  of  the  disease  and  the 
inflammation location along the gut can also vary markedly between patients, likely affecting 
the absorption and secretion of ions, bile salts and fatty acids, and all of which will influence 
the  solubility  of  ionizable  drugs.  As  the  diet  of  the  individuals  in  this  study  was  not 
controlled, however, the data presented should also reflect the variability among individuals 
with varying diets, reflecting circumstances in everyday life. The combination of all these 
factors can explain the high variability in the solubility of both drugs. 
 
The  positive  correlation  to  pH  in  the  case  of  furosemide  in  both  simulated  fluids  and 
ileostomy fluids is quite surprising. As discussed, furosemide is a weak acid with pka of 3.8, 
and  its  solubility-  dependent  pH  would  not  be  expected  at  this  pH  range.  A  possible 
explanation of its pH dependent solubility in that range might be related to the buffer capacity 
of these fluids. In our in vitro measurement at equilibrium drug solubility, pH values in the 
human and simulated media were decreased for furosemide experiments due to an excess of 
weak acid (attributable to the low buffer capacity of the fluids). For example, the final pH 
values decreased by 1 to 0.5 units in the simulated media relative to the starting pH. The 
changes in pH may affect the saturation solubility of the drug, as previously described by 
Avdeef (2007). In vivo, if the fluids buffer capacity is low and the administered dose is high, 
this may likely cause changes in the intraluminal pH. A further decrease in the gut fluids pH 
might also be observed in the case of a weak acid, hence decreasing drug solubility.  
 
Further regression analysis was performed to understand the effect of both pH and buffer 
capacity  on  the  solubility  of  furosemide  in  ileostomy  fluids.  Standard  multiple  linear 
regression (SPSS  statistics software release 22.0.0, SPSS Inc., Chicago, IL) was used to 
explore  the  influence  of  pH  and  buffer  capacity  of  intestinal  fluids  on  the  solubility  of 
furosemide. Solubility was found to be dependent on both buffer capacity and pH (R
2 =0.983, 
F=57.98 p˂0.01), and it was found that the solubility of furosemide increases with higher 
buffer  capacity  and  higher  pH  values  (Figure  3.7).  Equation  3.3,  obtained  by  multiple Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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regressions, enables the prediction of solubility of furosemide in the human intestinal fluids 
based on the knowledge of pH and buffer capacity in the range measured in this publication.  
 
 
Equation 3.3: The effect of buffer capacity and pH on furosemide solubility 
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Figure 3.7: The Effect of Buffer capacity and pH on furosemide solubility Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Aside  from  pH  and  buffer  capacity,  furosemide  solubility  also  increased  with  bile  salt 
concentration in simulated fluids. Therefore, it is reasonable to assume that due to its low 
solubility in gastric fluids and considering its lipophilic nature, solubilization of furosemide 
in intestinal fluids may be dependent on the presence of bile salts in the intestine. It can be 
seen that for furosemide, pH changes in simulated fluids yield a 90% increase in solubility, 
whereas bile salt concentration changes from the lowest to the highest in simulated intestinal 
fluids yield an increase of only 30%. Buffer capacity changes furthermore cause an increase 
of 45% in solubility, indicating that both pH and buffer capacity play important roles in 
influencing the solubility of furosemide in vivo. 
 
Dipyridamole is a weak base with pka of 6.4. As expected for weak bases, the solubility is 
significantly  influenced  by  changes  in  pH  in  both  ileostomy  fluids  and  simulated  fluids. 
Therefore, significant differences can be anticipated between individuals with different pH 
values along the GI tract.  However, with  weak basic drugs,  there is  a need to  take into 
consideration possible precipitation when transferring from low gastric pH to the higher pH 
in the duodenum. It is reasonable to assume that changes in factors such as gastric pH and 
gastric emptying time will add to the complexity of GI fluids composition, and augment an 
increased variability in  drug solubility. Furthermore, dipyridamole showed an increase in 
solubility as bile salts concentration increased in simulated fluids.   It can be assumed that the 
effect of bile salts will be more significant in the intestine, owing to their lower solubility in a 
region of higher pH. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.2.6  Summary  
 
In this study, the regional gastrointestinal solubility of furosemide and dipyridamole – two 
model  drugs  with  reported  high  inter-subject  variability  in  bioavailability  in  man  -  was 
investigated. Characterization of ileostomy fluids from individuals revealed high variability 
for buffer capacity and to a lesser degree for pH. Solubility measurements in ileostomy fluids 
for both furosemide and dipyridamole showed high inter-variability. The correlation analysis 
to  solubility  measurement  showed  that  dipyridamole  solubility  in  these  fluids  is  pH-
dependent, whereas furosemide solubility was highly correlated to buffer capacity and pH. 
Simulated intestinal fluids were used to investigate possible effects of bile salt concentration 
on drug solubility; dipyridamole solubility correlated with bile salt concentration in the fasted 
state,  while  slight  variation  in  furosemide  solubility  was  observed  in  the  same  bile  salt 
concentration range. Based on these results, it was decided to further investigate the rate and 
extent  dissolution  of  dipyridamole  under  different  conditions  of  pH  and  bile  salt 
concentration in bio-relevant media. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.3  Evaluation of the Effects of Bile Salt and pH on the Dissolution of 
Dipyridamole and Furosemide  
3.3.1  Introduction  
3.3.1.1 In Vitro Dissolution Tests  
 
There is an increasing interest in the development of dissolution tests to establish in vitro in 
vivo correlations (IVIVC). A number of GI factors should be considered when developing in 
vitro dissolution test models, such as pH, ions, surfactants, lipid, enzymes, volumes, flow 
rate, viscosity, and mechanical stress. In addition, the variation of these factors may also be 
included in the in vitro model.  
 
Many  attempts  have  been  made  to  simulate  the  dissolution  rate  and  extent  of  different 
formulations in vitro, the most conventional and widely used systems being the USP I/II 
apparatus, in which dissolution is performed in litre round-bottom vessels usually containing 
900mL of dissolution media and either a rotating basket or rotating paddle to mimic GI 
hydrodynamics. More recent developments based on these models have included the USP 
apparatuses  III/IV  to  TIM-TNO’s  intestinal  model,  which  incorporates  different  GI 
compartments (Kostewicz et al., 2013). Further attempts have also been made to develop bio-
relevant dissolution media and so improve the IVIVC. The stomach is the main region where 
IR drug products disintegrate after oral administration, and the acidic pH environment here 
can be crucial for the dissolution of poorly soluble weakly basic compounds: Indeed, in the 
fasted state, weakly basic drugs dissolve primarily in the stomach, whereas the weak acid will 
remain  largely  undissolved.  In  order  to  assess  dosage  form  performance  in  the  stomach, 
simulated gastric media are often employed - the most simple dissolution media simulating 
gastric fluids being that media used in the USP method. Vertzoni et al. (2005), for instance, 
developed a FaSSGF media with more relevant pH, surface tension and pepsin level values, 
and  low  levels  of  taurocholate,  along  with  other  attempts  by  other  researchers  to  make 
dissolution media utilised more clinically relevant (Pedersen et al., 2013; Vertzoni et al., 
2005). For the lower compartments of the gut, Dressman et al. (1998) proposed and evaluated 
the fasted stated simulated intestinal fluids (FaSSIF) and the fed stated simulated intestinal 
fluids (FeSSIF) as bio-relevant media to test the dissolution of poorly soluble drugs (Vertzoni 
et  al.,  2004).  Second-generation  simulated  media  in  turn  are  largely  based  on  better 
understandings of  gastrointestinal conditions and contents (Jantratid et al., 2008), and Fotaki Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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and  Vertzoni  (2010)  published  a  comparative  account  of  different  media  in  relation  of 
IVIVC. The content and properties of these media are described in Table 3.5 and Table 3.6. 
 
 
Table 3.5: The content and properties of FaSSIF media (Jantratid et al., 2008) 
  FaSSIF  FaSSIF-V2 
Sodium taurocholate (mM)  3  3 
Lecithin (mM)  0.75  0.2 
Dibasic sodium phosphate (mM)  28.65   
Maleic acid (mM)    19.12 
Sodium hydroxide (mM)  8.7  34.8 
Sodium chloride (mM)  105.85  68.62 
pH  6.5  6.5 
Osmolality (mOsmol/kg)  270±10  180±10 
Buffer capacity (mmol/L/pH)  12  10 
 
 
 
Table 3.6: The content and properties of FeSSIF media (Jantratid et al., 2008) 
  FeSSIF- V1  FeSSIF-V2 
Sodium taurocholate (mM)  15  10 
Lecithin (mM)  3.75  2 
Glyceryl monooleate (mM)  --  5 
Sodium oleate (mM)  --  0.8 
Acetic Acid  144  -- 
Maleic acid (mM)  --  55.02 
Sodium hydroxide (mM)  101  81.65 
Sodium chloride (mM)  173  125.5 
pH  5  5.8 
Osmolality (mOsmol/kg)  635±10  390 ± 10 
Buffer capacity (mmol/L/pH)  76  25 Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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It can be seen, however, that the buffer capacity of 10mM/L/∆pH (fasted) and 25mM/L/∆pH 
(fed), used in the updated version is still higher then what has been measured in luminal 
fluids  (Fadda  et  al.,  2010a).  In  addition,  the  ion  composition  in  these  media  is  not 
representative of physiological fluids in humans; small intestinal luminal fluids are buffered 
primarily by bicarbonate, which is secreted by the pancreas and epithelial cells in the gut. 
Aside  from  pH,  the  constituent  buffer  salts,  ionic  strength  and  buffer  capacity  of  the 
dissolution media can influence the drug release from ionisable polymers and compounds 
(Boni et al., 2007; McNamara et al., 2003; Sheng et al., 2009).  
 
Sheng  et  al.  (2009)  investigated  the  significance  of  physiological  buffer  species  and 
concentration without inclusion of any bile salts in dissolution testing of BCS II acidic drugs: 
It  was  found  that  the  higher  the  concentration  of  bicarbonate,  the  faster  the  drug  flux. 
However,  the  intrinsic  dissolution  rates  in  phosphate  buffers  were  higher  than  in  all 
bicarbonate buffers, even when pH was maintained and the same buffer concentration was 
used. It was concluded that not only the pH but also the buffer species and concentrations 
should be considered in composing the in vitro dissolution media to closely reflect the in vivo 
dissolution fluids. That would be highly important to consider for weak compounds with pka 
values close to or higher than the intestinal pH range. For weak bases with pka lower than the 
pH range and very low solubility, the intrinsic flux is independent of the buffer species or 
concentration.  Hence,  bicarbonate  buffers  can  be  said  to  closely  resemble  the  intestinal 
environment, and provide a more physiological medium for the in vitro assessment of drug 
release. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Based on the results from the previous section where pH and bile salt were found to have an 
effect on the drugs solubility, further investigations into these conditions impact on the extent 
of drug release and the dissolution rate were carried out. Bicarbonate buffers which were 
further modified by Fadda et al. (2009b) and Liu et al. (2011) were  utilised in this research  
to  better  evaluate  ionisable  drug  release,  under  different  conditions  of  pH  and  bile  salt 
concentration simulating different individuals. As has been described, the bicarbonate buffer 
mimics the intestinal fluids closely in regards to buffer capacity and ion composition, but lack 
bile salts otherwise present in human intestinal fluids. In this investigation, the bicarbonate 
buffer used was modified by adding crude bile salts. In addition, since the buffer conditions 
resemble the intestinal fluids from the average person, a number of further changes were 
made to the buffer pH and bile salts concentration in order to mimic 9 different individuals in 
the fasted state, and to understand how these differences affect the dissolution rate and extent.  
Moreover, to understand how different conditions in the gastric fluids with respect to pH and 
bile  salt  concentration  affect  the  dissolution  of  weak  acid,  FassGF  was  utilised  in  this 
research.  pH  and  bile  salt  concentration  ranged  from  1.2  to  2.5  and  0.03  to  0.6mM 
respectively, based on a recent publication from  Pedersen et al. (2013).  
 
3.3.2  Objectives 
 
  To  test  dipyridamole  and  furosemide  dissolution  in  the  form  of  the  active 
pharmaceutical ingredient and the commercial tablet in Hanks buffer under different 
conditions of pH and bile salt concentration to simulate possible changes between 
individuals in the proximal small intestine in the fasted state, and investigate possible 
effects on drug dissolution. 
  To test the dissolution of furosemide in FaSSGF under different conditions of pH and 
bile  salt  concentration  to  simulate  possible  changes  between  individuals  in  the 
stomach in the fasted state, and investigate possible effects on drug dissolution. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.3.3  Materials  
3.3.3.1 Chemicals and Supplies 
 
Magnesium  sulphate  heptahydrate,  sodium  hydroxide,  potassium  dihydrogen  phosphate, 
sodium bicarbonate, sodium chloride, potassium chloride, calcium chloride were purchased 
from VWR (Dorset,Uk). Carbon dioxide gas and medical oxygen gas were purchased from 
BOC  (UK).  Bile  salt  (B8756)  and  pepsin  from  porcine  gastric  mucosa  (77161)  were 
purchased from Sigma. SIF powder containing taurocholate and lectin was purchased from 
biorelevant.com.  Dipyridamole  (D9766)  and  furosemide  (F4381)  of  pure  pharmaceutical 
grade,  in  crystalline  powder  form,  were  obtained  from  Sigma-Aldrich  (St  Louis,  USA). 
Dipyridamole Tablets 100 mg and Furosemide 40 mg BP Tablets, from Generics UK Ltd 
(Potters  Bar,  England)  and  Teva  UK  Ltd  (Eastbourne),  respectively,  were  selected  as 
immediate release commercial solid dosage forms. 
3.3.3.2 Instruments  
 
USP-II  Dissolution  Apparatus  (PTWS,  Pharma  Test,  Hamburg,  Germany)  controlled  by 
software IDIS EE2.11.16 (Icalis Data System Ltd., Berkshire, UK) equipped with in –line 
UV spectrophotometer (Cecil 2020, UK), pH meter (pH 211 Microprocessor) equipped with 
H11131 probes (Hannah Instruments, Bedfordshire, UK), Sho-Rate gas flow meter (Brooks, 
Veenendaal, Netherlands) calibrated for carbon dioxide.   The pH stabilization was confirmed 
through pH measurements about every ten minutes with a pH electrode (H11131, Hanna 
Instruments Ltd.) attached to a pH 211 Microprocessor (Hanna Instruments). Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.3.4  Methods  
3.3.4.1 Buffers Preparation  
 
  mHanks  
Hanks  balanced  salt  solution  closely  resembles  the  ionic  composition  of  the  small 
intestinal fluids, however, it has a pH of 7.4, which is too high, and a buffer capacity of 1 
mmol/L/ΔpH, which is too low, as compared to that of human jejunal fluids (Table 3.7). 
Consequently, this buffer was further modified to achieve a pH of 6.8 and a higher and 
more  relevant  buffer  capacity  by  Liu  et  al.  (2011).  Hanks  solution  is  primarily  a 
bicarbonate buffer, in which bicarbonate (HCO3‐) and carbonic acid (H2CO3) co‐exist, 
along with CO2 (aq) resultant from the dissociation of the latter (Equation 3.4). 
 
Table 3.7: Comparison of the ionic composition (mM) and buffer capacity of the small intestinal fluids, phosphate buffer 
and mHanks adopted from Liu et al. (2011) 
Composition   Human Jejunal 
fluids 
Phosphate bufeer 
(0.05M) 
mHanks buffer 
Bicarbonate  7.1  Not present  4.17 
Phosphate  0.8  50  0.8 
Potassium   5.1  50  5.8 
Sodium  142  29  142 
Chloride  131  Not present  143 
Calcium  0.5  Not present  1.3 
Magnesium      0.8 
pH  6.8  6.8  6.8 
Buffer Capacity 
(mmol\L\ΔpH) 
3.2  23  3.1 
 
Equation 3.4: Bicarbonate disassociation  
 
Where bicarbonate (HCO3
-) and carbonic acid (H2CO3) coexist, along with CO2(aq) resultant 
from the dissociation of the latter. The pH of the buffer system can be altered by adjusting the 
concentration of the acid (H2C03) and its conjugate base (HCO3
-). Therefore, purging CO2(g) 
into Hanks buffer in excess increases the concentration of CO2(aq), promoting the formation of 
carbonic acid and thus resulting in a decrease in the pH of the buffer system.  
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The modified Hanks bicarbonate buffer was prepared by mixing 136.9mM NaCl, 5.37mM 
KCl,  0.812mM  MgSO4*7H2O,  1.26mM  CaCl2,  0.337mM  Na2HPO4*2H2O,  0.441mM 
KH2PO4 and 4.17mM NaCO3 (Liu et al. (2011)) The preparation of the media included the 
addition of bile salts (mixture of sodium cholate and sodium deoxycholate) in the following 
concentration 1, 3, 6mM. pH was measured after the addition of bile salts and was around 
7.4: To further  adjust the pH, CO2(g) was purged  into the buffer solution using polyurethane 
flow gas tubes (Freshford Ltd., Manchester, UK) to obtain pH 6.8, and for a longer time to 
obtain a pH of 6.4. The flow of the gas was monitored using the gas flow meter. Each tube 
was positioned 2cm below the liquid surface of its corresponding vessel at a very low flow 
rate  (at  pressure  of  2mbar)  compared  to  what  had  been  used  previously,  so  as  to  avoid 
significant  influences  in  the  hydrodynamics  of  the  dissolution  apparatus.  Buffer  capacity 
measurements for all buffers were carried out according to the method described in section 
3.2.4.5.  
 
Cross-over  study  design  was  used  to  simulate  the  conditions  of  different  individuals’ 
proximal small intestine with respect to pH and bile salt concentration. The following pH 
condition and bile salt concentrations were chosen as 6.4, 6.8, 7.4 and 1, 3, 6mM (Table 3.8). 
Increasing the concentration of bile salt further was not possible, however, given that the 
continuous purging of CO2 with higher bile salt concentration produced foam in the vessel.  
Lower pH could  also  not  be attained by purging CO2  alone without changing the initial 
bicarbonate concentration in the media. 
 
Table 3.8: Cross over study to simulate different individuals’ proximal small intestine with changes in pH and bile salts 
concentration 
pH \ Bile salt 
concentrations 
1mM  3mM  6mM 
6.4  X  X  X 
6.8  X  X  X 
7.2  X  X  X 
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  FaSSGF 
 
Simulated gastric fluids, FaSSGF, were prepared according to Vertzoni et al. (2005). The 
concentrations of the components are given in Table 3.9. Some modifications were made 
with respect to f pH and bile salt concentration so as to mimic individual’s variability in 
gastric fluids, based on publication from Pedersen et al. (2013), where aspirated gastric fluids 
were characterised. The pH was found to range from 1.16 to 5.96. The high measurement 
above pH 5, however, was probably due to the dilution of the gastric contents by saliva 
and/or  nasal  secretion,  or  due  to  high  reflux  from  the  intestine.  In  terms  of  bile  salt 
concentration, a mean value of 0.3mM was found, ranging from 0 up to 0.6mM. Therefore, 
the following pH conditions were chosen to simulate differences between individuals as 1.2, 
1.8 and 2.5 and 0.08, 0.3 and 0.6mM bile salts. Cross over study design was again used to 
simulate  different  individuals’  stomach  conditions  with  respect  to  pH  and  bile  salt 
concentration (Table 3.10) 
 
Table 3.9: Simulated gastric fluids composition Vertzoni et al. (2005) 
Composition   
Sodium taurocholate(µM)  80 
Lecithin  (µM)  20 
Pepsin (mg/mL)  0.1 
Sodium chloride (mM)  34.2 
Hydrocholic acid  QS pH 1.6 
pH  1.6 
 
 
 
 
Table 3.10: Cross over study to simulate different individuals’ gastric fluids with changes in pH and bile salts concentration. 
pH\Bile salt 
concentration  
0.08  0.3  0.6 
1.2  X  X  X 
1.8  X  X  X 
2.5  X  X  X 
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3.3.4.2 Drugs  
 
Furosemide (40mg) and dipyridamole (100mg) were weighted into gelatine capsules, and the 
drug release under different conditions was evaluated using USP-II apparatus. In addition, the 
commercial immediate release tablets of furosemide and dipyridamole were tested under the 
same conditions. The amount release from capsules was determined using an in line UV 
spectrophotometer with 1 or 10mm flow cells at 285nm and 238nm for dipyridamole and 
furosemide,  respectively.  Data  were  processed  using  Icalis  software  and  the  tests  were 
conducted in  triplicate,  in 900mL dissolution  medium  maintained at  37ﾱ0.5˚C.  A paddle 
speed of 50 rpm was employed. The tests were lasted for 2 hours and pH was measured 
periodically along the experiment and was maintained at the desired pH ±0.5 by sparging 
CO2 into the media.  
3.3.4.3 Calculations and Statistical Analysis  
 
The dissolution profiles were analysed by one way ANOVA repeated measurements using 
general linear model followed by a Tukey post- hoc analysis in PASW statistics 22 (SPSS 
Inc., Illinois, USA).  
 
Dissolution Efficacy (AUC2h/ AUC Theoretical *100) was calculated at 120 min and the effect of 
both bile salt and pH was evaluated by a mixed effect model. The experimental assay was 
adapted  to  the  structure  of  a  two  factorial  experimental  design  -pH  and  bile  salts 
concentration. A multiple standard regression was used to quantify the effects of all variables 
under study on the dissolution of both drugs and to construct the corresponding response 
surfaces graph (SPSS, v.22). 
Dissolution rate was calculated based on the following equation for all dissolution profiles 
(Equation 3.5).  
 
Equation 3.5: Calculation for dissolution rate  
 
CV % for the dissolution efficacy and dissolution rate was calculated by dividing the standard 
deviations to the mean.  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
 
- 103 - 
 
3.3.5  Results & Discussion 
 
Further modifications of mHanks were implemented successfully in this research.  Addition 
of bile salt up to concentration of 6mM did not change the initial pH and decrease in pH to 
6.4 was achievable without changing the recipe composition. The continuous purging of CO2 
along  the  experiments  did  not  create  any  foam  during  two  hours  of  experiments.  Buffer 
capacity  was  measured  for  all  solutions.  Buffer  capacity  increased  with  bile  salts 
concentration (5mmol/L/ΔpH for media with 6mM bile salt concentration) and decreased 
with pH changes (1.4mmol/L/ΔpH for media with pH 7.4). 
 
It  can  be  seen  that  dipyridamole  was  not  dissolved  completely  after  2  hours  under  all 
conditions (Figure 3.8). In addition, the dissolution rate and extent of dipyridamole release 
were influenced primarily by bile salt concentration. At higher bile salt concentration, the 
extent of release after 2 hours was around 60%. pH did not influence the drug release to a 
similar extent, as  under different  pH conditions at  the same bile salts  concentrations  the 
percentage of release was not significantly different. It was also found that release from the 
commercial  dipyridamole  tablet  followed  the  same  dissolution  pattern  as  for  the  active 
ingredient alone (Figure 3.9). The solubility/dissolution increase of poorly soluble drugs in 
the presence of bile salts can be attributed to two mechanisms: When the bile salts are present 
at a level below their CMC, adsorption of bile salts on the surface of dipyridamole particles 
may reduce their free surface energy and facilitate wetting and removal of molecules, with a 
parallel  increase  in  saturation  solubility  in  the  bulk  solution.  However,  at  concentrations 
higher than the critical micelle concentration (CMC), bile salts should theoretically enhance 
drug dissolution by forming submicron-mixed micelles in which the lipophilic dipyridamole 
molecules are solubilised (Holm et al., 2013).  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Figure 3.8: Dissolution of dipyridamole in mHanks buffer under different conditions of bile salt and pH. 
 
Figure 3.9: Dissolution of dipyridamole commercial tablet in mHanks buffer under different conditions of bile salt and pH. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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In comparing dissolution profiles of commercial tablets of dipyridamole and the API, it is 
safe  to  conclude  that  the  excipients  in  the  commercial  tablet  did  not  affect  the  drug 
dissolution and were not able to minimize bile salts effect.  
 
Further  regression  analysis  was  performed  to  understand  the  effect  of  pH  and  bile  salts 
concentration  on  the  extent  of  dipyridamole  release  (AUC0-120)  of  in  mHanks.  Standard 
multiple linear regression (SPSS statistics software release 22.0.0, SPSS Inc., Chicago, IL) 
was used to evaluate the influence of pH and bile salts concentration in mHanks on the drug 
release.  The drug release was found to be primarily dependent on bile salt concentration and 
marginally  on  pH  (R
2  =0.923,  F=19.97  p˂0.01).  Equation  3.6,  obtained  by  multiple 
regressions,  enables  the  prediction  of  drug  release  in  the  mHanks  media  based  on  the 
knowledge of pH and bile salts concentration in the range measured in this research.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
 
Equation 3.6: The effect of bile salts and pH on dipyridamole release in mHanks. 
 
Interestingly, at that clinical dose, the furosemide mean extent of release was around 80%. 
Furosemide dissolution did not show any particular trend as for pH and bile salt concentration 
(Figure 3.10) However, great variability in the percentage of release was observed under 
different conditions, ranging from 70 to 100% at 120 min (10% CV in dissolution efficacy 
under all conditions). In addition, high variability in the dissolution rate (between 0-30 min) 
was observed with calculated CV of 80%. Surprisingly, the dissolution of the commercial 
tablet gave around 70-80% release with low variation in the extent and dissolution rate (2% 
and 30% CV in dissolution efficacy and dissolution rate, accordingly) under all conditions 
(Figure 3.11).  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Figure 3.10: Dissolution of furosemide in mHanks buffer under different conditions of bile salt and pH. 
 
Figure 3.11: Dissolution of furosemide commercial tablet in mHanks buffer under different condition of bile salt and pH. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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As  has  been  described  previously,  furosemide  is  a  weak  acid.  As  its  disintegration  and 
dissolution first occur in the stomach for immediate release forms, changes in the stomach 
fluid  need  to  be  considered  in  terms  of  their  effects  on  furosemide.  The  dissolution  of 
furosemide under different conditions of both API and the commercial tablet in the stomach 
gave a low percentage release from 8 to 16%. Again, no trend was observed as for pH or bile 
salt concentration changes, with great variability around dissolution rate and percentage of 
release at 120 minutes (Figure 3.12 and Figure 3.13). 
 
Figure 3.12: Dissolution of furosemide in FaSSGF buffer under different conditions of bile salt and pH. 
 
 
Figure 3.13: Dissolution of furosemide commercial tablet in FaSSGF buffer under different conditions of bile salt and pH. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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The great variability under different conditions of furosemide API can be attributed to the 
wetting capacity of the powder after the gelatine capsules dissolved. Based on the lab work 
experience with furosemide, furosemide powder was very difficult to handle (fluffy and had 
static  properties).  It  was  observed  that  in  a  simple  buffer  solution,  furosemide  was  not 
dispersed equally and instead agglomerates to bigger particles. This was not observed in the 
commercial tablet dissolution, and it may well be that the excipients or compressing the 
powder in the form of tablet contributed to the wetting and dispersion of the tablet. In  section 
3.1, it was found that saturated solubility of furosemide is both pH and bile salt dependent. 
However, when examining the dissolution in bicarbonate buffer and FaSSGF, no dependency 
on pH or bile salts was observed. This can be attributed to the low ratio of dose to the 
dissolution  volume.  However,  the  high  variability  in  the  rate  of  furosemide  dissolution 
observed in vitro due to the powder characterisation might explain some of the variability in 
vivo. Moreover, based on the low dissolution of furosemide in the stomach, it might be that 
erratic  gastric  emptying  time  between  individuals  will  markedly  influence  the  drug 
dissolution rate and eventually on the extent of absorption in combination of variation in 
intestinal transit time.  
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3.3.6  Summary                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
As for solubility studies, use of simulated intestinal fluids in dissolution test can provide 
valuable information about the different factors affecting changes in drug release between 
individuals. It is always preferable to simplify the situation in order to understand variability 
mechanism; therefore, based on the results from the solubility study in section3.2, bile salt 
and  pH  were  investigated  in  relation  to  dissolution.  It  was  found  that  dipyridamole 
dissolution was relatively low and varied significantly with increasing bile salt concentration 
and to a lesser extent with pH. The dissolution of furosemide was complete although fairly 
variable under all conditions and did not vary with increasing bile salt concentration or in the 
investigated pH range. These results are relatively surprising considering the results from the 
previous study. Moreover, as furosemide is classified as a BSC IV drug in the administered 
clinical dose, one would not expect complete drug release. Based on these results, it will be 
interesting to investigate if these conditions affect the drug permeability and how it affects 
the overall process of drug absorption.                                                                                                                                                                                                                                                                                 Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.4  Evaluation of the Dissolution and Permeability of Dipyridamole and 
Furosemide under Different Conditions of Bile Salt Concentration and pH  
3.4.1  Introduction 
3.4.1.1 Prediction of Absorption in the Dissolution Permeation System  
 
In vitro evaluation of dissolution or solubility-limited absorption focuses on the estimation of 
intraluminal concentrations by dissolution and precipitation assessment in setups that ignore 
intestinal  permeation.  To  predict  drug  flux  and  hence  the  fraction  absorbed,  estimated 
dissolved concentrations need to be combined with drug permeability. The advantages in 
modelling a set up that includes both dissolution and permeation assessments are that it better 
mimics sink conditions for highly permeable drugs. Secondly, it was reported that in some 
cases, developing new formulations in order to increase solubility, might compromise its 
permeability (Beig et al., 2012; Kostewicz et al., 2013; Miller and Dahan, 2012; Miller et al., 
2011). As such, an account of both dissolution/solubility and permeability is highly valuable 
to simulate the dissolution and permeation process in vitro. The first published attempt to 
develop  an  integrated  dissolution  Caco-2  system  to  predict  dissolution–absorption 
relationships describes a system where first dissolution occurs in bio-relevant media. Due to 
incompatibility of the Caco-2 monolayer to the conditions of the bio-relevant media, samples 
were treated to adjust its composition similar to Hanks balance buffer, and their permeability 
tested through the monolayer (Ginski and Polli, 1999) (Figure 3.14). It was found that the fast 
and  slow  formulations  of  piroxicam,  metoprolol,  and  ranitidine,  predicted  dissolution-
absorption relationships from a continuous dissolution/Caco-2 system qualitatively matching 
the in vivo data. However, it is important to note that this system requires that drug solubility 
and permeability are not adversely affected by conversion from the dissolution medium to the 
final Caco-2 donor solution. A decrease in solubility may precipitate the drug and reduce the 
donor concentration in the Caco-2 permeation studies. In addition, the pump flow rate might 
also affect the permeation assessment. 
 
 
Figure 3.14: Dissolution/Caco-2 system developed by Ginski and Polli (1999) Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Vertzoni et al. (2012) assessed danazol permeation through Caco-2 monolayer using real 
human intestinal fluids (Figure 3.15). Duodenal aspirates were collected after administration 
of  the  lipophilic  drug  danazol  together  with  a  meal,  and  increasing  luminal  lipid 
concentration reduced danazol permeability. However, increasing the solubility of danazol in 
the aspirates  thanks to  the lipids  more than compensate for the reduced permeation flux 
obtained with the aspirates, leading to a higher overall rate of transport. 
  
 
 
Figure 3.15: Assessment drug solubility by real human fluids following permeation through Caco-2 cells (Vertzoni et al., 
2012). 
 
A further development of this system by addition of  the gastric compartment was done by 
Kobayashi et al. (2001). This system was designed to enable prediction of the absorption rate 
of not only water-soluble drugs, but also drugs that have poor water solubility (Figure 3.16). 
For  instance,  dissolution  and  permeation  of  albendazole  and  dipyridamole  from  different 
formulations were tested in this system (Sugawara et al., 2005).  
 
 
Figure 3.16: Adding gastric compartment to assess dissolution/permeation (Kobayashi et al., 2001) Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Motz et al. (2007) utilized USP apparatus 4 combined with Caco-2 permeation flow cell 
using  a  stream  splitter.  The  apparatus  has  been  validated  using  several  formulations  of 
propranolol  HCl,  but  its  added  value  for  more  challenging  drugs  has  not  been  reported 
(Figure 3.17). 
 
 
Figure 3.17: USP apparatus 4 combined with Caco-2 permeation flow modifications developed by Motz et al. (2007) 
 
All  the  systems  mentioned  above  integrated  separate  absorption  compartments,  and  the 
transfer of the dissolved samples was dependent either on flow rate detected by pumps or 
sample  treatment  prior  permeation  assessment.  Moreover,  sink  conditions  were  not 
maintained. Kataoka et al. (2012) optimized  a side-by-side dual chamber system to allow for 
dissolution of solid dosage forms at the apical side of a Caco-2 cell monolayer, known as the 
dissolution –permeability system (D/P system- Figure 3.18). 
 
 
 
Figure 3.18: A side-by-side dual chamber system called the dissolution –permeability system developed by Kataoka et al. 
(2012) Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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In this setup, buffer media were optimized to simulated intestinal fluid. Since FaSSIF media 
based on phosphate ions due to its high osmolality caused a rapid decrease in the monolayer 
TEER (indicating damage to the monolayer integrity), a modified FaSSIF based on Hanks 
balanced buffer with low osmolality at pH 6.5 was used as the apical medium (8mL)(Kataoka 
et al., 2006). Isotonic buffer (pH 7.4) with serum albumin was used as basal medium (5.5mL) 
to ensure sink conditions. Both compartments were stirred at 200rpm (Kataoka et al., 2003). 
The  advantage  of  this  system  is  that  permeation  and  dissolution  are  determined 
simultaneously  at  the  same  time  point,  ensuring  that  dissolved  drug  can  permeate  the 
intestinal  membrane.  In  vitro–in  vivo  correlations  (IVIVC)  using  the  D/P  system  was 
demonstrated by using clinically relevant doses. The group showed that an increased amount 
of  the  applied  dose  especially  for  poorly  soluble  drugs  increased  the  permeated  amount. 
Therefore, in order to evaluate in vivo absorption by using in vitro experiments with the D/P 
system, the applied amount should be decided based on the in vivo clinical dose of each drug. 
1% of clinical dose should be applied to the D/P system when correlating the results to the in 
vivo  absorption  data.  The  explanation  for  that  is  the  GI  fluid  volume  was  reported  as 
approximately 500mL and 900–1000mL at fasted and fed state, respectively and considering 
the apical volume (8mL) in the D/P system, a proportion of 1/100 corresponds to about the in 
vivo volume. As such, a correlation between the human fraction absorbed and the permeated 
amount in  the D/P system  has  been established for poorly water-soluble reference drugs 
(Kataoka et al., 2003) (Figure 3.19).  
 
Figure 3.19: Correlation between in vivo human absorption and in vitro permeated amount in the D/P system (Kataoka et al., 
2003) . Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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The D/P system has been further utilised to predict the net food effect on the absorption of 
poorly soluble drugs. 13 drugs were tested in the fed and fasted states, and good correlation 
was obtained to the fraction absorbed reported in the literature.  In addition, the D/P system 
has  also  been  used  to  rank  the  effectiveness  of  drug  formulations  to  improve  the  oral 
absorption of poorly soluble drugs. Buch et al. (2009) tested different formulations (solid 
dispersion,  nano-  and  microsized)  of  fenofibrate  in  the  D/P  system,  and  successfully 
predicted the formulation performance in rats. Similarly, Katoka et al.  (2012) investigated 
the effect of different formulations of danazol (BCS II) and pranlukast (BCS IV) using the 
D/P system for evaluation of solubilizing and supersaturating effects. On the apical side, an 
increased extent of release was observed with both drugs in the D/P system; however, the 
permeated amount was only improved for danazol. Good IVIVC was obtained for danazol 
with increasing bioavailability in the rat, but was not observed for pranlukast. These results 
demonstrate the importance of simultaneously assessing dissolution and permeation when 
evaluating  absorption-enhancing  strategies.  Another  application  of  the  D/P  system 
demonstrated the use of the system to learn about transporter-related drug-drug, drug-food, 
and drug-excipient interactions. When erythromycin - an inhibitor of the efflux carrier P-gp – 
was applied to the apical medium, permeations of fexofenadine and talinolol P-gp substrates 
were significantly enhanced without change in their dissolution. Moreover,  the effect of  the 
surfactant Cremophor EL as a P-gp inhibitor and surfactant was tested on the dissolution and 
permeation of saquinavir, and it was found that both solubility/dissolution and permeation as 
a  result    of  P-gp  inhibition  were  increased  (Kataoka  et  al.,  2011).  Recently,  the  group 
demonstrated  that  the  D/P  system  enables  evaluation  of  the  limiting  steps  in  the  oral 
absorption  of  poorly  water-soluble  drugs,  and  prediction  of  dose-dependent 
pharmacokinetics. For instance, increasing applied doses of zafirlukast slightly decreased the 
dissolution and permeation in the D/P. Although the difference in the dose of zafirlukast was 
eightfold (10–80mg), the obtained fa value was predicted to be around 35%, irrespective of 
the  dose.  It  was  suggested  that  the  limiting  step  of  zafirlukast  absorption  could  thus  be 
dissolution rate, and not solubility. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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An understanding of both dissolution and permeation simultaneously is crucial to understand 
drug absorption. Dissolution tests practically show the free concentration in the fluids which 
is available to be absorbed, however it does not mean that the entire drug in solution will be 
able to permeate through the gut wall such in the case of BCS IV drugs. In the previous 
section,  different  conditions  of  pH  and  bile  salt  concentration  of  GI  fluids  resembling 
individuals with different composition of GI fluids have been shown to affect the dissolution 
profile  of  dipyridamole.  Therefore,  it  will  be  highly  desirable  to  understand  how  these 
changes  might  be  reflected  in  the  permeation  profiles  and  affectively  its  absorption.  In 
addition, no significant differences in the dissolution of furosemide were observed previously 
under different conditions of bile salt concentrations and pH. However, as furosemide is a 
poorly permeable drug, it will be useful to determine whether these different conditions affect 
its  permeation.  In  this  research,  the  D/P  system  was  utilised  to  investigate  the  effect  of 
different  bile  salt  concentrations  and  pH  conditions,  relevant  to  the  fasted  state,  on  the 
dissolution and the permeability of dipyridamole and furosemide in order to predict possible 
variable absorption in human.  
 
3.4.2  Objective 
 
  To investigate the effect of bile salt concentrations and pH, relevant to the GI fasted 
state, on the dissolution and the permeation of dipyridamole and furosemide to predict 
possible variable absorption in humans Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.4.3  Materials  
 
Caco-2  cells  human  adenocarcinoma  cell  line  (86010202),  Dulbecco’s  modified  Eagle’s 
medium (DMEM)(D5671), fetal bovine serum (F7524) , non essential amino acids (M7145), 
L glutamine (G7513), 0.25% trypsin-EDTA (T4049), gentamicin (G1264) (50mg/ml), HBSS 
10X  with  no  calcium  and  magnesium  (55037C),  sodium  bicarbonate  (S5761)  ,  dextrose 
anhydrous (158968), HEPES (hydroxyethyl piperazineethanesulfonic acid) (H3375),  bovine 
albumin  serum  (A9418),  NaOH  and  HCl  5M  standard  solution,  acetonitrile  and  water  
HPLC/LCMS  grade  were  purchased  from  sigma  Aldrich  (Dorset,  UK).  SIF  powder  was 
obtained from Biorelvent.com (London, UK). Transwells Cornining Costar Corporation (6 
wells,    2.4cm
2  surface  area,  3µm  pore  size,  PET  clear  membrane,  3452),  syringe  filters 
(Millex, SLLHH04NL, 4mm, 0.45µm, Millipore) and 162 cm
2 flasks were obtained from 
Fisher ( Leicestershire , UK). 
 
3.4.4  Methods 
3.4.4.1 Cell Culture  
 
 The following protocol was adapted from Ashiru D, PhD thesis (2009) 
  Cell maintenance  
 
Caco-2 cells were grown and maintained in culture as previously described (Hidalgo et al., 
1989). Briefly, cells were grown in 162cm
2 cell culture flasks and subcultured weekly on 
achieving 80-90% confluency. Cell culture growth medium was DMEM, supplemented with 
10% v/v fetal bovine serum, 1% v/v non-essential amino acids, 1% v/v L- glutamine, 0.1% 
v/v gentamicin (50 mg/mL). Cells were stored in an incubator at 37˚C with a humidified 
environment of 95% and 5% CO2. The medium was changed every 2-3 days. All processes 
were carried out using trained techniques and precautions relative to cell culture in class II 
flow cabinet.  
  Subculture  
 
On reaching 80-90% confluency, the cells were visualised under an inverted microscope to 
verify the general appearance of the culture and look for signs of microbial contamination. 
The culture was also observed with an unaided eye to look for fungal colonies that could be 
floating at the medium- air interface.  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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The Caco-2 monolayers in the flasks were detached from the surface with 0.25% trypsin-
EDTA. The trypsin was inactivated by the addition of medium containing FBS. The exact 
procedure is thus: 
1.  Using a sterile pipette, old culture medium was removed and discarded. 
2.  The  monolayer  was  rinsed  with  5mL  of  calcium  and  magnesium-free  phosphate 
buffer (CMF-PBS) to remove all traces of FBS.  
3.  3mL pre-warmed trypsin solution was then added to the flask, cells incubated for at 
least 1 minute on the bench and then the flasks were transferred to a shaking incubator 
for detachment of cells. 
In order to avoid subpopulation selection, 100% of cells were detached at each passaging 
procedure. The process of detaching the cells took between 5 to 10 minutes; the cells were 
regularly inspected under an inverted microscope to determine the point at which all cells had 
been detached. The cells from the flask were transferred to a centrifuge tube, and the cell 
suspension centrifuged at 200xg for 5 minutes with the pellet then re-suspended in medium. 
A  cell  count  was  performed  by  taking  a  100µL  sample  from  the  cell  suspension  and 
combined  with  100µL  trypsin  blue;  this  was  mixed  vigorously,  and  the  suspended  cell 
density  determined  using  a  Neybauer  Hamocytometer.  The  number  of  cells/mL  was 
calculated, and the required cell concentrations generated by appropriate dilution.  
  Cell freezing  
 
At regular intervals, cells that had reached confluency in 162cm
2 flasks were prepared for 
cryopreservation. Prior to freezing, as with subculturing, the cells were visualised under an 
inverted  microscope  to  verify  the  general  appearance  of  the  culture  looking  for  signs  of 
microbial contamination. The culture was  also observed with an unaided eye to look for 
fungal colonies that could be floating at the medium- air interface. The cells were harvested 
in the same manner as described above for subculture. However prior to centrifugation, a 
sample was taken for counting. Whilst the cells were spinning, a viable cell count was carried 
out as previously described, and the number of cells/mL was calculated as well as the total 
cell number. After centrifugation, the supernatant was removed from the centrifuged cells and 
the cell pellets re-suspended in enough cryprotective medium (freezing medium in DMSO) to 
give a final cell concentration of 1 to 2*106 cells/mL.  
 
Cryogenic vials were labelled with the cell line, passage number and date, and 1.8 mL of the 
freezing media containing cell suspension was added to each of the vials and sealed. The cells Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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were frozen in a -80˚C freezer using a ‘Mr Frosty’ cell freezer containing room temperature 
isopropanol in the bottom compartment to ensure a gradual freezing of the cells. After 24 
hours, the vials were transferred to a liquid nitrogen storage vessel until required.  
  Cell revival 
 
 The required vial was transferred from the liquid nitrogen storage and rapidly thawed in a 
37˚C  water  bath  within  60  to  90s.  The  contents  of  the  vial  were  transferred  to  a  flask 
containing 15mL of cell culture medium. The tube was centrifuged for 5 min at 200 x g. 
After centrifugation, the supernatant was removed from the centrifuged cells, and the cell 
pellets  were re-suspended in  fresh  growth media. The  cell suspension  was  transferred to 
25cm
2 flask and was incubated for at least 3 days until a monolayer was formed, after which 
the media was replaced by fresh media until 90% confluency was achieved.  
  Seeding cells on transwells 
 
For D/P studies, cells were seeded at a density of 60,000 cells/cm
2 (1.2 x 10
5 cells/well) onto 
6 Transwell polyesther membranes with 24 mm diameter, poor size of 3µm and surface area 
of  2.4  cm
2.  Cells  growing  on  transwells  membranes  were  provided  with  fresh  complete 
medium three times a week until the time of use. To feed the cells,  1.5mL of complete 
medium was added to the top of the cell layer, and 2.6mL was added to the bottom of each 
transwell. All cells used in this study were between passages 47 to 56. The filters were used 
between the 17
th and 21
st day of culture.  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.4.4.2 Buffer Preparation  
 
  Preparation of transport medium 
100mL DI water were transferred in a 300mL volumetric flask and HBSS solution was 
added. Sodium bicarbonate, glucose and HEPES were added and dissolved stepwise. The 
volume was completed to 300mL with purified water, and pH was adjusted to 6.5 using 
NaOH/HCl solution (Table 3.10).  
Table 3.11: Transport medium, pH 6.5 
Composition  Amount per 300mL 
HBSS Solution  30mL 
Sodium bicarbonate  105mg 
Dextrose anhydrous (D+/-glucose)  750mg 
HEPES*  675mg 
DI Water  QS 300mL 
 
  Preparation of fasted state simulated intestinal fluid (FaSSIF) 
SIF powder was weighted to create the following concentrations of 1,3 and 6mM of sodium 
taurocholate, and dissolved in about 50 mL of transport medium. The volume was completed 
to 50mL, and the pH was adjusted to 6, 6.5, 7.4 using NaOH/HCl solution (Table 3.12). 
Table 3.12: FaSSIF, pH 6.5 
Composition  Amount per 150mL 
SIF powder 
*  328mg 
Transport medium  QS to 150mL 
 
  Preparation of Basal Solution 
BSA (bovine serum albumin) was weighted in a beaker, and 100mL of the transport medium 
were added. Gentle stirring was applied for an hour to complete dissolution.  Upon complete 
dissolution, the pH was adjusted to 7.4 with 5M NaOH solution before use (Table 3.13). 
Table 3.13: Basal solution, pH 7.4 
Composition  Amount per 100mL 
BSA *  4.5g 
Transport medium  100mL 
Sodium hydroxide solution, 5M  QS to pH 7.4 
 
3.4.4.3 D/P Experiment 
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Caco-2  cultured  in  a  six  well  plate  for  17  to  21  days  was  used  as  source  of  intestinal 
monolayer for this study. The plate was removed from the incubator, and the growing media 
was removed from the wells.  2.6mL of the basal solution were added to the basolateral sides 
first,  before  adding  1.5mL  of  the  transport  medium  to  the  apical  side.    The  plates  were 
incubated at 37˚C under 5% CO2 for 20 minutes to acclimatise the cells with the transport 
media. After 20 minutes, the plates were removed from the incubator and the media was 
decanted from the transwells.  The transwell inserts were attached in between the apical and 
basolateral chambers of the D/P system so as to mount the membrane vertically, as shown in 
Figure 3.18. 8mL FaSSIF solution on the apical side and 5.5mL of the basal solution on the 
basolateral side were added. The magnetic stir bars were placed in both sides (apical and 
basolateral) rotating at 200rpm (150-250, adjusted using a tachometer) using multi magnetic 
stirrers.  Once  the  chambers  preparation  was  completed,  they  were  transferred  into  an 
incubator  to  maintain  temperature  of  37˚C.  The  TEER  values  were  measured  prior  the 
beginning of the experiment, and whenever a sample was withdrawn (set point 2000Ω, mode 
R-  measured  values  varied  between  300  to  400Ω  during  experiments).  The  drug  or  the 
formulation were added into the apical side of the D/P system, and 200µL aliquots of samples 
were withdrawn from the apical and the basolateral sides to measure the amount dissolved 
and permeated with time at 5, 15, 30, 60, 90, and 120 minutes. The apical samples were 
filtered via 0.45µm syringe filters. After taking the last sample, the TEER was measured 
again to confirm the integrity of the monolayer during the experiment. The apical samples 
were  diluted  10  times  for  HPLC  and  100  times  if  analysed  by  LCMS  with  acetonitrile. 
Basolateral samples were diluted 7 times (for HPLC) by adding 1.2mL of ACN in the tubes 
to precipitate proteins. The basolateral samples were vortexed and centrifuged at 15,000 rpm 
at 20 ˚C for 10 minutes to remove the precipitates. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.4.4.4 Analytical Methods 
 
  HPLC methods for furosemide and dipyridamole  
Furosemide analysis was carried out using a HPLC system (LC-10A Shimadzu Co., Kyoto, 
Japan) with variable wavelength ultraviolet detector (SPD-10A, Shimadzu Co., Kyoto, Japan) 
and fluorescence detector (RP-10A, Shimadzu Co., Kyoto,  Japan). The column was  C18 
YMC  J'sphere  H-80  4.6  ×  75,  with  the  following  composition  of  mobile  phase:  50mM 
Phosphate buffer (pH 2.5): Acetonitrile (72:28% V/V). The excitation and emission were at 
333 and 415nm for and the UV wavelength was 280nm. The flow rate was 1.0mL/min and 
column temperature of 40˚C. The injection volume was 20µL. 
 
Dipyridamole analysis was carried out using C18 Column YMC J'sphere H-80 4.6 × 75, with 
mobile phase composition of 50mM Phosphate buffer (pH 2.5): Acetonitrile (72:28% V/V). 
The UV absorbance was at 270nm with flow rate: 1.0mL/min and column temperature of 
40˚C. The injection volume was 20µL. 
 
  LCMSMS analysis of dipyridamole  
The amounts of dipyridamole in the solutions from the basolateral side were determined by 
an UPLC system (ACQUITY
® UPLC, Waters, Milford, MA) equipped with a tandem mass 
spectrometer  (ACQUITY
®  TQD,  Waters,  Milford,  MA).  The  reversed-phase  Waters 
ACQUITY
® UPLC BEH C18 analytical column of 50mm length × 2.1mm I.D. and 1.7µm 
particle size (Waters, MA) was used with a mobile phase consisting of 0.1% (V/V) formic 
acid in water (solvent A) and acetonitrile containing 0.1% (V/V) formic acid (solvent B) with 
a  gradient  time  period.  The  initial  mobile  phase  was  98%  solvent  A  and  2%  solvent  B 
pumped at a flow rate of 0.3mL/min. Between 0 and 1.0 min, the percentage of solvent B was 
increased linearly to 95%, where it was held for 1.0 min. Between 2.01 and 2.5 min, the 
percentage of solvent B was decreased linearly to 2%. This condition was maintained until 3 
min, at which time the next sample was injected into the UPLC system. All samples were 
injected as 5 µL into the UPLC system. Protonated precursor and production ions (m/z) for 
detection were 505.328 and 429.328, respectively. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.4.4.5 Statistical and Data Analysis  
 
Calculation of fa based on permeation results were calculated as followed (Kataoka et al., 
2012) 
 
Equation 3.7: fa estimations from the D/P system  
 
Where Absmax is the maximum absorption (defined as 100%), PA is the in vitro permeated 
amount in the D/P system (% of dose/2 h), PA50 is the permeated amount, which corresponds 
to 50% of the absorption in vivo, and   is a Hill’s coefficient. PA50 and   were obtained by 
fitting the permeated amount (PA) of drugs in the D/P system and their oral absorption in 
human (on system validation). 
 
The  dissolution  and  permeation  data  were  analysed  by  one  way  ANOVA  repeated 
measurements followed by a tukey post- hoc analysis using Univariate General Linear Model 
tool  in PASW statistics 22 (SPSS Inc., Illinois, USA).  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.4.5  Results & Discussion  
 
The dissolution  and permeation of dipyridamole were tested under different  condition  of 
sodium  taroucholate/lecithin  and  pH  (Figure  3.20  and  Figure  3.21).  As  can  be  seen,  the 
dissolution  of  dipyridamole  in  mFaSSIF  in  the  apical  side  under  different  bile  salts 
concentration  gave  a  higher  extent  of  release  under  6mM  concentration  of  sodium 
taurocholate (p˂0.05), followed by 3mM and  1mM. As for the different pH conditions, at pH 
7.4 the dissolution extent was the highest, followed by pH 6 and 6.5, although they were not 
significantly different from each other (p˃0.05). The dissolution results obtained in this study 
confirmed that bile salt concentration has a more significant influence on the dissolution of 
dipyridamole, as the percentage of drug release after 2 hours was higher at pH 6.5 with 6mM 
taurocholate concentration than at pH 6 and 3mM taurocholate concentration (12 and 5% 
respectively).  The  differences  in  the  extent  dissolved  under  different  conditions  reported 
previously (Figure 3.8) in mHanks were also more significant compared to the differences in 
the extent and dissolution rate found herein (60% release at 2 hours compared to only 12% 
release). This might be explained by the different composition of the media. As discussed, the 
mHanks buffer resembles more closely the intestinal fluids in terms of ion composition and 
buffer capacity, and therefore the differences might be attributed to these factors. However, 
considering the significant effect of bile salt on the dissolution of dipyridamole and the basic 
nature of the drug, the differences in the bile salt composition of the two buffers might be 
better  explanation  for  these  differences  in  the  extent  of  release.    The  bile  salts  used  in 
mHanks  buffer  are  comprised  of  two  bile  salts,  whereas  in  this  study  only  the  effect  of 
taurocholate  with  lecithin  was  investigated.  Interestingly,  the  permeation  profile  of 
dipyridamole  under  different  bile  salt  concentrations  did  not  differ  (p˃0.5),  although 
increasing bile salt concentration increased the percentage of the drug dissolved on the apical 
side.  However,  a  significant  decrease  was  observed  in  the  permeation  amount  of 
dipyridamole under pH 6.  It seems that although bile salt concentration had a significant 
effect  on  the  extent  of  dipyridamole  dissolution,  the  pH  was  a  more  significant  factor 
influencing  permeation  of  the  drug  through  the  monolayer.  On  predicting  the  fraction 
absorbed in human, fa was estimated to be around 30% with variation of 23% under all 
conditions (Figure 3.22)  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Figure 3.20: Dipyridamole dissolution and permeation under different bile salts concentration in the D/P system 
 
Figure 3.21: Dipyridamole dissolution and permeation under different pH conditions in the D/P system 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22: Predicted fraction absorbed based on D/P system. Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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Furosemide dissolution under different pH condition produced a general trend, with a higher 
extent of release at pH 7.4 and lower at pH 5.5. Significant differences were observed in the 
case  of  furosemide  dissolution  at  pH  5.5  as  compared  to  the  other  conditions  (p˂0.05). 
Similarly, at concentrations of 1mM taurocholate, the lowest extent of release was obtained. 
However, the extent released at taurocholate concentrations of 3 and 6mM did not differ 
significantly from one other similar permeation profiles which were obtained for furosemide 
under all conditions, with no significant differences (Figure 3.23 and Figure 3.24).  
 
Figure 3.23: Furosemide dissolution and permeation under different bile salts concentration in the D/P system 
 
 
 
 
Figure 3.24: Furosemide dissolution and permeation under different pH conditions in the D/P system Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
 
- 126 - 
 
Kataoka  (2003)  reported  previously  that  addition  of  taurocholate  facilitates  both  the 
dissolution  and  permeation  of  griseofluvin,  although  taurocholate  was  seen  to  be  less 
effective on permeation than dissolution. With 6mM taurocholate, dipyridamole dissolved 
rapidly, and the dissolved amount reached a plateau level at around 10% of the dose. It can be 
suggested  that  micelle  formation  facilitates  increased  dipyridamole  solubility,  though  the 
dissolved drug was not available to permeate through the monolayer since it was incorporated 
in the micelles. The pH effect was more significant for the permeation of dipyridamole. A 
compound  diffuses  across  the  lipid  bilayer  portion  mainly  as  an  uncharged  and  largely 
desolvated species, depending on its molecular size and affinity to the centre of the lipid 
bilayer. As mentioned, dipyridamole pka is 6.4, and so at that pH it is expected that around 
half of the applied amount will be present in the ionized form and the other half unionized; it 
is the unionized form which is available to be absorbed. With decreasing pH, the ionized 
form of the weak base will increase (therefore increased solubility/dissolution on the apical 
side). However, it is not available to permeate through the membrane, as only neutral species 
can penetrate the membrane in passive diffusion. In a different experiment, Kataoka et al. 
(2006)  tested  the  in  vitro  permeation  of  propranolol,  danazol,  and  albendazole  with 
FaSSIFmod and FeSSIFmod as the apical media in the D/P system. The FaSSIF and the FeSSIF 
pH was adjusted to pH 6.5 and 5, respectively, based on the updated version published by 
Jantraid et al. (2008). It was found that although the dissolution of albendazole was much 
faster in FeSSIFmod, the permeated amount only slightly increased by FeSSIFmod. In addition, 
the  permeated  amount  of  propranolol  was  dramatically  decreased  when  FeSSIFmod  was 
applied.  It  was  proposed  that  the  lower  pH  of  FeSSIFmod  (pH  5.0)  might  facilitate  the 
ionization of the basic drugs (propranolol and albendazole), and decreased its permeability 
through the Caco-2 monolayer.  
 
As  reported,  the  in  vivo  regional  pH  of  the  gastrointestinal  fluid  varies  significantly.  
Moreover,  it  was  suggested  that  an  acidified  (pH=5.3)  microenvironment  existed  in  the 
mucosal surface of enterocytes (Hogben et al., 1959). Those results were further confirmed 
by direct microelectrode pH measurements in inverted intestinal segment in vitro experiments 
(Lucas  et  al.,  1975).  Additional  studies  suggested  the  surface  of  cells  was  metabolically 
enriched with protons, predominantly by Na+/H+ antiporter (McEwan et al., 1988). All of 
these conditions might therefore affect the ionization of weak bases and acids, and need to be 
considered in order to better understand mechanisms of drug absorption. As described, most 
of the dissolution tests actually measure the drug concentration in the vessel; However, based Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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on the D/P system  results  presented herein, it is  clear that the free drug  available to  be 
absorbed needs to be considered in order to predict absorption kinetics, and not only for 
predicting the luminal concentration in GI fluids.  
 
As in the previous dissolution studies, highly variable dissolution ranging from 80 to 100% of 
furosemide release was attained under different conditions. This again supports the need for 
re-evaluating the classification of furosemide as BCS IV, considering its high dissolution in 
the given clinical dose. A possible explanation for the lack of correlation from the dissolution 
to the permeation profiles in the case of furosemide could be related to the accuracy and 
sensitivity of Caco-2 monolayers to detect small changes in the drug permeation. Considering 
the facts that the differences in the extent of release of furosemide in the apical side were not 
found to be significant, and furosemide is a very poorly permeable drug, the ability of the 
Caco-2 monolayer to detect these differences in the dissolution might be limited. The low 
sensitivity of the monolayer might be highly relevant to poorly permeable drugs including 
furosemide, which gave only a 0.01-0.02% permeated amount. Kataoka et al. (2012), for 
instance, tested different formulations of danazol (BCS II) and pranlukast (BCS IV) in the 
D/P system. For danazole (highly permeable drug), the differences that were obtained in the 
dissolution  were  well-reflected  in  the  permeation  profiles.  However,  for  pranlukast  (low 
permeable drug), although differences in the dissolution of the formulations were significant, 
the  extent  of  drug  permeation  at  2  hours  did  not  differ  significantly  for  the  different 
formulations,  and  ranged  from  0.006  to  0.032  (%of  dose/2h).  Moreover,  as  discussed 
previously,  the  Caco-2  monolayer  is  derived  from  colon  carcinoma  cells,  and  usually 
characterized  by  tight  junctions.  Consequently,  for  poorly  permeable  drugs  such  as 
furosemide, it might be that other cell lines like MDCK will reflect better the changes in 
permeation and the prediction of in vivo absorption. It was also suggested that furosemide is a 
P-gp substrate and this effect in its permeation through the Caco-2 monolayer might be more 
significant than its effects on bile salt and pH. It will be interesting to test this hypothesis by 
adding P-gp inhibitor to the system.  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.4.6  Summary  
 
The  D/P  system  was  utilised  in  this  investigation  to  investigate  the  effect  of  bile  salt 
concentrations and pH on the dissolution/permeation of dipyridamole and furosemide. The 
results  presented  herein  emphasise  the  fact  that  investigation  of  both  dissolution  and 
permeability processes simultaneously is highly valuable as dipyridamole dissolution was 
significantly  affected  by  the  bile  salt  concentration,  while  permeability  was  significantly 
affected by the pH and the ionized and unionised form of the drug. For furosemide, poorly 
permeable drug, the adequacy of Caco-2 cell as measure of permeability was questioned to 
predict possible effects of different conditions.  Inter-subject Variability in Solubility, Dissolution and Permeability “In Vitro” of Two Model Drugs 
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3.5  Chapter Conclusions 
 
As discussed, the complexity of the GI tract is difficult to mimic in vitro. In this chapter to 
simplify our understanding as for the possible factors affecting drug absorption, solubility, 
dissolution and permeability were investigated stepwise in vitro. In the first section, it was 
found  that  the  saturated  solubility  of  dipyridamole  is  pH  and  bile  salt  dependent.  These 
results were confirmed by the dissolution test in the second section, where it was shown that 
bile  salts  at  this  concentration  range  increased  the  extent  of  dipyridamole  release.  The 
saturated solubility is an important factor in determining dissolution rate and extent. In this 
investigation, it is clear that bile salts have the greater effect on the saturated solubility, and 
hence  the  dissolution  rate  and  extent  of  release.  However,  when  both  dissolution  and 
permeability  were tested simultaneously, it was  found that although bile salt has  a  great 
impact on the solubility/dissolution of dipyridamole, pH plays an important factor in the 
permeation of dipyridamole. The results presented herein, in addition to the solubility data, 
can  explain  to  some  extent  the  variability  between  individuals  in  the  absorption  of 
dipyridamole.  In  addition,  the  results  emphasis  the  fact  that  absorption  is  a  continuous 
process and dissolution data alone might not always reflect the in vivo situation.   
 
With regards to furosemide, BCS IV drug, solubility experiments showed that pH, buffer 
capacity and to a lesser extent bile salt affect its saturated solubility. Surprisingly, almost 
complete  drug  release  was  observed  under  all  simulated  conditions  in  this  clinical  dose. 
Similarly, the permeation of furosemide did not differ under different conditions. This might 
be attributed to the Caco-2 cell monolayer sensitivity to detect these changes. 
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4.1  Chapter Overview 
 
In the previous chapter, the effect of bile salt and pH in the GI tract was investigated in two 
model drugs with regards to solubility, dissolution and permeability. Once identifying the 
mechanism that might cause variation among individuals, it is desirable to find a solution to 
increase  absorption  and  minimise  these  effects.  Different  formulation  approaches  are 
available to increase solubility and dissolution of drugs. In this chapter, it was our interest to 
compare different formulation approaches in increasing absorption and minimising the bile 
salts and pH effect in the GI tract. Moreover, usually formulation design for poorly soluble 
drugs is done based on the formulator experience and does not always take into consideration 
the API properties, the excipients fit and the preparation process. Therefore, comparison of 
different common formulation approaches is of great interest to minimise efforts and cost in 
designing the right formulation. Three formulation approaches were utilised to investigate 
how increasing solubility will increase absorption. The solid dispersion approach was chosen 
to represent the administration of a drug in its amorphous form, Self-Micro Emulsifying Drug 
Delivery  System  (SMEDDS)  formulation  represented  the  solubilisation  of  lipophilic 
compounds in oils and eventually nano-particle formulation was investigated to understand 
how reducing particles size affects solubility and hence absorption. Formulation evaluations 
were carried out by different techniques available in the lab. In addition, in vitro performance 
of the different furosemide and dipyridamole formulations were investigated using simple 
dissolution  tests  in  mHanks  buffer,  modified  FaSSGF  and  in  the  D/P  system.  The 
formulations  performance  under  different  pH  and  bile  salt  concentration  were  also 
investigated.  As  described,  to  further  validate  the  in  vitro  system  for  evaluation  of 
formulation performance, in vivo trials need to be carried out. Here, the rat model was chosen 
as the most available and easy to execute for initial evaluation of formulation in vivo. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.2  Development of Different Formulations and Evaluating their 
Performance In Vitro 
4.2.1  Introduction  
 
Recently, it was recognized that a significant percentage of the molecular entities undergoing 
evaluation as part of industrial drug development pipelines are poorly soluble drugs (Dahan 
et al., 2009; Ku and Dulin, 2012). Many attempts have been made in order to improve oral 
absorption  and  decrease  absorption  variability  of  these  compounds  by  improving  drug 
solubility  and  developing  new  dosage  forms  that  enhance  these  characteristics.  It  was 
reported that for the same drug in different dosage forms, differences in the oral absorption 
can be expected to range widely (Block et al., 1981; Chiou and Riegelman, 1970; Levy et al., 
1961; Weis et al., 1994). Those factors which can affect formulation performance and hence 
absorption  typically  include  formulation  excipients,  disintegration  characteristics,  and  the 
type of the dosage form (solution, dispersion, emulsion, gel, tablet, capsule and etc...). Many 
approaches  to  increase  the  solubility  of  crystalline  drugs  have  been  developed  by  the 
pharmaceutical  industry  and  the  scientific  community  (Figure  4.1):  Arguably,  the  easiest 
approach  currently  utilised  is  the  salt  formation  for  weak  bases  or  acids.  However,  this 
formulation has limitations, and does not always produce reliable release profiles - as such,  
other solutions need to be considered (Elder et al., 2013; Serajuddin, 2007). Some of these 
alternative approaches notably include cyclodextrins, solid dispersions, self-emulsifying drug 
delivery systems, solid nano-particle, liposomes, micelles, soft gelatine capsules, co-crystals 
and  pH  micro  environmental  modifiers.  Of  these,  the  most  investigated  methods  in  the 
scientific literature and the most commonly used in industry are solid dispersions in their 
amorphous forms, self-emulsifying drug delivery systems, and nano-particle delivery systems 
(Kawabata et al., 2011).  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.1: Formulation approaches considering the drug properties based on the BCS adapted from (Kawabata et al., 2011) Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
 
- 134 - 
 
4.2.1.1 Solid Dispersion  
 
An amorphous solid dispersion consists of an amorphous active API stabilized by a polymer, 
with the amorphous form of the drug providing increased apparent solubility (Leuner and 
Dressman, 2000). The advantage of solid dispersion in increasing drug solubility is related to 
the enthalpic energy. Lipinski et al. (2012) showed that the solubility (S) of a given solid 
solute is determined by the crystal packing energy (accounting for the energy necessary to 
disrupt the crystal pattern and remove isolated molecules), cavitation energy (accounting for 
the energy required to shift water in order to create cavity into which  the solute molecule can 
penetrate)  and  salvation  energy  (accounting  for  the  release  of  energy  as  favourable 
interactions are formed between the solvent and solute) (Equation 4.1). 
 
  
Equation 4.1: The factors affecting solubility adapted from Lipinski et al. (2012) 
 
The crystal packing energy is the major driving force behind solubility: By formulating an 
amorphous form, this energy is reduced by disrupting the drug crystal pattern in the delivery 
form. This can be achieved by adding solubility-enhancing polymeric carriers to the drug. 
However, the decrease in this energy results in an unstable amorphous form comparatively to 
the crystalline form. Thus,  when the  amorphous  form  is  placed in  a  media, its  potential 
energy is released and the solid dispersion turns into its supersaturated solution state. It is 
well known that supersaturated states are thermodynamically unstable, and the drug is much 
more  likely  to  precipitate  into  its  crystalline  form  under  these  circumstances.  Many 
publications  have  attempted  to  characterise  this  phase  and  understand  how  different 
excipients and polymers can prolong this super-saturation in order to increase the window for 
drug  absorption  (Brouwers  et  al.,  2009;  Higashino  et  al.,  2014;  Janssens  and  Van  den 
Mooter, 2009; Lindfors et al., 2008; Sarode et al., 2013). Moreover, re-crystallization is a 
major concern for the appropriate storage of the solid drug, and can limit its shelf life.  Not 
only can moisture promote drug crystallization, but the use of hygroscopic polymers may 
additionally  result  in  phase  separation  or  crystalline  growth.  Re-crystallization  prior  to 
administration will consequently decrease drug solubility, and no effect on absorption will be 
observed.    Some  of  the  other  challenges  in  the  development  of  solid  dispersion  include 
optimization of the preparation method and its formulation into a dosage form, reproducing 
its physicochemical properties, and scaling up manufacturing processes (Serajuddin, 1999) . Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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In order to  avoid  this, many efforts  have been made to  further optimize the formulation 
process through selection of an appropriate polymer, optimising drug load, and packaging 
selection, in  addition to optimizing the manufacturing process  (Brough and Williams  III, 
2013; Laitinen et al., 2013). 
 
Amorphous dispersions can be prepared either by evaporating a solvent from a drug and 
polymer solution, or by  melting/fusing methods in which the drug and the carrier solution is 
heated above their melting or glass transition temperature and then cooled gradually to keep 
the drug in its amorphous form. Both processes encompass challenges, and the end product 
might differ significantly in its stability or in the amorphous form (Agrawal et al., 2013). In 
solvent evaporating methods, the required temperature is usually much lower than in the 
melting methods. However, selection of the appropriate solvent is not always straightforward, 
and is typically highly dependent on the polymer and drug liphophilic/hydrophilic properties. 
Moreover, a second stage of drying any residual solvent needs to be carried out in order to 
avoid organic toxicity issues or formulation instability (Brough and Williams III, 2013).  
 
Two common manufacturing processes of solid dispersions in the solvent method are spray 
drying or freeze drying. In spray drying, the feed solution (drug and polymer) is atomized 
into hot gas that causes the solvent to evaporate, resulting in spherical particles containing an 
amorphous drug. Process parameters to consider during a spray drying process include inlet 
temperature, drying gas properties (humidity, flow rate), feed rate, compressed air flow rate 
for  a  bi-fluid  nozzle,  pressure  for  a  pressure  nozzle,  and  disk/wheel  speed  for  a  rotary 
atomizer. On the other hand, formulation parameters to consider are the feed composition 
(API, carrier, solvent), solid content in the feed, solvent type, viscosity and surface tension of 
the drying solution (Paudel et al., 2013). Freeze drying is a process in which the feed solution 
is  frozen  and  the  solvent  evaporates  under  vacuum  (Betageri  and  Makarla,  1995).  One 
common fusion method gaining increasing interest recently is that of hot melt extrusion. In 
this process, the drug and carrier are pumped through a heated barrel by one or more screws 
under pressure followed by discharging the extrudate through a dye (Crowley et al., 2007; 
Lang et al., 2014). No solvents are involved in this process, and so all challenges generated 
from the use of solvent are not relevant here. Another fusion method used in industry is spray 
congealing where molten compositions are atomized into particles and then cooled to solid 
form (Fini et al., 2002).  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Physicochemical characterization of solid dispersions such as the physical states of drugs, the 
drug–carrier interaction and the physical and chemical stability of drugs should be assessed in 
order  to  evaluate  its  pharmaceutical  applicability  and  physicochemical  stability.  The 
crystalline state of drugs is commonly characterized by the following techniques: thermo-
analytical  techniques  such  as  Differential  Scanning  Calorimetry  (DSC),  powder  X-ray 
diffraction (PXRD) and Confocal Raman Spectroscopy. Moreover, it is possible to obtain a 
qualitative  image  about  the  crystalline  state  by  microscopy  techniques  such  as  optical 
microscopy, transmission electron microscopy (TEM), scanning electron microscopy (SEM) 
and atomic force microscopy (AFM). Fourier  Transformed  Infrared spectroscopy (FTIR), 
solid state nuclear magnetic resonance, and Thermal Gravimetry Analysis (TGA) are used to 
investigate the chemical stability and molecular interaction of the drug and carrier. 
 
Dissolution  tests  in  bio-relevant  media  can  also  provide  an  insight  into  the 
solubility/dissolution  enhancement  mechanism  of  solid  dispersion;  however  it  is  highly 
desirable to investigate the formulation performance in vivo.  Newman et al. (2012) reviewed 
40  research  papers  reporting  active  pharmaceutical  ingredient  (API)  dissolution  and 
bioavailability from various solid dispersion formulations. Generally, it was concluded that 
most amorphous dispersions produced improvements in bioavailability (∼82% of the cases), 
with 8% of the amorphous dispersions exhibiting lower bioavailability than the reference 
material and 10% of the amorphous dispersions demonstrated similar bioavailabilities as the 
reference material. 
  
4.2.1.2 Self-Emulsifying Drug Delivery System 
 
Lipid based drug delivery systems  include  formulations  such as  oil solutions,  emulsions, 
micellar  systems  and  self  (micro)  emulsifying  drug  delivery  systems  (SMEDDS).  Lipid-
based  drug  formulations  are  presented  to  the  GI  in  the  solubilised  formulation;  as  a 
consequence, no solubilisation from the solid state is required. Under these conditions, the 
solute-solvent interactions are reduced, resulting in enhanced solubility. It was suggested by 
Porter  et  al.(2007)  that  there  are  three  possible  primary  mechanisms  by  which  self-
emulsifying drug delivery systems affect drug absorption. These include the alteration of the 
composition  and  character  of  the  intestinal  milieu  (increase  in  bile  secretion  and  easier 
partition of the drug into the mixed micelles that are believed to facilitate drug absorption), 
the recruitment of intestinal lymphatic drug transport, and the interaction with enterocyte-Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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based transport processes (increased intestinal permeability). The absorption mechanism was 
further developed to incorporate an explanation on the supersaturated state that lipid based 
formulation may promote (Williams et al., 2013). It is important to note that the unstirred 
water layer forms a major diffusional barrier for lipids and lipophilic molecules, as their 
solubility in aqueous media is extremely low and needs to be considered when understanding 
the absorption mechanism of lipid-based formulations.  
 
Recently, SMEDDS especially have attracted an increasing interest in the pharmaceutical 
community.  Self-emulsification  formulations  are  defined  as  “isotropic  mixtures  of  oil, 
surfactant,  co-solvent,  and  solubilised  drug.  Upon  mild  agitation  followed  by  dilution  in 
aqueous media, such as GI ﬂuids, these systems can form ﬁne oil−in−water (o/w) emulsions 
or micro-emulsions ( MEDD )” (Neslihan Gursoy and Benita, 2004). The droplet size of 
SEDDS  ranges  between  100  and  300nm,  whereas  SMEDDS  form  transparent  micro-
emulsions  with  a  droplet  size  of  less  than  100nm.  Another  form  of  SEDDS  is  the  self-
emulsifying  nano-emulsion  drug  delivery  system  (SNEDDS),  which  does  not  differ  in 
emulsion size from SMEDDS, but are also non-equilibrium systems and kinetically stable 
compared to SMEDDS, which are themselves thermodynamically stable; thus, by definition, 
will be in equilibrium in the solution. Moreover, in the case of SNEDDS, the droplet size is 
independent of dilution (Anton and Vandamme, 2011). This implication is not significant, 
however, given that the long-term stability of these formulations in the GI is not important.  
 
The development of lipid base formulations is not simple, and investigation of the physical 
chemistry, thermodynamics and gastrointestinal digestion needs to be carried out. Usually, 
this  includes  a  two-step  process:  first,  a  mixture  of  lipids,  surfactants  and  co-solvents 
containing the drug in solution are chosen by assessing the drug solubility in these excipients. 
Then, the mixture is selected which forms an emulsion by addition of water or buffer and 
with  the  desired  appearance  and  characteristics  upon  gentle  agitation  and  with  no 
precipitation of drug. Highly lipophilic drugs are generally the most suitable to formulate as 
SMEDDS  thanks  to  their  high  solubility  in  lipids;  however,  non-  lipophilic  hydrophobic 
drugs can also be incorporated in lipid- based formulations with the addition of surfactant or 
co-solvents  (Müllertz  et  al.,  2010).  Some  of  the  factors  to  consider  in  the  selection  of 
excipients include regulatory issues (i.e. toxicity), solvent capacity, miscibility, morphology 
at  room  temperature,  self-dispersibility  and  a  role  in  promoting  self-dispersion  of  the 
formulation, digestibility and fate of the digested products, and finally the chemical stability Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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and capsule computability (Pouton and Porter, 2008). Many scientists also utilise ternary or 
pseudo-ternary phase diagrams in the development of SMEDDS, which enables optimisation 
of the concentration ranges of different excipients, along with assessing the mixture, self-
emulsification ability and drug loading.  
 
As described in the second step of development, the ability of the oil mixture to form a 
microemulsion is assessed usually in water or simulated gastric/intestinal fluids. The water 
absorption and emulsification process during addition of an aqueous phase to the oil mixture 
can be characterised by viscosity and conductivity. Viscosity measurements help to determine 
the transition between mesomorphic structures, whereas conductivity measurements are able 
to determine the point of aqueous phase addition where the system changes from having a 
continuous oil phase to a continuous water phase (Kumar and Mittal, 1999). The rate of self-
emulsification can be determined by a visual observation, or by monitoring the change of 
turbidity  of  a  dispersion  using  a  UV  spectrophotometer  after  adding  the  oil  mixture  to 
aqueous media. Simple dissolution tests are conducted to assess the rate of dispersion and 
possible  precipitation  with  dilution.  However,  it  is  important  to  note  that  the  “usual” 
dissolution test cannot accurately predict the amount of available drug to be absorbed, given 
that some of the drug is incorporated into micelles. Dialysis bags can be utilised to this extent 
to determine the fraction dissolved and available for absorption. Particle size distribution in 
the  formed  nano-  or  microemulsion  is  measured  by  dynamic  light  scattering  techniques 
(Müllertz et al., 2010). In addition to the above formulation assessments, it is important to 
understand the fate of the oil droplets and their digestion pathway in the gastrointestinal tract. 
It is possible that once the excipients in the SMEDDS are digested, the drug will precipitate 
and hence a decrease in solubility will be observed in vivo. This can be evaluated using in 
vitro lipolysis models (pH-stat model) (Kaukonen et al., 2004; Zangenberg et al., 2001). 
Some studies have shown that some surfactants are subject to digestion in the gastrointestinal 
tract, leading to the drug precipitation and a decrease in solubility (Dahan and Hoffman, 
2008; Larsen et al., 2008; Sek et al., 2006). The above mentioned in vitro lipolysis setup is 
fairly complicated, suffering from low throughput and more importantly only partly mimics 
the gastrointestinal tract conditions.  Kilic and Dressman (2013) have developed a simple 
method  to  mimic  the  lipolysis  process  by  using  their  FaSSIF/FeSSIF  recipes.  Using  a 
modified FaSSIF-V2, the same rank order in performance of four danazol formulations as 
previously observed in a pH-stat model was observed, and these results also reflected the in-Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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vivo  study  results  in  dogs.  Using  this  method,  it  was  also  possible  to  identify  whether 
precipitation of the drug is promoted by dilution or by lipolysis, with or without pancreatin. 
  
Neoral®,  a  cyclosporin  SNEDDS  formulation,  showed  an  increase  in  Cmax  and  AUC 
compared with Sandimmune®, a coarse SMEDDS formulation, in human. This increase was 
attributed  to  the  decrease  in  the  droplet  size  (Mueller  et  al.,  1994).  Despite  SEDDS 
formulations showing an increase in bioavailability in most of the clinical trials that were 
conducted (Fatouros et al., 2007), there are few approved SEDDS products currently on the 
market. Indeed, until  2010, only 9 SEDDS formulation were approved for use by patients 
(Kawabata  et  al.,  2011).  This  might  be  related  to  the  fact  that  there  is  still  a  gap  in 
understanding of its absorption mechanism and an inability to accurately predict the fate of 
the formulation in vivo during early stages of development. Moreover, drug solubility in the 
oils/surfactants/cosolvents needs to be relatively high, given that the drug should be dissolved 
in a limited amount of oil. High chemical stability of the dissolved drug in oil phase would 
also be required for the lipid formulations. In addition, there is a lack of data on toxicity of 
some of the newly-developed excipients used. Therefore, more in vivo studies are required to 
investigate their effect on the gut membrane. 
  
4.2.1.3  Nano-Particles 
 
Nano-suspensions are defined as those which feature pure drug particles with a mean particle 
size of less than 1000 nanometers (nm), and which are suspended in an aqueous medium. 
Those particles that can exist in partially or fully crystalline states, are referred to as drug 
nano-crystals  (Moschwitzer  and  Muller,  2007).  The  mechanism  by  which  nano-particles 
improve solubility/dissolution is simply by reducing the particle size to a nano-size, hence 
increasing the surface area available for drug dissolution. Moreover, it has been reported that 
decreasing  particle  size  will  also  reduce  the  thickness  of  the  diffusion  layer  and  thus 
eventually results in an increased dissolution rate: This is well reflected in Nernst-Brunner 
equation  (Galli,  2006;  Möschwitzer  et  al.,  2011).  In  addition  to  the  dissolution  rate 
enhancement described above, an increase in the saturation solubility of the nano-sized API 
by reducing the particle size to less than 1µm as described by Ostwald–Freundlich’s equation 
is also expected, as saturated solubility is affected by particle radius (Kesisoglou et al., 2007; 
Müller  and  Peters,  1998).  Similar  to  solid  dispersions,  nano-particles  are  less Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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thermodynamically stable then micro-particles, mainly due to change in Gibbs free energy 
and an increase in the surface energy. Therefore, nano-particles will tend to agglomerate in 
order to reduce their total energy (Van Eerdenbrugh et al., 2008). This phenomenon can be 
reduced by adding a stabilizer. A prerequisite for a good stabilizer is that it will increase the 
wetting  properties  of  the  hydrophobic  surface,  in  addition  to  functioning  as  a  barrier  to 
agglomeration, likely achieved by electrostatic and steric forces (Van Eerdenbrugh et al., 
2008).  
 
Top-down and bottom-up technologies  are the two primary technical  approaches  to  drug 
nano-crystal production, and a combination of the two approaches may be applicable in some 
cases. The top-down methods are essentially high energy processes in which drug particles 
are  broken  down  to  nano  size.  Pearl  milling  (wet/dry),  high  pressure  homogenization 
including piston gap homogenizer, and jet stream homogenizer are commonly used methods 
to decrease drug particle size (Möschwitzer, 2013). Though no harsh solvents are used in 
these techniques, some of the limitations of the top-down process include long process times 
for reducing particle sizes below 100nm, using a minimum amount of drug (which might not 
be available in early development stages), solid state changes, chemical degradation due to 
high heat during the milling, residual metal content production (zirconium, yttrium), and a 
usually  low  yield  (Verma  et  al.,  2009).  Bottom-up  approaches  by  contrast  utilise  the 
precipitation process from supersaturated solutions to grow crystals up to nano size. Sinha et 
al.  (2013)  reviewed  the  common  techniques  that  are  used,  and  classified  them  into  four 
categories as follows: Precipitation by liquid solvent–anti-solvent addition, precipitation in 
the presence of supercritical fluid, precipitation by removal of solvent, and precipitation in 
the presence of high energy processes. The advantages of the bottom-up approaches include 
these being low energy processes, require simple instruments, are less expensive, and can be 
operated at a low temperature, making them particularly suitable for thermo-labile drugs. 
Most importantly, it is the ability to obtain smaller drug nano-crystals with a narrow particle 
size distribution that makes  these technologies  particularly useful. However, some of the 
issues related to the bottom-up methods include polymorphism, due to less time available for 
orderly molecular organisation. It is often very difficult to control the particle growth using 
this technique, and the formulator has to be careful in choosing the solvent, the antisolvent, 
the stabilizer (s) and the process parameters in order to obtain stable nano-suspensions with 
the desired particle size profile. Moreover, bottom-up approaches include dissolving the drug 
completely in an organic solvent, and the additional stage of removing organic residuals is Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
 
- 141 - 
 
required.  This  may  lead  to  further  precipitation  of  the  dissolved  solute,  which  might  be 
uncontrolled and could  result in  an increased  mean particle size with wider particle size 
distribution (Sinha et al., 2013). 
 
As for other formulations, it is essential to characterise nano formulations in terms of size and 
size  distribution,  particle  charge,  crystalline  status,  solubility/dissolution  in  bio-relevant 
media and stability (Müller et al., 2001). Moreover, it is highly desirable to investigate the 
effectiveness of these formulations in vivo on increasing oral absorption. Kawabata et al. 
(2011) reported that there are five nano-crystal oral formulations using NanoCrystal® (Elan 
Drug  Technologies)  and  IDD-P®  (SkyePharma)  technologies  which  are  available  on  the 
market and have proven efficacy. Moreover, numerous studies demonstrating the enhanced 
oral bioavailability of pharmaceuticals and neutraceuticals by nanocrystal technologies were 
published, and 1.7–60-fold and 2–30-fold enhancement in Cmax and AUC respectively were 
found as compared to the crystalline formulations with micrometre particle size (Fakes et al., 
2009; Hanafy et al., 2007; Hecq et al., 2006; Jia et al., 2002; Jinno et al., 2006; Kondo et al., 
1993; Liversidge and Cundy, 1995; Wu et al., 2004; Xia et al., 2010). Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Each of the approaches to improve the aqueous solubility of poorly water-soluble drugs, 
encompasses challenges for drug development and manufacturing. In general, salt formation, 
micronization,  and  pH  modification  in  dosage  forms  are  categorized  into  conventional 
technologies  and  usually  are  the  first  line  to  improve  formulation  performance.  Other 
technologies, such as nano-crystal formation, amorphization, and SEMDDS, can be identified 
as non-conventional technologies. For formulation scientists, it is not always clear which 
method  is  preferable,  since  direct  comparison  between  the  methods  are  not  available. 
Usually, the most commom method is utilised first, but this does not always indicate that this 
is the most useful method for increasing solubility, increasing absorption and the formulation 
stability. As such, this was addressed in the present study. The three formulation approches 
described herein were compared in terms of development and in vitro performance in order to 
predict which approach will best increase the dissolution/solubility and reduce inter-subject 
varibility caused by bile salts and pH.  
 
4.2.2  Objectives 
 
  To  utilize  three  common  approaches  for  increasing  drug  solubility  to  prepare  the 
following  formulations:  solid  dispersion,  SMEDDS  and  nano-suspension  for 
dipyridamole (BCS II) and furosemide (BCS IV). 
  To  evaluate  formulation  performance  in  vitro  and  assess  the  advantages  and 
disadvantages in developing and preparing each formulation approach.  
  To investigate formulation dissolution (dipyridamole and furosemide in mHanks buffer 
and  furosemide  in  FaSSGF)  under  different  bile  salts  and  pH  conditions  in  order  to 
understand which approach will increase the percentage of drug release and reduce the 
effects of pH and bile salts.  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.2.3  Materials  
 
Furosemide, dipyridamole, polyvinylpyrrolidone K 30, polyvinylalchol (PVA) and mannitol 
were purchased from Sigma- Aldrich. Labrafac lipophile WL1349 (batch No. 135990) was 
kindly supplied as a gift from Gattfosse SAS.  Kolliphor HS15 (batch No. 29749816KO) was 
kindly supplied as a gift from BASF. Povacoat Type F was supplied as a gift from Daido, 
NSK. Acetonitrile, ethanol and isopropyl  alcohol and all solvents were HPLC grade and 
purchased from Fisher. 
 
4.2.4  Methods  
4.2.4.1 Formulation Development  
A.  Solid Dispersion  
 
Furosemide and dipyridamole solid dispersions were prepared using a solvent method by 
spray-drying. PVP-K30 was chosen as the model polymer based on previous experience in 
developing furosemide and dipyridamole solid dispersion in various methods. Furosemide 
and dipyridamole were dissolved separately in 500mL ethanol, and PVP-K30 was added to 
prepare a feed solution for the spray-drying process. The solutions were mixed until clear 
solutions were obtained, and then subsequently spray-dried using a Niro SD Micro spray 
dryer (GEA Pharma systems  Inc., Switzerland) with an inlet temperature of 40°C, outlet 
temperature of 40°C, and a feed rate of 18% (out of a maximum 5L/h). With all formulations, 
the following parameters remained constant: air ﬂow rate 600 L/h, atomizer ﬂow rate: 2.5 
kg/h, chamber ﬂow rate: 25/2.5 kg/h, and nozzle pressure: 1.5 bar. All spray dried material 
was kept in an oven for overnight drying at 25 ◦C. The dried solid dispersions were stored in 
a sealed vial. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
 
- 144 - 
 
B.   Self-Micro Emulsifying Drug Delivery System (SMEDDS) 
 
Dipyridamole SMEDDS formulations were adopted  from a publication by Guo et al. (2011). 
The original published formulation was prepared as described in the publication; however, 
the  size  measurements  were  not  consistent  with  the  published  results,  and  so  further 
modifications  to  the  formulation  were  carried  out.    Based  on  the  solubility  test  of 
dipyridamole in different oils and the emulsifying characteristics of the mixtures of various 
oils and surfactants published by Guo et al. (2011), the following ingredients were selected; 
Labrafac  lipophile  WL  1349  and  Isopropyl  alcohol  as  surfactant  and  co-surfactant 
respectively. Solutol  (kolliphor) HS  15 was selected as the oil phase.  Different  ratios  of 
((surfactant: co-surfactant): oil) were tested, as described in Table 4.1. In addition, different 
drug loads were tested in the following ratios 1:10, 1:25 and 1:50 (w/w). The oil, surfactant 
and co-surfactant at finite proportions were mixed in screw-capped glass vials. Thereafter, 
dipyridamole was added into the mixture and the formulation was left to mix overnight. After 
the drug was dissolved completely by vortex and mixing, a clear and transparent solution was 
obtained.  
Table 4.1: Composition of tested SMEDDS formulation 
Formulation  1  2  3  4  5  6 
Smix 
(surfactant:cosurfactant)   
3:1  1:1 
Oil   9:1  4:1  2:1  9:1  4:1  2:1 
 
The  furosemide  SMEDDS  formulation  was  initially  adopted  from  Zvonar  et  al.  (2010). 
Similar to dipyridamole experiments, the size results were not consistent with the published 
results,  and  a  higher  micelle  size  was  attained.  Further  experiments  were  carried  out  to 
optimise this formulation. Smix of labarsol and plurol oleique in the ratio of 4:1 was kept 
constant. Based on solubility tests of furosemide in different oils, the following oils were 
tested in combination of Smix: soybean oil (3:1), castor oil, tocopherol acetate, oleic acid and 
iso propyl alcohol. In addition, the formulations developed for dipyridamole were tested for 
furosemide. Furosemide final formulation was carried out in the same manner as described 
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C.  Nano-Particles  
 
Nano  formulations  were  developed  in  Setsunan  University,  Osaka,  Japan,  with  the  kind 
guidance  of  Mr.  Kayo  Yuminoki.  A  rotation/revolution  mixer  (Nano  Pulverizer  NP-100, 
Thinky Co., Ltd., Tokyo, Japan) was used to pulverize the compounds.  
 
I.  Preparation of Solutions  
 
For the furosemide suspension, 10g of povacoat was added to 100mL of DI water, and after 1 
hour  of  mixing,  10g  of  mannitol  was  then  added  to  the  solution.  For  the  dipyridamole 
suspension, 5g of PVA was added to 100mL DI water, and again after 1 hour of mixing, 10g 
of mannitol was then added to the solution.  Povacoat and PVA were used to stabilise the 
nanomilled API, and mannitol was used a stabiliser in the freeze drying process.  
 
II.  Nano Suspension Preparation  
 
100mg furosemide was  added to 2.5g zirconium beads (0.1mm diameter) in a zirconium 
container. 0.5mL of 10% povacoat and mannitol solution was added and milled at 2000 rpm 
for 2 min at -20 ˚C (milling speed, orbital to axial ratio, 1:1). 4.5mL of the same solution was 
then added and mixed at 500 rpm for an additional 1 min.  
 
200mg dipyridamol was added to 2.5g zirconium beads (0.1mm diameter) in a zirconium 
container. 1mL of 5% PVA and D-mannitol was then added and milled at 2000 rpm for 5 min 
at -20˚C (milling speed, orbital to axial ratio, 1:1). An additional 19mL of 5% PVA and D 
mannitol solution was then added and mixed at 500 rpm for 1 min.  
 
III.  Freeze Drying  
 
Prior to freeze drying, the suspensions were sonicated for 10 minutes. The suspensions were 
then frozen at -80 ˚C for 30 minutes in an acetone dry ice bath, and thereafter freeze dried at a 
pressure of 10 µm Hg (under vacuum) at 25 ˚C for 48 hours. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.2.4.2 Formulation Evaluation 
 
I.  Differential Scanning Calorimetry 
 
A DSC 7 Differential Scanning Calorimeter (PerkinElmer Instruments, Beaconsfield, UK) 
calibrated  with  indium  was  used  to  assess  the  presence  of  crystalline  drug  in  the  solid 
dispersions and nano-particles. Formulation powder (3–5mg) was accurately weighed and 
placed in a non-hermetic aluminium pan.  Furosemide samples were scanned from 25 to 
300°C at a rate of 10°C/min or 100°C/min in 2 cycles. Dipyridamole samples were scanned 
first from 40 to 120°C at a rate of 10°C/min and a second cycle from 40 to 300°C at the same 
rate. Pyris Thermal Analysis Software was used to record and analyse the data. 
 
II.  X-Ray Powder Diffraction 
 
X-ray  diffraction  patterns  were  obtained  for  the  samples  using  an  X-ray  diffractometer 
Rigaku MiniFLEX 600 (Rigaku, Kent, UK) to perform qualitative and quantitative analysis 
of polycrystalline materials. The data sets obtained were processed and scaled using PDXL 
(full-function powder diffraction analysis software suite- minflex guidance). The data were 
scanned at a step size of 0.2 theta from 2 to 40 degrees at a speed of 5 deg/min.  
 
III.  Size Analysis 
 
The  median  volume  diameter  of  each  formulation  suspended  in  water  or  in  simulated 
intestinal  fluids  was  measured  in  triplicate  using  laser  light  scattering  using  a  Malvern 
Mastersizer with a 45mm lens (Malvern Instruments Ltd, Malvern, UK). The particle size is 
reported D(v,0.9), D(v,0.5) and D(v,0.1) where the particle diameters are at the 90th, 50th 
and 10th percentile, respectively, of the microsphere size distribution curve. Particle size 
analysis of each formulation was carried out in triplicate. 
 
A Zetasizer (Malvern Nano ZS, Malvern Instruments Ltd, Worcestershire, UK) was used to 
analyse the mean particle size of the nano-carriers and self-emulsifying drug delivery systems 
using dynamic light scattering (DLS). Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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IV.  Transmission electron microscope (TEM) & Scanning electron microscopy (SEM) 
  
Scanning electron microscopy (SEM) was used to analyze the morphology of the API, solid 
dispersion  and  the  physical  mixtures  of  the  solid  dispersion  formulations.  Samples  were 
coated with gold using a K550 sputter coater (Emitech, Ashford, Kent, UK) and observed 
using a Philips/FEI XL 30 SEM (Phillip, Cambridge UK) at 10 kV. 
 
Nano suspension and self-emulsifying drug delivery systems morphology was analysed using 
a FEI CM 120 Bio Twin transmission electron microscope (TEM, Philips Electron Optics 
BV, Netherlands). Approximately 1 drop of the preparation was placed on a copper grid with 
a nitrocellulose covering and negatively stained with 1% uranyl acetate. 
 
V.  Dissolution Tests  
 
Dissolution tests  under  different conditions  were carried out  as specified in  the previous 
section. All formulations were tested in mHanks buffer under different conditions of bile salts 
and pH (in the range of 1-6mM and 6.4-7.4 respectively) as described in chapter 3. In the 
case of nano-particles, samples were taken manually at 5, 15, 30, 60, 90 and 120 min, filtered 
via 0.45µM PTFE syringe filters and immediately centrifuged at 25˚C 13,000 RPM for 15 
min. Samples were then diluted 10 times with mobile phase and were analysed by HPLC.  
 
In addition, further dissolution tests were carried out to evaluate the precipitation effect from 
the stomach to the duodenum. An unpublished recipe from the laboratory of Prof. Yamashita 
(Setsunan University, Osaka) was adopted.  The study was performed in pH 1.6 fasted state 
simulated  gastric  fluids  (FaSSGF),  followed  by  in-situ  transfer  to  a  pH  6.5  fasted  state 
simulated intestinal fluids (FaSSIF). The study was also performed using small volumes, with 
proportional clinical doses of the drug. The drug dose was calculated as follows ( 
Equation 4.2): 
 
Clinical concentration= Clinical dose \ Gastric volume 
 
Equation 4.2: Calculated dose tested in the dissolution test 
 
Where: gastric volume is a sum of gastric residual volume (30mL) and volume administered 
with drug (250mL) 
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Preparation of FaSSGF and pre-FaSSIF is given in Table 4.2 and Table 4.3, respectively. For 
FaSSGF preparation, sodium chloride was added and dissolved in DI water, followed by 
addition of SIF powder (mixture of 0.75mM sodium taurocholate and 3mM lecithin). The 
volume with DI water was made up to 100mL, and pH was accurately adjusted to 1.6 using 
5M HCl. For pre-FaSSIF preparation, KCl and KH2PO4 were completely dissolved in DI 
water, followed by the addition of SIF powder and NaOH solution. The solution was mixed 
and sonicated until clear solution was obtained. MES was then added and dissolved, and the 
volume made up to 50mL with DI water. The final pH of this media was between 9 and 9.5, 
which on addition to FaSSGF gives a final pH of 6.5. This was prepared in-situ, when 5mL of 
pre-FaSSIF was added to 10mL of FaSSGF using a syringe pump at a rate of 0.5mL/min over 
10 minutes.  
Table 4.2:  Composition of FaSSGF 
Composition  Amount per 100 mL 
Sodium chloride  200 
SIF powder  5.8µg 
DI water  QS to 100 mL 
5 M HCl  QS to pH 1.6 
 
Table 4.3: Composition of Pre-FaSSIF 
Composition  Amount per 50 mL 
Potasium chloride  1.155 g 
KH2PO4  0.585 g 
SIF powder  0.327 g 
5 M NaOH  1.025 mL 
MES 
*  0.15975 g 
DI water  QS to 50 mL 
* (n-morpholino) ethane sulfonic acid (Nacalai Tesque, 216-23) Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Experimental Procedure 
 
An experimental dose was added to 10mL FaSSGF in a glass vial, placed on a magnetic 
stirrer and mixed continuously at 200 RPM. The temperature was maintained at 37 ˚C by 
placing the stirrer in an incubator.  After 1 minute the first sample was withdrawn and the 
syringe pump was started immediately to transfer 5mL of pre-FaSSIF at 0.5mL per minute. 
Aliquots of 100µL were withdrawn at 1, 3, 5, 7, 9 and 11 minutes. Sampling was continuous 
for 4 hours, and the samples were subsequently filtered via 0.45µm 4mm PTFE syringe filters 
(Millex LH, SLLHH04NL, Millipore) and further diluted by use of an ACN: water mixture 
(1:1). The samples were analysed using HPLC by methods described in the previous section. 
Figure 4.2 shows a schematic of the experimental run and sampling frequency. 
 
1 min 11 min 4h 11 min
10 min 4h
Gastric emptying time, 10 minutes 
@ 0.5 mL/min
Small intestinal transit time, 4 hours
 
Figure 4.2: A schematic of the experimental run and sampling frequency of the dissolution test. 
 
4.2.4.3 Statistical and Data Analysis  
 
The  dissolution  and  permeation  data  were  analysed  by  one  way  ANOVA  repeated 
measurements followed by a tukey post- hoc analysis using Univariate General Linear Model 
tool in PASW statistics 22 (SPSS Inc., Illinois, USA).  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.2.5  Results & Discussion  
4.2.5.1 Solid Dispersion Preparation and Evaluation  
 
Furosemide and dipyridamole were successfully prepared in their amorphous forms using the 
spray  drying  method.  The  preparation  was  relatively  straightforward,  involving  a  simple 
procedure of dissolving the drug in an organic solvent, adding the carrier and spray-drying it. 
The yield for dipyridamole and furosemide solid dispersions was 52% and 33% respectively. 
This relatively low yield is related to the low batch size used (15-30g) as compared to the 
minimum solid material usually used for Niro SD micro (200g). Moreover, a high percentage 
of the powder was left on the walls of the spray cylinder, cyclone and tubing due to the static 
properties of the polymer, and only a limited amount of the powder reached the collecting 
container. 
 
A reduction in the particle size was observed in the case of dipyridamole. Dipyridamole and 
furosemide solid dispersion particle sizes were measured at 0.88, 2.84 and 4.87µm and 0.74, 
3.34 and 5.79µm at the 10, 50 and 90 percentile, respectively (compared to 5.15, 39.20 and 
69.57µm  and  1.09,  3.33  and  8.53µm  for  dipyridamole  and  furosemide  API).  The  SEM 
micrographs of dipyridamole, furosemide, their solid dispersion formulations and physical 
mixture are presented in Figure 4.3 and Figure 4.4. 
 
As can be seen, both drugs produced sharp, long particles; structures not produced in the 
solid dispersion formulations characterised by the presence of spherical particles. This may 
indicate a possible interaction between the polymer and the drugs in the solid-dispersion 
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Figure 4.3: SEM micrographs A) Dipyridamole and PVP K30 Physical mixture, B) Dipyridamole, C) Dipyridamole solid 
dispersion.  
 
     
Figure 4.4: SEM micrographs A) Furosemide and PVP K30 Physical mixture, B) Furosemide, C) Furosemide solid 
dispersion.  
 
Powder X-ray diffractograms of furosemide, dipyridamole, their physical mixture and solid 
dispersion formulations are shown in Figure 4.5 and Figure 4.6. The presence of numerous 
distinct peaks in the PXRD spectrum indicates that both furosemide and dipyridamole are 
presented in their crystalline form. The spectrum of PVP was characterized by the complete 
absence  of  a  diffraction  peak,  otherwise  characteristic  of  an  amorphous  compound.  The 
diffraction patterns of solid dispersion formulations show a broad peak due to PVP present in 
the formulations, and an absence of major diffraction peaks corresponding to furosemide and 
dipyridamole, with most of the diffraction indicating the drugs were present as amorphous 
material inside the PVP matrix. In the case of the physical mixtures, in both diffractograms of 
furosemide  and  dipyridamole,  the  peaks  indicated  the  detection  of  crystallinity,  and  the 
absence of the interaction of the drug with its carriers in the physical mixture.  
A
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Figure 4.5: Powder X-ray diffractograms of A) Dipyridamole, B) Dipyridamole solid dispersion, C) Physical mixture of 
Dipyridamole and PVP-K30.  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.6: Powder X-ray diffractograms of A) Furosemide, B) Furosemide solid dispersion, C) Physical mixture of 
furosemide and PVP-K30.  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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The DSC thermographs for pure furosemide, dipyridamole, PVP-K30, their physical mixtures 
and solid dispersion  formulations  are shown in  Figure  4.7 and  Figure  4.8. Dipyridamole 
showed a sharp endothermic peak at 166˚C, corresponding to its melting point.  The DSC 
scan of PVP showed a broad endotherm peak, ranging from 80 to 120°C due to the presence 
of residual moisture in PVP in the first cycle. The Tg at 146˚C could be observed when the 
sample was further heated. Furosemide showed a small melting peak at 220°C followed by an 
endothermic  peak.  Another  exothermic  peak  was  observed  at  270°C.  Similar  DSC 
thermographs were reported by Patel et al. (Patel et al., 2008). Samples of solid dispersion 
showed a complete absence of drug peak at the aforementioned melting points with Tg at 
90°C. This complete absence of peaks indicates that the drugs are amorphous, or are in a 
solid solution inside the PVP matrix. This further type of interaction confirmed the results 
which were observed in the PXRD studies. 
 Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
 
- 155 - 
 
 
 
 
 
 
 
Figure 4.7: DSC thermographs for A) Dipyridamole, B) Dipyridamole solid dispersion, C) Physical mixtures of 
dipyridamole and PVP-K30  
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Figure 4.8: DSC thermographs for A) Furosemide, B) Furosemide solid dispersion, C) Physical mixtures of furosemide and 
PVP-K30 
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4.2.5.2 Self- Micro Emulsifying Drug Delivery System Preparation and Evaluation 
 
The process of developing SMEDDS formulations for both drugs was more complicated. The 
attempt to adapt published SMEDDS formulations was not successful, and was not consistent 
with  the  published  results.  Guo  et  al.  (2011)  developed  SMEDDS  formulation  for 
dipyridamole with the following composition: oleic acid, labrfac, kolliphor and iso propyl 
alcohol at the ratio of 18, 12, 42 and 28% w/w respectively.   It was reported that the average 
droplet size was 89nm, and the size of all droplets was below 100nm. However, when the 
formulation was repeated in our lab, the average droplet size was 320nm and polydispersed. 
Thus, further modifications were carried out. The oleic acid and the labrfac represented the 
oil phase in the origin formulation. It was reported that the purpose of adding oleic acid to the 
original formulation was to increase dipyridamole solubility in the oil phase. However, the 
addition  of  the  oleic  acid  also  increased  the  droplet  size,  and  decreased  the  emulsifying 
capability.  For  this  investigation  needs,  it  was  decided  to  omit  the  oleic  acid  from  the 
formulation and decrease  the drug load (compromising dipyridamole solubility in  the oil 
formulation).  
 
The effects of changing labrfac and kolliphor ratios in the formulations on droplet size and 
emulsifying  capabilities  were  investigated.  The  droplet  size  of  the  dipyridamole  micro-
emulsion decreased with a reduction in oil content (labrfac) in SMEDDS. When Smix: oil ratio 
was  2:1  and 4:1,  a bigger particle  was  formed in  comparison with  ratio 9:1  of Smix:  oil 
(formulations 2, 3, 5 and 6- Table 4.1 ). Moreover, the emulsifying capability increased at the 
ratio of 1:9 of Smix: oil, and both formulations 1 and 4 were dispersed within seconds under 
gentle  conditions  of  stirring  to  produce  clear  solutions.  The  average  droplet  size  of 
formulations 1 and 4 was around 20 to 25nm, and the size of all droplets was below 100nm. 
The droplet size did not differ when the formulation was dispersed in water, SGF or SIF 
(Figure 4.9). As seen in Figure 4.10, the SMEDDS formulation containing dipyridamole, 
following self-emulsification observed under TEM, was spherical in shape and uniform in 
size. The following drug loads were tested as ratios of 1:10, 1:25 and 1:50. It was found that 
the drug load did not affect the droplet size (around 20nm) nor the emulsifying capability. As 
such, larger ratios of 9:1 (Smix: oil) and 3:1 (surfactant: co-surfactant) were used for further 
studies. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.9: Micelles size measurements for dipyridamole SMEDDS after self-emulsifying A) In water and B) In SGF 
 
 
Figure 4.10: Dipyridamole SMEDDS formulation, following self-emulsification observed under TEM. 
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Zvonar  et  al.  (2010)  developed  SMEDDS  formulation  for  furosemide.  The  formulation 
included the following ingredients: labrasol, plurol oleique and mygliol 812 as the surfactant, 
cosurfactant  and  the  oil  phase  respectively.  As  with  previous  attempts  to  replicate 
dipyridamole  SMEDDS  formulations  from  published  literature,  preparing  furosemide 
SMEDDS formulation with this composition proved to be unsuccessful, with a droplet size of 
more  than  4µm  attained  with  polydispersed  micro-emulsion.  To  improve  upon  this 
furosemide SMEDDS formulation, a Smix of labarsol and plurol oleique (as described by 
Zovenar et al. (2010) in the ratio of 4:1 was tested. The following oil phases were tested: 
soybean oil, castor oil, tocopherol acetate, oleic acid and IPA. Soybean oil and oleic acid as 
the oil phase did not yield one oil phase solution. With tocopherol acetate and castor oil, 
precipitation of the drug was observed when water was added, and the emulsions were not 
unambiguous. With IPA, a clear micro-emulsion was obtained; however, on measuring the 
droplet size, values around 100nm were attained with polydispersed micro-emulsions. Based 
on the success of developing a dipyridamole formulation, the composition for dipyridamole 
SMEDDS formulation was investigated for furosemide. This evaluation produced a droplet 
size similar to that of the dipyridamole formulation at around 20-30nm, and a monodispersed 
microemulsion was attained. The droplet size also did not alter when the formulation was 
dispersed in water, SGF or SIF (Figure 4.11). As seen in Figure 4.12, the micro-emulsion of 
the  SMEDDS  formulation  containing  furosemide,  following  self-emulsification  observed 
under TEM, was spherical in shape and uniform in size. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.11: Micelles size measurements for dipyridamole SMEDDS after self-emulsifying A) In water and B) In SGF 
 
 
Figure 4.12: Furosemide SMEDDS formulation, following self-emulsification observed under TEM. 
 
A 
B Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
 
- 161 - 
 
4.2.5.3 Nano -Particle Preparation and Evaluation 
 
The  development  of  furosemide  and  dipyridamole  nano  suspensions  and  the  choice  of 
excipients was based on the kind guidance of Mr. Kayo Yuminoki at Setsunan University 
labs  (Takatsuka  et  al.,  2009).  Particle  reduction  to  nano  size  was  successful  for  both 
furosemide and dipyridamole by this approach. For furosemide and dipyridamole suspended 
in water, particle size was measured as 0.0573 6.95 and 34.4µm and 11.7, 36.1 and 116µm at 
10, 50 and 90 percentiles, respectively. Nano particle sizes for furosemide and dipyridamole 
were measured as 0.071, 0.152 and 0.485µm and 0.068, 0.139 and 0.289µm at 10, 50 and 90 
percentiles respectively. As freeze drying processes might otherwise promote crystal growth, 
the particle size was also measured after freeze drying. The powder was then re-suspended in 
water, and it was found that the particle size measurements were not affected by the freeze 
drying process. In addition, particle size was measured after 6 days of storage as suspension, 
and no aggregation was observed either for furosemide or dipyridamole suspensions (Table 
4.4).  Size  measurement  was  also  carried  out  6  months  after  storage  of  the  freeze  dried 
powder.  Re-suspension  the  freeze  dried  powder  after  storage  of  6  months  in  water  gave 
particle size measurements of  0.0238, 0.0881 and 0.341µm and 0.0248, 0.0908 and 0.315µm 
for  dipyridamole  and  furosemide  at  10,  50  and  90  percentile  accordingly,  indicating  the 
particle size was stable after six months of storage.  
 
Table 4.4: Particle size measurements for nano suspension formulations 
  Particle size (nm) 
10%  50%  90% 
Dipyridamole nano-suspension   68  139  298 
Dipyridamole nano-suspension after 6 
storage days 
89  216  622 
Freeze dried nano-particles 
dipyridamole  
76  174  450 
Furosemide nano-suspension   70  149  494 
Furosemide nano-suspension (after 6 
storage days) 
70  146  356 
Freeze dried nano-particles furosemide   73  163  639 
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The freeze-dried powders after resuspension of dipyridamole and furosemide were analysed 
by TEM (Figure 4.13). For dipyridamole, the same range of particle size was observed under 
the microscope; in addition, some of the particles (bigger size) retained their elongated and 
sharpened shape, while others (smaller size) were identified as spherical but well-defined.  
Furosemide sample was more uniform in size and shape. Most of the particles were identified 
as being spherically-shaped. 
 
   
   
Figure 4.13: A) Dipyridamole nano suspension and B) Furosemide nano suspension under TEM.  
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PXRD was performed to investigate the crystalline form of furosemide and dipyridamole 
nano particles. Figure 4.14 shows the X-ray powder diffraction of the formulation excipients, 
their  physical  mixture,  and  the  freeze-dried  samples  of  the  pulverized  dipyridamole  and 
furosemide. It can be seen that PVA and povacoat generate broad peaks which are reflected 
in  the  freeze  dried  samples.  However,  other  peaks  can  also  be  seen  in  the  spectrum  of 
dipyridamole  and  furosemide  in  the  freeze  dried  samples,  and  can  be  found  in  the  API 
spectrum alone. This may indicate that some of the drug in the nano- particle formulation is 
found in its crystalline form. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.14: Powder X-ray diffractograms of A) Dipyridamole nano particles B) Physical mixture of dipyridamole, 
mannitol  and PVA, C) Furosemide nano particles D) Physical mixture of furosemide, mannitol  and povacoat, E) PVA, F) 
Povacoat, G) Mannitol 
E 
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The freeze-dried sample of the pulverized dipyridamole and dipyridamole were analysed in 
DSC.  DSC  thermographs  of  the  formulations  excipients,  dipyridamole,  furosemide,  their 
physical mixtures and freeze dried formulations are presented in Figure 4.15 and Figure 4.16. 
For dipyridamole, it can be seen that the melting point for the freeze dried sample decreased 
from 166˚C to 154˚C. An acceptable explanation is that, less energy is required to melt the 
particles due to the reduction in the particle size and a higher surface area. Another possible 
explanation is that it might be that the inclusion of PVA and mannitol affected the melting 
point  of  the  composition,  and  the  melting  point  decreased  due  to  a  decrease  in  the 
composition eutectic temperature.  A similar effect was observed for freeze dried phenytoin 
nano particles with methyl cellulose  (Takatsuka et al., 2009), whereby the exothermal peak 
was not found. The physical mixture also showed a similar melting point to dipyridamole 
alone. The decrease in melting point was not observed in the physical mixture, probably due 
to the fact that the physical mixture was only ground together and not freeze dried. Therefore, 
the interaction between PVA, mannitol and dipyridamole was not observed in the physical 
mixture thermograph. As for furosemide, the pattern of melting point at 220˚C followed by a 
big  endothermic  peak  (recrystallisation)  and  a  second  peak  at  270˚C  of  melting  point 
followed by a second re-crystallisation may indicate on solid solid transition. This pattern 
disappeared  for  the  nano-particles  formulation.  Similar  to  dipyridamole  nano-particles,  a 
melting point at 153˚C was observed. Considering the DSC thermographs similarity between 
furosemide  and  dipyridamole  nano-particles  formulations,  it  might  be  that  only  mannitol 
melting point can be observed in the DSC. The physical mixture gave an exothermic peak at 
167˚C similar to the peak observed for mannitol, which might further emphasise the fact that 
the interaction in the case of the nano-formulation might affect the sensitivity of the DSC to 
observed  further  phase  transitions  for  nano-formulations.  To  further  understand  this,  the 
heating rate was increased to 100°C/min. It can be seen that for furosemide, the pattern of 
solid solid transition was kept the same (big endothermic peak followed by exothermic peak 
at 236°C, and second transition at 277°C). Similar pattern was observed for the physical 
mixture and the nano-formulation (Figure 4.17). This may indicate that part of furosemide 
exits in its crystalline form in the nano-formulation.  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.15: DSC thermographs for A) Dipyridamole, B) Dipyridamole nano particles, C) Physical mixtures of 
dipyridamole, PVA and mannitol, D) PVA E) Mannitol 
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Figure 4.16: DSC thermographs for A) Furosemide, B) Furosemide nano particles, C) Physical mixtures of furosemide, 
povacoat and mannitol D) Povacoat, E) Mannitol at 10°C/min heating rate 
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Figure 4.17: DSC thermographs for A) Furosemide, B) Furosemide nano particles, C) Physical mixtures of furosemide at 
100°C/min heating rate  
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4.2.5.4 Dissolution Tests 
 
The extent of dipyridamole release from the solid dispersion under different conditions of pH 
and bile salts concentration increased significantly, and was around 80-95%. Moreover, no 
effect of bile salts or pH was observed (Figure 4.18), as was observed in the case of the API 
alone or the marketed tablet in the previous section (Figure 3.8) Similar results were obtained 
for dipyridamole as SMEDDS (Figure 4.19). No drug precipitation was observed during 2 
hours of experiments, and the percentage of drug release at 2 hours was around 80-90% under 
all conditions. For the dipyridamole nano-formulation, no increase in drug dissolution was 
observed.  Moreover,  the  bile  salt  concentration  affected  the  extent  of  drug  release,  with 
higher dissolution observed at 6mM, followed by 3 and 1mM. Similarly to the API, it seems 
that pH had a slight effect on the dissolution (Figure 4.20).  
 
Figure 4.18: Dissolution of dipyridamole solid dispersion under different conditions of bile salt and pH in mHanks buffer Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.19: Dissolution of dipyridamole SMEDDS under different conditions of bile salt and pH in mHanks buffer 
 
   
Figure 4.20: Dissolution of dipyridamole nano particles under different conditions of bile salt and pH in mHanks buffer Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Furosemide solid dispersion gave similar values of percentage of drug release to the API 
alone. The variability in dissolution rate and extent of release was not reduced in the case of 
the solid dispersion formulation (Figure 4.21). For SMEDDS, it can be seen that the range of 
the extent released was narrow relatively to the other formulations; however, the dissolution 
rate  still  appeared  to  be  variable  (Figure  4.22).  The  furosemide  nano-formulation,  gave 
similar results to that of the SMEEDS formulation (Figure 4.23). 
 
Figure 4.21: Dissolution of furosemide solid dispersion under different conditions of bile salt and pH in mHanks buffer Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
 
- 175 - 
 
 
Figure 4.22: Dissolution of furosemide SMEDDS under different conditions of bile salt and pH in mHanks buffer 
 
 
Figure 4.23: Dissolution of furosemide nano-particles under different conditions of bile salt and pH in mHanks buffer Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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As described previously, the percentage of furosemide release from the API alone in FaSSGF 
under different conditions ranged from 8 to 16%. For the furosemide SMEDDS formulation 
in acidic conditions, no drug precipitation was observed, and the percentage release was very 
high (90%) at 2 hours (Figure 4.24). The nano particle formulation gave similar results to that 
of the API and the marketed tablet, for which a low percentage of release was observed 
(Figure 4.25). Interestingly, the solid dispersion increased the percentage of the drug release 
(80-100% under all conditions) until one hour, and precipitation of approximately 20% was 
observed  at  2  hours  (Figure  4.26).  In  terms  of  variability  in  the  extent  of  release  and 
dissolution  rate,  it  seems  that  only  SMEDDS  reduced  the  variability  under  different 
conditions.  
 
 
Figure 4.24: Dissolution of furosemide SMEDDS under different conditions of bile salt and pH in FaSSGF. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.25: Dissolution of furosemide nano particles under different conditions of bile salt and pH in FaSSGF 
 
 
Figure 4.26: Dissolution of furosemide solid dispersion under different conditions of bile salt and pH in FaSSGF. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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For weak acids and bases, it is important to investigate the change in drug release when the 
drug transfers from the acidic conditions of the stomach to the basic pH in the duodenum.  
Dissolution of all formulations was tested under changing pH conditions from 1.6 to 6.5. The 
dissolution profiles for dipyridamole and furosemide under these conditions is presented in 
and Figure 4.27 and Figure 4.28. It was found that precipitation of the dipyridamole-marketed 
tablet was fast, and the percentage of drug dissolved at 10 min after changing the pH to 6.5 
was 10%.  Precipitation was observed for all dipyridamole formulations. Solid dispersion and 
nano-suspension formulations precipitated at approximately the same rate, and after 20 min 
in the neutral phase, only 20% of the dose was dissolved. The precipitation rate decreased, 
and at the end of 4 hours, only 10% of the dose was dissolved. For SMEDDS, it can be seen 
that precipitation of 30% of the dose was observed with the addition of pre-FaSSIF; however, 
after 10 minutes, 50% of the dissolved drug was dissolved and no further precipitation was 
observed up to 4 hours.  
 
For furosemide, the marketed tablet gave the lowest dissolution in the stomach conditions 
(less than 10%), followed by the nano-particle formulations (10%), solid dispersion (50%) 
and SMEDDS (90%). Upon increasing pH, the percentage of drug release for all formulations 
increased, and ranged between 70-80% without a significant difference. The marketed tablet 
dissolution rate was slower as compared to the other formulations, however, at around 5 min 
the same extent of release was observed.  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.27 : Dissolution of dipyridamole formulations in modified FaSSGF (pH=1.6) followed by FaSSIF (pH=6.5) 
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Figure 4.28: Dissolution of furosemide formulations in modified FaSSGF (pH=1.6) followed by FaSSIF (pH=6.5) 
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An attempt to interpret dissolution results in the context of the in vivo situation is not straight 
forward, and the interplay of many factors needs to be considered.  Formulating dipyridamole 
as  a solid dispersion  in the amorphous  form  or as  SMEDDS increases  its  solubility and 
dissolution, as can be seen from the dissolution tests. However, as dipyridamole is a weak 
base and precipitation on transferring from the stomach to the duodenum was observed, a 
formulation  that  is  able  to  maintain  dipyridamole  in  its  supersaturated  state  for  a  longer 
period of time in the duodenum will eventually increase its chances for absorption. Based on 
the  results  presented  herein,  it  appears  that  SMEDDS  offers  the  possibility  for  longer 
absorption in vivo, as 50% of the drug was dissolved. However, one has to bear in mind that 
the 50% dissolved will also be readily available for absorption, as some of dipyridamole will 
be incorporated into oil micelles. Solid dispersion and nano-suspensions were precipitated at 
lower rates than the marketed tablet, which can offer a comparatively longer time for the 
dissolved drug to be absorbed.  
 
For furosemide, dissolution of the clinical dose was high in the simulated intestinal fluids; the 
formulations did not increase the dissolved amount of drug in the duodenum. However, the 
extent of drug release from the solid dispersion and SMEDDS increased under the acidic 
conditions of the stomach. For drugs with a narrow absorption window, this is especially 
relevant and important. The shift from low pH to high pH therefore needs to be considered 
for these weak acid drugs. All formulations increased the dissolution rate of the drug as 
compared to the marketed tablet; a higher dissolution rate upon transfer of the formulation 
from the stomach to the duodenum will offer more of dissolved drug available to be absorbed 
earlier. Based on this study, SMEDDS will offer the highest amount of dissolved drug upon 
emptying  from  the  stomach,  followed  by  the  solid  dispersion  and  by  nano  particle 
formulation.  
 
In terms of furosemide variability, in the dissolution test no effect of bile salt or different pH 
(either in the gastric or intestinal simulated fluids) was observed. It can be assumed that a 
different concentration of bile salts and different pH conditions will not affect the dissolution 
of furosemide in vivo in the upper GI at this clinical dose. However, the variable dissolution 
rate might have significant effects in the case of drugs with narrow absorption windows. The 
formulations tested did not show an improvement in the dissolution rate variation, which can 
be attributed to the wetting properties of the formulation powder. Moreover, in the previous 
chapter, it was reported that the excipients in the marketed tablet or compressing the powder Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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to tablet reduced the dissolution rate variation. It can be assumed that further development of 
the tested formulations by adding simple excipients or compressing the powder to a tablet 
form will give similar results. 
 
4.2.5.5 Comparison of Formulation Development and Preparation  
 
Each method presented herein might encompass challenges in development, and will not be 
suitable  for  some  drugs  depending  on  their  physicochemical  properties.    For  instance, 
preparing nano-crystal particles using the wet ball method will not be suitable for drugs with 
low melting points,  given that during the milling process, the generation of friction heat 
results in amorphization, and lead to instability of the formulation. With regards to SMEDDS, 
administering a liquid formulation would not be an appropriate choice for those drugs with 
low solubility in lipid excipients, and with low stability in the liquid state. Due to inherent 
stability problems associated  with the amorphous form, the solid dispersion approach might 
also be unsuitable for those drugs with low chemical and physical stability (Kawabata et al., 
2011). Therefore, it is clear that the physicochemical properties as well as the clinical dose 
could  affect  the  strategic  selection  of  a  formulation  to  improve  drug  solubility  and 
performance in vivo. 
 
Based on the experience in this study, and considering the development stages of the different 
formulations, the solid dispersion preparation was fairly straightforward in terms of planning 
and choosing the excipients. There is a great deal of knowledge and published literature for 
planning, executing and assessing solid dispersion formulations. The SMEDDS development 
involves many stages. Moreover, the fact that the repetition of the published formulations 
was not successful in this study indicates that small changes in the preparation due to human 
practice  and  differences  in  excipient  batches  might  affect  the  end  product  and  its 
performance. Unlike the literature for solid dispersion, the published literature for SMEDDS 
is limited, although an increasing interest in the pharmaceutical community is becoming more 
apparent. Moreover, IVIVCs for SMEDDS are scarce, mainly due to a lack of understanding 
of  the  absorption  mechanism.  Common  dissolution  tests  cannot  predict  the  free  fraction 
available to be absorbed, and as such, the use of dialysis bags is required during dissolution 
tests. However, the transfer of drugs from dialysis bag can take a long time, and is not always 
reflective of the in vivo dissolution process. The published setups which assess the in vitro Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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lypolysis are also fairly complicated and not available and further IVIVC validation for these 
methods is required. All of these factors consequently make the SMEDDS formulation a less 
attractive strategy. Nano-milling by contrast  has  gained a  great  deal  of interest  in  recent 
years: Nano particle development also includes many stages, however, and excipients choice 
is not always simple. On the other hand, assessing the formulation performance can be done 
by the same tools  as  used for solid dosage  forms,  and interpretation  is  not  complicated. 
Assuming that all three methods increase solubility to the same extent, a solid dispersion 
formulation will be the preferred strategy based on the method limitations described herein.  
 
A comparison of all three approaches increasing dipyridamole solubility/dissolution rates in 
vitro indicates that the highest solubility for the longest time and after increasing pH was 
attained with SMEDDS, in addition to reduced variability due to bile salt and pH. However, 
as mentioned previously, it is difficult to extrapolate these results to the in vivo absorption 
results, given that the free fraction to be absorbed out of the 50% dissolved drug is not 
known. Similarly, solid dispersion appears to increase the solubility and decrease the effects 
of  intra-luminal  differences  on  solubility.  When  precipitation  was  assessed  for  the  solid 
dispersion, it produced similar percentages of dissolved drug at the end of 4 hours to those of 
the nano-particle and the marketed tablet formulation. However, the precipitation rate was 
slower in the case of solid dispersion than the marketed tablet, which might give a longer 
window for the dissolved drug to be absorbed in vivo. A reduction in particle size did not 
yield an increase in the solubility of the drug. 
 
In the case of furosemide, dissolution in the intestine is not, however, a limiting step for the 
tested clinical dose. Considering the limited dissolution in the stomach, SMEDDS was shown 
to increase the extent of drug release in the stomach, followed by the solid dispersion. In 
contrast, nano-particles did not yield an increase in drug release. Again, the implication of 
increasing drug release in the case of SMEDDS is not clear due to the limitation of the 
dissolution  test  for  SMEDDS  formulations.  The  high  extent  of  release  from  the  solid 
dispersion might offer a better chance for furosemide to be absorbed in the upper parts of the 
intestine. Similar effect but to a lesser extent might be observed in the case of the nano- 
particle formulation thanks to the higher dissolution rate of the nano-particles compared to 
the marketed tablet during the pH change. It is important to note that most of the efforts in 
improving drug physicochemical properties are focused on improving drug solubility and less 
focused on improving drug permeability (BCS III/IV). Some investigations have shown that Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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the  addition  of  permeation  enhancers  such  as  fatty  acid,  bile  salts,  surfactants,  and 
polysaccharides  play  a  role  in  enhancing  the  permeability  of  drugs  via  the  paracellular 
pathway;  however,  some  of  them  are  known  to  have  membrane-damaging  effects,  and  
therefore the formulation approaches in the case of BCS III is limited to an immediate-release 
tablet (Kawabata et al., 2011). Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.2.6  Summary  
 
Different  formulation  approaches  to  increase  solubility  and  dissolution  of  poorly  soluble 
drugs are available in the scientific community and pharmaceutical industry. Herein, three 
different formulation approaches were compared in increasing solubility/dissolution. Solid 
dispersion appeared as the most convenient method for preparation and increased the extent 
of  release  of  dipyridamole  and  minimised  the  effect  of  bile  salt  and  pH  on  the  drug 
dissolution. SMEDDS formulation also increased the extent of release, however due to the 
limitation in the in vitro dissolution tests to estimate the percentage of drug available to be 
absorbed, it is difficult to draw a conclusive conclusion compared to the other formulations. 
Reduction in the drug particle size did not yield an increase in the extent of dissolution under 
different bile salt and pH conditions. Different in vitro tools can be utilised to investigate 
formulation performance in vivo. Due to ethical consideration, it is difficult to conduct in vivo 
studies  in  humans  to  assess  the  formulation  absorption,  therefore  in  the  next  section  the 
formulation pharmacokinetics will be assessed in animal model.  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.3  In Vivo Evaluation of Formulations in a Rat Model  
4.3.1  Introduction  
4.3.1.1 In Vivo Studies to Evaluate Formulation Performance 
 
There  are  several  biopharmaceutical  tools  used  in  pharmaceutical  development  to 
characterise formulation performance, including  in  vitro tests,  animal studies  and clinical 
trials  in  healthy  human  subjects  (and  sometimes  in  patients).  There  is  no  doubt  that  the 
information gained from in vivo human clinical trials is much more valuable and reflects the 
real  situation  more  closely.  The  key  limitations  of  human  studies  are  providing  ethical 
justification for the trial in addition to limitations in throughput and cost. In vitro tests can 
circumvent  these  limitations  but  fail  to  adequately  mirror  the  complexity  of  the 
gastrointestinal environment in vivo. Conditions such as volume and composition and static 
environment in the compendial dissolution tests do not take permeability, metabolism or the 
dynamic nature of the gut into consideration, and can contribute to lack of IVIVC. Moreover, 
to validate in vitro models, in vivo data in humans is also needed. Therefore, a proof-of-
concept study in a suitable laboratory animal is important in order to gain more information 
of formulation performance in a living body before it is subject to any human trials.  
 
The choice of the right animal model is not always straightforward. A recent review article 
summarizes the current knowledge on anatomy and physiology of the human gastrointestinal 
tract  compared  with  that  of  common  laboratory  animals  (dog,  pig,  rat  and  mouse)  with 
emphasis on in vivo methods for the testing and prediction of oral dosage form performance. 
Needless to say,  there is no definite conclusion as for the best model to predict human in vivo 
data,  and  each  decision  needs  to  be  taken  based  on  drug  properties,  the  physiological 
differences between the animal model and human, and its possible effect on the formulation 
performance in vivo (Sjögren et al., 2014).   Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.3.1.2 Rat GI Physiology Compared to Humans 
 
The rat  is  the most investigated  animal  model to  yield  IVIVC. However, there  are some 
remarkable differences between the GI physiology of the rat and humans, namely that rodents 
feature  a  well-defined  caecum,  whereas  in  humans  the  caecum  is  very  small  and  is 
continuous with the colon. Moreover, gastric volume adjusted to body weight of rats is larger 
than in man, which might feature implications for drug solubility when dosing rats based on 
body weight (Davies and Morris, 1993).  
 
In recent research by our group, the gastrointestinal environment in rats and how it affects 
drug solubility was investigated, knowing that differences in the GI milieu such as pH, buffer 
capacity, osmolality and surface tension may lead to differences in drug solubility. In rats, the 
highest  buffer  capacity  was  measured  in  gastric  fluid,  which  decreased  down  the  small 
intestine and increased  again  in  the caecum  and colon.  The buffer capacity  from  human 
jejunal and ileal fluids (Fadda et al., 2010b) were appreciably lower than those in rats. The 
inter-species differences in buffer capacity are important aspects for consideration, especially 
for the administration of pH-responsive formulations and ionisable drugs. 
 
The  osmolality  of  the  gastrointestinal  contents  of  rats  in  turn  was  low  in  the  stomach, 
increasing in the proximal small intestine and decreasing in the distal gut. This pattern of 
osmolality  in  general  is  in  agreement  with  the  physiology  of  the  rat  digestive  system, 
whereby most of its food is digested and broken down into component molecules such as 
glucose, amino acids and fatty acids in the small intestine, hence producing a higher fluid 
osmolality.  As  nutrients  are  absorbed  further  down  the  gut,  osmolality  of  the  contents 
decrease. 
 
Surface  tension  of  rat  gastrointestinal  fluids  was  significantly  lower  than  that  of  water 
throughout the gut. Surface tension in rats was found to be higher in the stomach and lower in 
the small intestine, increasing again in the distal gut. Surface tension of the human gastric 
aspirates was reported to be ~30mN/m in the fed state, which was relatively constant over a 
period of time and was lower than the surface tension of the rat (Kalantzi et al., 2006). A 
similar observation was noted with human duodenal aspirates, where surface tension was 
lower (~28mN/m) than in rats. Surface tension of the supernatants from human ascending Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
 
- 188 - 
 
colon fluids was also lower (39.2mN/m) (Diakidou et al., 2009) as compared to the surface 
tension of the proximal colon fluids from the rat.  
 
McConnell et al. (2008b) reported that the gastric pH in rats was found to be higher than in 
humans, and especially in the fasted state (4 compared to 1.6). In addition, the intestinal pH 
of rats did not reach the pH values reported in man in the distal small intestine, caecum and 
colon.  The  low  intestinal  pH  in  rats  has  implications  for  the  in-vivo  testing  of  oral 
pharmaceuticals  in  rats.  For  example,  drugs  which  require  a  basic  pH  to  dissolve  may 
precipitate at lower pH values seen in the rat. Moreover, lack of correlation and ability to 
extrapolate in vivo results from rats to humans may occur where pH-responsive drug carriers 
are being investigated. 
 
Similarly to human, taurocholate is the major bile acid at a total concentration of 8–25mM in 
rats,  and bile salt secretion is  also  induced endogenously by food intake. As for species 
differences, the total bile acid and phospholipid concentration in rat GI tracts were found to 
be much higher than those of humans. This might have significant implications for rat in vivo 
results for lipophilic drugs, where an improvement in oral absorption might not be observed 
due to the high concentration of bile salts (Tanaka et al., 2012).   
 
In situ perfusion of intestinal segments of rats is frequently used to study the permeability and 
absorption kinetics of drugs. In situ study provides the advantage of isolating comparisons to 
the level of the intestine, focusing on the epithelial permeability in small and large intestines. 
Peff from rat jejunal studies were found to correlate strongly with the corresponding human 
jejunal Peff (Cao et al., 2006; Fagerholm et al., 1996). Moreover, good correlation was found 
between  the  expression  levels  of  transporters  and  metabolic  enzymes  in  rat  and  human 
jejunum. However, a moderate correlation for the transporter expression levels in duodenum 
and no correlation in metabolizing enzyme levels were found (Cao et al., 2006). This can 
explain  the  lack  of  correlation  in  plasma  clearance  of  54  extensively  metabolized  drugs 
between humans and rats (Chiou and Barve, 1998).  Characterisation of the GI tract of rats is 
summarised in Table 4.5 (adapted from Sjögren et al. (2014)). Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Table 4.5: Charctersation of the GI tract of rats adapted from (Sjögren et al., 2014) 
Parameters  Location  Rat 
pH fasted  Stomach  4–5 (glandular region);  
7 (anterior region) (Davies and Morris, 1993; Kararli, 1995) 
SI  4.5–7.5 (Davis and Wilding, 2001; Lennernäs and Regårdh, 1993)   
LI  N\A   
pH fed  Stomach  3.8–5.0 (Davies and Morris, 1993)   
SI  6.5–7.1 (Davies and Morris, 1993)   
LI  6.6–6.9 (Davies and Morris, 1993)   
Transit time 
fasted 
Stomach  15–30 min (T1/2) (Langguth et al.  1994)  
5–65 min (t1/2) (Maerz et al. 1994) 
 
SI  3–4 h (Davis and Wilding, 2001; Lennernäs and Regårdh, 1993)   
LI  10–11 h based on a total GI transit 
time of 15 h (DeSesso and Jacobson, 2001) 
 
Transit time fed  Stomach  N\A   
  SI  N\A   
  LI  N\A   
Length SI    102–148 cm (Kararli, 1995)   
Length LI    26–26 cm (Kararli, 1995)   
Bile concentration  SI  33.5–61.3 mM (fasted) (Staggers et al. 1982)  
17–18 mM (fasted) (Kararli, 1995) 
Compared to man higher BS/PL ratio but PL 
concentration similar to man 
 
Metabolic 
activities 
  CYP related activities (Takemoto et al. 2003) 
In general not correlated to humans 
 
Major drug 
transporters 
  Similar transporter expression 
patterns as in humans (Cao et al. 2006) 
 
Permeability    Less than in humans, good correlation   
Water volumes  Stomach  2.4 mL (Takashima et al. 2013)   
SI  3.0–4.6 mL (Takashima et al. 2013)   
LI  N\A   Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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In this  section, the in  vivo and the in vitro performance of the different  furosemide and 
dipyridamole  formulations  were  investigated  in  the  rat  model  and  the  D/P  system.  In 
addition, an attempt to assess the inter-subject variability in bioavailability was carried out for 
the different formulations in rat model. 
 
4.3.2  Objectives 
 
  To evaluate in vitro performance in terms of dissolution and permeability of three 
formulation approaches (solid dispersion, SMEDDS and nano-particles) using the D/P 
system.  
  To compare three different formulation approaches in increasing bioavailability  in 
vivo in the rat model.  
  To estimate the effectiveness of the formulations in decreasing in vivo bioavailability 
variability in rats.  
  To establish the in vitro in vivo correlation.  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.3.3  Materials  
 
Dipyridamole  (D9766)  and  furosemide  (F4381)  were  obtained  from  Sigma  Aldrich 
Chemicals  (Poole,  UK).  Solvents  used  in  HPLC  and  LCMS  were:  HPLC\LCMS  water, 
acetonitrile and phosphoric acid. All were of HPLC grade or LCMS grade and purchased 
from Fisher Scientific (Loughborough, UK).  
4.3.4  Methods 
4.3.4.1 D/P System Set Up 
 
A more detailed method is described in Chapter 3. Briefly, the drug or the formulations were 
added to the apical side of the D/P system, and 200µL aliquots of samples were withdrawn 
from the apical and the baso-lateral sides to measure the amount dissolved and permeated 
with time at 5, 15, 30, 60, 90, and 120 minutes. The dipyridamole dose was equivalent to 
1mg, and furosemide absorption was tested at dosages of 0.4mg and 1.4mg. 
4.3.4.2 Animal Experiments 
 
All  animal  experiments were approved by the  UCL School  of Pharmacy Ethical  Review 
Committee,  and  were  conducted  in  accordance  with  Home  office  standards  under  the 
Animals (Scientific Procedures) Act, 1986. Male Wistar rats (average weight app. 200-250g) 
were  supplied  by  Harlan  (Oxfordshire,  UK).  Studies  were  performed  in  6  rats  for  each 
formulation.  The  animals  were  restrained  in  the  laboratory  for  one  week  before  the 
commencement of any experiment to allow the animal to adjust to a new environment and to 
avoid any dramatic change in feeding behaviour. Twelve hours prior to dosing, the rats were 
fasted but were allowed free access to water.  
 
Rats were given an oral gavage of the sole API and solid dispersion (The Size 9 Dosing Kit 
for rats - Dosing Syringe) in capsules with an additional 0.4mL of water immediately after 
capsule  administration.  SMEDDS  and  nano-suspension  and  the  preparation  of  nano- 
formulation with un-milled API were administered as a 0.4mL suspension/solution using the 
oral gavage. For furosemide, drug suspensions and solutions were administered as 0.4mL. All 
administered  doses  were  equivalent  to  10mg/kg  for  both  drugs.  To  calculate  the 
bioavailability of these formulations, an IV bolus injection was administered to 6 rats to the Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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tail in a dose of 16mg/kg. Blood samples (200µL) were collected from the rat tail at time 
points of 20 ,40 ,60 ,90 ,120 ,150, 180, 240, 360 and 400 minutes, and transferred into EDTA 
BD microtainer capillary blood tubes (New Jersey,U.S.) before being immediately vortexed 
for 20 sec. Blood tubes were centrifuged for 10 min at 13,000 rpm using Centrifuge 5415D 
(Eppendorf AG, 22331  Hamburg, Germany). Plasma was placed into labelled Eppendrof 
tubes and stored at -20˚C for HPLC/LCM  assay.  
 
4.3.4.3 Plasma Samples  
 
Furosemide and dipyridamole extraction from rat plasma samples were carried out following 
a method developed based on previous work (Bauza et al., 1985; Qin et al., 2010). For both 
furosemide and dipyridamole samples, 300µL of acetonitrile were added to 100µL of plasma 
samples. The samples were vortexed for at least 1 minute, and centrifuged for an additional 
10 min at 13,000 rpm at 4˚C. 300µL of the organic phase was taken and transferred into a 
2mL Eppendorf tube. The tubes were then transferred to a vacuum centrifuge (Speed Vec) to 
evaporate the organic solvent for 300 min at room temperature, and reconstituted with 100 µl 
of  the  mobile  phase  in  the  case  of  furosemide,  and  300µL  mobile  phase  in  the  case  of 
dipyridamole.  
4.3.4.4 Furosemide HPLC analysis 
 
The  equipment  consisted  of  an  integrated  HP  1200  Series  HPLC  system  comprising  an 
HP1200 autosampler, a HP 1200 pump and a HP 1200 multiple wavelength detector system, 
a UV Vis spectrophotometric detector and fluorescence detector (Agilent Technologies, West 
Lothian, Scotland). The detector was interfaced with a pv with PC/Chrom + software (H&A 
Scientific Inc, Greenville,NC, USA). Furosemide was assayed using a 150x4.6 mm particle 
size 3µm reserved- phase C18 column Hypersil Gold (Fisher scientific) at 40˚C. The mobile 
phase used for analysis consisted of acetonitrile (A) and 0.05M phosphate buffer adjusted pH 
to 2.5 (B). The following gradient was applied: 80:20 B:A (V/V%) gradually changed to 
60:40 (B:A) for 15 minutes, followed by a change to initial conditions 80:20 (B:A) for 5 
minutes,  and  thereafter  conditioning  the  column  to  initial  conditions  for  4  minutes, 
constituting a total run time of 24 min.  The flow rate was 1mL/min and the injection volume 
was 80µl. The detection wavelength for vis-UV was 238nm, and for fluorescence detection, Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
 
- 193 - 
 
excitation and emission were set to 233 and 389nm, respectively. The drug retention time was 
12.5 min. 
 
The standard curves were linear in the range of 0.1 to 10µg/mL (R
2=0.998). The HPLC 
method was tested for accuracy and precision at low, medium and high concentrations. The 
extraction rate ranged between 80-105%, with a limit of detection as 0.05µg/mL and the limit 
of quantification being 0.1µg/mL. Chromatograms of blank plasma sample and furosemide-
spiked plasma sample from a Wistar rat are shown in Figure 4.29. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.29: Chromatogarms of A) Blank Wistar rats and b) Furosemide spiked (0.1µg/ml ) Wistar rat’s plasma Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.3.4.5 Dipyridamole LCMS analysis 
 
Dipyridamole LCM  was developed at  ing’s College University, MS unit. The method was 
used in equipment consisting of a HPLC system comprising an HP1260 autosampler, a HP 
1260 pump and 6400 Series Triple Quadrupole LC/MS (Agilent Technologies, West Lothian, 
Scotland). Separation of dipyridamole was achieved with a 150x4.6 mm particle size 3µm 
reserved- phase C18 column Hypersil Gold (Fisher scientific) at 40˚C. The mobile phase used 
for analysis consisted of 30:70% (V/V), acetonitrile 0.1 formic acid and 0.1% formic acid in 
water. The flow rate was 0.4 ml/min and the injection volume was 5µL. Drug retention time 
was  8  min.  Protonated  precursor  and  production  ions  (m/z)  for  detection  were  505.328, 
429.328 and 385.5, respectively. Ionization conditions for analysis of dipyridamole were as 
follows:  electrospray  ionization,  positive  mode;  source  temperature  250°C;  cone  voltage 
4000V; and collision energy 52 and 36 for 429.328 and 385.5, respectively;  
 
The standard curves were linear in the range of 10 to 1000ng/mL (R
2=0.99). The LCMS 
method was tested for accuracy and precision at low, medium and high concentrations. The 
extraction rate ranged between 90-120%. The limits of detection and quantification were 
5ng/mL  and  10ng/mL  respectively.  Chromatograms  of  blank  plasma  sample  and 
dipyridamole-spiked plasma sample from a Wistar rat are shown in Figure 4.30. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.30: Chromatogarms of a) Blank Wistar rats and B) Dipyridamole spiked 10ng/mLWistar rat’s plasma Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.3.4.6 Statistical Analysis  
 
All  results  are  presented  as  mean  ±  SEM.  AUC0-8  calculations  were  done  based  on  the 
Trapezoidal Rule. Bioavailability was calculated according to Equation 4.3. The variation 
coefficient (%CV) was calculated in the same way as indicated in Section 2.3.3.4 
 
    
Equation 4.3: Bioavailability calculation 
 
The plasma concentration vs. time data and the permeation and dissolution profiles of the 
different formulations were analysed by one way ANOVA repeated measurements, using a 
linear model followed by a tukey post- hoc analysis (SPSS Inc., Illinois, USA). AUC0-8 and 
bioavailability values were analysed by one way ANOVA with post hoc tests using PASW 
statistics 22 (SPSS Inc., Illinois, USA). Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.3.5  Results & Discussion  
4.3.5.1 Furosemide Formulations Assessment In Vitro Using the D/P System 
 
Evaluation of furosemide formulations in vitro using the D/P system revealed that at the 
apical side, all formulations gave a similar extent of drug release of around 80% after 2 hours. 
This is in agreement with the formulation dissolution results under different conditions using 
mHanks buffer described previously herein. Although a high percentage of dissolved drug 
was attained on the apical side, a very low permeated amount was achieved at 2 hours for all 
formulations (less than 0.1%). All formulations showed similar permeation profiles, while 
furosemide SMEDDS resulted in higher permeation (Figure 4.31). This emphasises the fact 
that the rate-limiting step in furosemide absorption is permeation through the gut membrane, 
and that the classification of furosemide in this clinical dose (40mg) as BCS IV needs to be 
reconsidered. Calculations of the predicted fa in humans are presented in  
Figure  4.32.  The  SMEDDS  furosemide  formulation  showed  an  increase  in  the  fraction 
absorbed  relative  to  the  other  formulations  (p˂0.5).  As  discussed,  these  formulation 
approaches are intended to increase the solubility/dissolution of poorly soluble drugs and as 
such, no effect on the drug permeability is expected. In the case of furosemide, no effect on 
solubility/dissolution of the different formulations in this clinical dose was observed in vitro, 
as  the  extent  of  release  was  already  high.  The  increase  in  the  permeation  and  hence 
absorption of the drug in the oil formulation might be attributed to a direct partitioning of the 
drug  from  the  micelle  to  the  membrane.  A  number  of  absorption  mechanisms  were 
summarised by Yano et al. (2010); Firstly, that the absorption of micelle drugs involves 
collisional transfer to the glycocalyx of the gut enterocytes. Secondly, the micelles can assist 
in transport of solubilised (incorporated) solutes across the aqueous diffusion layer to the 
surface  of  the  cell  membrane,  which  reduces  the  effect  of  the  unstirred  water  layer  on 
absorption.  In  addition,  it  was  suggested  that  some  of  the  surfactants  in  SMEDDS 
formulation  might  have  the  ability  to  inhibit  transporters  like  P-gp.  It  was  reported  that 
furosemide might be sensitive to efflux transport and therefore the SMEDDS formulation was 
successful in increasing the permeation by inhibiting P-gp transporters.  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.31: Dissolution and permeability of furosemide formulations-D/P system 
 
 
 
Figure 4.32: Furosemide fraction absorbed calculated based on the D/P system Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.3.5.2 Dipyridamole Formulations Assessment In Vitro Using the D/P System 
 
The extent of drug release on the apical side was the highest for the dipyridamole SMEDDS 
formulation, followed by the solid dispersion. A reduction in the drug particle size did not 
yield any increase in dipyridamole release, and instead gave a similar dissolution to the API 
alone. On the baso-lateral side, it was observed that the highest permeated amount was for the 
solid  dispersion  formulation,  followed  by  SMEDDS.  No  increase  in  the  permeation  was 
attained  in  the  case  of  nano  suspension  (Figure  4.33).  This  is  not  surprising,  however, 
considering the fact that the extent of drug release in the case of SMEDDS formulation does 
not reflect the free drug amount available for permeation through the membrane due to the 
micelle structure created by the oil-in-water phase. In terms of the fa (Figure 4.34), it can be 
seen that solid dispersion increased absorption to 80%, followed by 70% to the SMEDDS 
formulation, with no increase in the case of the nano-suspension (30%).  Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Figure 4.33: Dissolution and permeation of dipyridamole formulations- D/P system 
 
 
 
Figure 4.34: Dipyridamole fraction absorbed calculated based on the D/P system 
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4.3.5.3 Furosemide Formulations In Vivo  
 
The  pharmacokinetics  of  furosemide  in  rats  was  evaluated  after  oral  administration  of 
furosemide as  a solution, oral  suspension  and the sole API in  capsule  (Figure  4.35). No 
significant differences were observed between all three dosage forms in AUC0-8  (p˃0.05). 
Tmax of furosemide caps was around 1 hour, while the Tmax of the suspension and the oral 
solution, came earlier at around 20-30 minutes. The calculated bioavailability of furosemide 
in rats was very low at 5, 6.5 and 10% for the suspension, oral solution and API capsules, 
respectively.   
 
 
Figure 4.35: Plasma concentrations vs. time of oral solution, oral suspension and API in capsules of furosemide Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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To  investigate  the  effect  of  different  formulations  on  furosemide  bioavailability,  the 
following were administered to the rats: solid dispersion, SMEDDS and nano-suspension 
(Figure 4.36). AUC0-8 and bioavailability values are presented in Table 4.6. Solid dispersion 
plasma concentration vs. time did not differ significantly compared to the API capsules, and 
generated similar AUC0-8 values (p˃0.05) around 3µg*h/mL. Thus, no increase in furosemide 
bioavailability was observed in the case of the solid dispersion (11%). The nano-suspension 
gave  the  highest  AUC0-8  value,  followed  by  SMEDDS,  and  for  both  formulations,  drug 
exposure  was  significantly  different  from  the  API  capsules  (p˂0.5).  With  respect  to 
bioavailability, the nano-suspension formulation increased furosemide bioavailability 3-fold, 
calculated  as  33%,  whereas  the  SMEDDS  formulation  increased  bioavailability  only 
moderately to a value of 15%. High variability was observed for both formulations (30-40%).  
Variability in AUC0-8 was also slightly lower for the solid dispersion as compared to API 
capsule  administration  (24  vs.  40%).  Tmax  values  for  SMEDDS  and  nano-suspension 
(administered  as  a  solution)  were  similar  at  around  30  minutes.  The  furosemide  solid 
dispersion Tmax was recorded around 1.5-2 hours; slightly later from the Tmax recorded for the 
furosemide API.   
 
Figure 4.36: Plasma concentrations vs. time of API in capsules, SMEDDS, nano-suspension and solid dispersion 
formulations of furosemide Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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To eliminate the hydrophilic effect of excipients on furosemide absorption in the case of the 
nano-suspension, the same composition of the nano-suspension formulation was mixed with 
the un-milled API and administered at the same dose to the rats  
Figure 4.37). The AUC0-8 of the excipients mixture with unmilled API increased as compared 
to the API alone, but was still lower than the nano suspension AUC0-8. This implies that the 
drug exposure was not affected by the excipients alone, but that the reduction in particle size 
also contributed to an increase in drug absorption.  
 
Figure 4.37: Plasma concentrations vs. time of nano-suspension and nano excipients with unmilled furosemide 
 
 
 
Table 4.6: AUC 0-8 and bioavailability values of the different furosemide dosage forms in rats 
Dosage form   AUC 0-8 (µg*h/mL)  Bioavailability (%) 
Mean ±SEM  CV % 
API in capsules  3.2±0.5 
(n=6) 
40.4  9.9 
SMEDDS  4.5±0.8 
(n=6) 
45.0  14 
Nano  Suspension   10.4±1.4 
(n=6) 
32.5  32.5 
Solid Dispersion   3.6±0.3 
(n=6) 
25.0  11 
Oral suspension  1.7±0.1 
(n=3) 
9.3  5.3 
Oral Solution  2.1±1.2 
(n=3) 
57.1  6.5 
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As  described,  furosemide  administered  as  solution  and  as  powder  in  capsules  yielded 
approximately similar AUC0-8 values with high variability. In the first instance, this might 
imply that the solubility/dissolution of furosemide in rats at the administered dose is not a 
crucial factor in furosemide absorption. Similar results were also recorded in humans. Based 
on  similar  extents  of  bioavailability/AUC  obtained  following  tablet  and  solution  dosing, 
Kelly et al. (1974) concluded that solubility may not be the sole factor decreasing furosemide 
absorption. A similar extent of absorption from furosemide capsules and solution might be 
related to the fact that furosemide is a poorly permeable drug, and permeability is actually the 
limiting  step  in  its  absorption  rather  than  solubility  and  dissolution.  This  was  further 
confirmed by Waller et al. (1982).  
  
The increase in the nano-suspension bioavailability in rats was fairly surprising considering 
that the in vitro results in FaSSGF /mHanks and in the D/P system where no increase in drug 
release from the nano- suspension was observed. Moreover, it contradicts the assumption that 
it is not the dissolution rate which controls furosemide absorption, but the permeability based 
on  the  similar  plasma  profiles  of  oral  solution,  suspension  and  API  powder.  Suggested 
explanations for this include, firstly, that the oral solution results might be misleading in rats 
at this administered dose. Indeed, the pH of the oral solution was adjusted to 8 in order to 
completely dissolve furosemide in water (the decision not to add any dissolving agent was 
made  based  on  the  understanding  that  these  agents  might  facilitate  the  drug  absorption). 
Unpublished results from our group of in vivo gastric (fundus) pH in rats ranged from 2.9 to 
5.6  (n=9).  Considering  the  high  variability  obtained  in  the  case  of  the  oral  solution,  the 
differences  in  the  gastric pH between rats  might  therefore contribute the high variability 
absorbed in the AUC0-8 in the case of the weak acid drug solution, and in vivo at low pH, 
precipitation cannot be ruled out. In which case, it may be that it is not permeability limited, 
and at the administered dose in rats, the dissolution has an effect on the drug absorption. The 
slight increase in the bioavailability of SMEDDS furosemide can be explained by additional 
absorption  mechanisms  such  as  direct  partitioning  of  the  drug  from  the  micelle  to  the 
membrane, as mentioned before in the interpretation of the in vitro results from D/P system. 
The slight increase in SMEDDS formulation compared to the in vitro results might be related 
to the high levels of bile salts excreted in rats, making it difficult to  observe significant 
differences in the absorption of lipophilic drugs. 
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The D/P system  failed to  predict the situation  in vivo  in  rats.  One explanation might  be 
related to the higher dose administered to the rats compared to the dose tested in D/P system 
(which  yields  the situation where furosemide  solubility is  limited by  dissolution  and not 
permeability  as  the  D/P  system  indicated).  To  further  establish  the  IVIVC  with  the  D/P 
system, a higher dose (1.4mg- comparable to the administered dose that was given to rats) 
was tested in the D/P system (Figure 4.38). Similar picture as was observed for the lower 
dose in the D/P system was obtained with the higher dose. High dissolution for all furosemide 
formulations  and  for  the  API  was  observed  on  the  apical  side  (equivalent  to  140mg  in 
humans), which might imply that even at this high dose, furosemide absorption is not the 
solubility/dissolution rate limited in humans. On the apical side, the permeation percentage 
was still low in the case of all furosemide dosage forms (less than 0.1% at 2h), apart from the 
SMEDDS  formulation,  which  increased  to  a  0.4%  permeated  amount  at  2h.  A  possible 
explanation for this might be related to the different ratios of surface area available for the 
drug to permeate to the fluid volume. Due to obvious restrictions, the surface area of the 
Caco-2  layer  membrane  is  limited  as  compared  to  the  intestinal  membrane  in  rats  or  in 
human. Therefore, the ability of the D/P system to capture the difference in permeation might 
be limited, and especially in the case of furosemide as a poorly permeable drug. Another 
possible explanation might be that the rat is not a good model to evaluate these formulations. 
Considering all the physiological differences in the gut from rat to human, it might be that the 
D/P  will  actually  predict  well  the  situation  in  humans  as  was  published  by  Professor 
Yamashita  but  not  in  rats  for  some  formulations  or  drugs.  Moreover,  in  this  study  the 
predicted  absorption  from  the  D\P  system  was  compared  to  the  bioavailability  values 
generated  in  rat  model.  It  might  be  that  a  direct  comparison  to  absorption  values  (by 
measuring the concentration of the drug in the portal vein of rats) in the rat model will yield a 
better correlation.   
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Figure 4.38: Dissolution and permeation of furosemide formulations-D/P system at higher dose 
 
High variability in AUC0-8 was observed across all formulations, with a relatively lower CV 
of oral suspension and solid dispersion. This might be due to the low number of rats analysed 
for each formulation. Moreover, Waller et al.(1988) suggested that the absorption was limited 
by occurring only from a specific site (absorption window) in the GI tract, and can explain 
the high inter-individual variability in man. However, this suggestion has not been verified in 
humans to date. Chungi et al. (1979) has confirmed that limited absorption might also occur 
in rats from the stomach, and slightly from the duodenum, yet  since high variability was 
observed for all formulations, no definite conclusions can be drawn in terms of formulation 
efficacy decreasing variability in exposure.   Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.3.5.4 Dipyridamole Formulations In Vivo in Rat Model 
 
The  pharmacokinetic  and  plasma  concentrations  vs.  time  of  the  different  dipyridamole 
formulations  were  assessed  in  the  rat  model  (Figure  4.39  and  Table  4.7).  Dipyridamole 
administered  as  API  in  capsules,  solid  dispersion  and  SMEDDS  yielded  similar  plasma 
concentrations  and AUC0-8 values around 150ng*h/mL  (p˃0.05). The dipyridamole nano-
suspension, gave a higher plasma concentration and the AUC0-8 value was two-fold higher 
compared to that for the other formulations (320ng*h/mL). Bioavailability of the API, solid 
dispersion and SMEDDS formulations in rats were 55, 49 and 66% respectively, and did not 
significantly differ from each other (p˃0.5). Nano suspension absorption was complete, and a 
bioavailability of 99% was calculated (Table 4.7).  
 
Figure 4.39: Plasma concentration vs. time of different dipyridamole formulations in rats. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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Dosage form   AUC 0-8 (ng*h/mL)  Bioavailability (%) 
Mean ±SEM  CV % 
API in capsules  155±42 (n=3)  41  53 
SMEDDS  195±100 
(n=4) 
55  66 
Nano  Suspension   324±138 
(n=3) 
73  99.9 
Solid Dispersion   145±12 
(n=6) 
12  49 
Table 4.7: AUC 0-8 and bioavailability values of the different dipyridamole dosage forms in rats 
 
Again, in order to evaluate the effect of particle size reduction in the case of the dipyridamole 
nano-suspension, a similar formulation for the nano-suspension with the un-milled API was 
prepared  and  administered  to  rats  (Figure  4.40).  Unlike  furosemide,  the  mean  plasma 
concentrations  were  similar  to  the  nano-suspension  formulation,  and  gave  complete 
absorption and 100% bioavailability. Variability for both formulations was high, indicating 
that in the case of dipyridamole; the excipients (polyvinyl alcohol and mannitol) in the nano- 
suspension  formulation  produced  an  increase  in  absorption  more  so  than  the  particle 
reduction size.   
 
Figure 4.40: Plasma concentration vs. time of nano suspension and nano excipients with unmilled dipyridamole in rats. Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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In  the  case  of  dipyridamole,  no  increase  in  the  drug  exposure  was  absorbed  in  vivo  as 
compared to the in vitro results in the D/P system. The low plasma concentration for the solid 
dispersion formulation can be attributed in the first instance to the fact that the dipyridamole 
solid dispersion was administered as a powder with no wetting agent  or other  excipients 
present in the formulation, whereas the nano-suspension and SMEDDS formulations were 
administered in their solution state in a similar way as for the furosemide solid dispersion. 
Thus, the wetting properties of the powder might affect its dissolution rate and extent of drug 
absorbed in vivo compared to the other formulations. Another possible explanation for the 
similarity in the absorption of dipyridamole solid dispersion and the API is the possibility that 
the drug dissolved from the amorphous form in the rat stomach. However, on reaching the 
higher pH environment in the duodenum, it precipitates back to its crystalline from, giving a 
similar plasma concentration. Interestingly, and similar to the furosemide nano-suspension, 
an increase in drug exposure of dipyridamole nano-formulation was observed which was not 
predicted form the D/P system. However in the case of dipyridamole, it was confirmed that 
this can be attributed to the hydrophilic properties of the excipients in the formulation, rather 
than the particle size reduction. Therefore, it might be that the differences in the rat GI fluid 
composition compared to the FaSSIF (bile salts) facilitated dipyridamole dissolution in vivo 
and not in vitro. Another possible explanation could be that the gastric environment affects 
the dispersion and dissolution of the nano suspension, which was simulated in vitro in the 
D/P system.  It  was  suggested by Mackie  et  al. (2009) and Ouwerkerk-Mahadevan  et  al. 
(2011) that the rat was a better model to assess nano suspension based on comparison of rat, 
dog and human clinical data. This is further confirmed by this study where high exposure for 
both furosemide and dipyridamole nano-formulations was observed in the rat model but not 
when tested in vitro.  
 
High variability in AUC0-8 values was observed for all formulations, which may be attributed 
to the use of small groups of rats (3-4) in each experiment. Although each formulation was 
administered to 6 rats, only 3-4 rats’ samples could be analysed due to analytical problems.  
Therefore, variability could not been accurately assessed. For solid dispersions, where six rats 
were analysed, relatively low variability was observed (12%).   Development of Three Formulations to Increase Drug Absorption and “In Vitro” “In Vivo” Evaluation 
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4.3.6  Summary  
 
Based on the in vitro results from the D/P system and other tools investigated in this research, 
it seems that furosemide absorption is governed by low permeability of the drug in the dose 
range of 40-140mg in humans. In rats, the increase in exposure for the SMEDDS and nano- 
formulation might indicate that absorption is dissolution limited. For dipyridamole, BCS II 
compound, it is clear that its absorption is dissolution limited based on the in vitro and the in 
vivo results in rats. However, the formulations performances in rats were not predicted by the 
D/P  system.  High  exposure  for  nano-formulations  for  furosemide  and  dipyridamole  was 
observed in rats but not in vitro, whereas solid dispersion formulations for both drugs did not 
increase bioavailability in rats. Due to the lack of correlation between the rat studies to the 
D/P system results, it is difficult to conclude which of these models will predict better the 
situation in humans. The missing link is indeed the human data. In addition, based on the rat 
model, it was difficult to draw any conclusion regarding variability as variability was very 
high. As described, it might be that increasing the number of rats in each test will increase the 
ability to predict variability.  
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5.1  General Discussion and Future Work  
 
Oral  drug  absorption  is  a  complex  process  which  is  affected  by  physiological, 
physicochemical  and  formulation  factors,  each  of  which  is  sensitive  to  inter-  and  intra-
individual variability. As described in this thesis, there is great interest in the pharmaceutical 
community to  understand this  process  and  the underlines  factors causing low and erratic 
absorption, in order to reduce drug development costs, efforts and most importantly to obtain 
a better therapeutic response in patients. As part of the research conducted in this PhD thesis, 
it was found that there is great confusion between bioavailability and absorption.  Moreover, 
it is very difficult to obtain an accurate estimation of absorption and inter-subject variability 
in  absorption  from  in  vivo  data  from  clinical  studies  in  humans  without  making  any 
assumptions. This is mainly related to the fact that there is no direct method to measure 
absorption in vivo (measuring drug concentration in the portal vein or in the gastrointestinal 
fluids in humans are rarely carried out due to ethical considerations). On the contrary, clinical 
trials are commonly carried out to evaluate drug pharmacokinetics and pharmacodynamics, 
hence, it is possible to estimate absorption values from bioavailability calculation based on 
different models. However, clinical trials involving a large number of subjects are not readily 
available in the public domain and some parameters which required estimating absorption 
and inter-subject variability are not routinely measured. In this investigation, 40 clinical trials 
with the required parameters to estimate absorption and inter-subject variability were utilised 
to  correlate  between  absorption  and  inter-subject  variability.  However,  due  to  limitations 
described previously, it was difficult to draw a definite conclusion. Moreover, in the attempt 
to explain inter-subject variability by correlating it to different physicochemical properties of 
the drugs, it was found that some of the physicochemical parameters may not reflect the in 
vivo situation reliably and there is a need to develop more robust in vitro methods to capture 
the complexity of the gut. 
 
Many  attempts  have  been  made  to  predict  the  “average”  absorption  using  different 
approaches.  Some  include  quantitative  structure-activity  relationships  based  on 
physicochemical properties, others use animal models to extrapolate to absorption in humans 
and another approach which has been gaining great interest recently is  the use of PKPB 
models. The later provides an approach utilising preclinical in vitro and in vivo data to predict 
the  plasma  concentration  time  profiles.  With  increasing  knowledge  on  the  GI  tract General Discussion & Future Work 
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environment, most of these PBPK models were extensively developed to consider different 
physiological factors and how they account for variability.  Population pharmacokinetics as 
represented  by  NONMEM,  is  successfully  used  to  model  drug  pharmacokinetics  and 
pharmacodynamics, especially when sparse data were collected in patients. Often NONMEM 
is used to estimate bioavailability and inter-subject variability to characterise drug absorption.  
Based on the difficulties of calculating fa from available clinical trials (in the public domain), 
it was decided to utilise phase 1 clinical trials to estimate fa using NONMEM to gain a better 
understanding of inter-subject variability in absorption instead of bioavailability. The well-
stirred model was successfully implemented in NONMEM to estimate the typical population 
absorption  profile.  Estimations  of  fa*fg  and  inter  variability  were  obtained  for  four 
compounds  with  different  formulations.  The  rate  limiting  step  solubility\dissolution  was 
identified by comparing oral solution, IR tablet in the base form and IR tablet in the salt form. 
It  was  additionally  found  that  variability  in  absorption  did  not  differ  between  different 
formulations  mainly  because  the  increase  in  absorption  was  not  significant.  Formulation 
effects and food effect were investigated in the case of oral solution and ER formulation. 
Analysing the in vitro data enabled a better understanding of the drug behaviour in the GI 
tract  based  on  the  absorption  estimations.  The  proposed  work  herein  offers  a  more 
quantitative  estimation  of  the  absorption  process  and  variability.    Accurate  estimation  of 
absorption from phase 1 clinical studies using NONMEM would enable better understanding 
of the factors contributing to low and erratic absorption and therefore would promote the 
selection of the right formulation for further development. Moreover, understanding drug 
absorption variability will enable better planning and execution of phase 2 and 3 clinical trials 
(aiding improved selection of sample size and dosage regimen, etc.). 
 
In recent years, more PBPK models are being implemented in NONMEM to evaluate drug 
performance  in  the  population.  The  estimations  for  absorption  in  this  research  did  not 
separate the fraction that escape gut wall metabolism to that absorbed. To our knowledge, 
there is no definite method to calculate fg from plasma concentration vs. time data. However, 
it would be highly desirable to acquire a separate estimation of fg either by using clinical 
trials that were conducted with co administration of P-gp or Cyps450 inhibitors, but it will 
then be necessary to consider the different intrinsic clearance of these subjects.  Another 
possibility for future work to separate fa from fg is by incorporating the Qgut model and the 
use of in vitro data.  
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For the purpose of this study, only parameters that were required to calculate the elimination 
from the liver and the kidneys were incorporated in the model (i.e. blood to plasma ratio, 
liver blood flow and renal clearance). However, there is no doubt that incorporating more 
physiochemical  factors  such  as  lipophilicity,  ionization,  solubility,  protein  binding,  tissue 
drug  concentration  partition  coefficients  and  physiological  parameters  such  as  gastric 
empting  and  transit  time  will  increase  the  model  accuracy  and  sensitivity  to  estimate 
absorption. Moreover, NONMEM’s advantage in explaining the inter-subject variability by 
including covariates such as age, weight, and gender could be further investigated to increase 
the model fit. 
 
Many  compounds  are  being  discovered  and  developed  in  the  pharmaceutical  industry, 
however, only a few have been successfully marketed. In the development of each compound 
great  knowledge  and  experience  is  being  generated,  but  due  to  the  competitive  industry 
environment, it is not always possible to define the factors which led to the compound failure.  
An initiative by the Orbito project (http://www.imi.europa.eu/content/orbito) aims to share 
the knowledge and experience to overcome the existing gaps in the biopharmaceutical and 
formulation science. One of the objectives of the Orbito project is, through the collaboration 
of pharmaceutical companies and academic groups, to construct a new database of poorly 
soluble drugs together with their clinical trials in humans and animals.  This database will be 
characterised for its physicochemical properties (e.g. logP, pKa, solubility, permeability, etc.) 
and the resulting data will be used to develop new in silico models available to the common 
research  community.  The  population  pharmacokinetic  approach  presented  herein  can  be 
further validated in such a data set once it is published.  
 
In silico estimation of absorption and inter-subject variability is very important, however in 
vitro  and  in  vivo  tests  are  still  required  to  identify  factors  contributing  to  inter-subject 
variability in drug solubility, dissolution and permeability. Two model drugs with reported 
with erratic bioavailability (attributed to absorption variability) in humans were chosen for 
this  investigative  purpose  (dipyridamole  and  furosemide).  Few  in  vitro  tests  to  measure 
solubility,  dissolution  and  permeability  were  utilised  in  this  research  to  simplify  our 
understanding as for the factors that cause variability, since there is no single in vitro tool that 
can capture the complexity of the GI tract. 
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Solubility measurements were carried out in pooled gastric, jejunum fluids and further in 
ileostomy fluids.  Based on the results from this investigation, it appears that pH and buffer 
capacity  vary  considerably  between  individuals  in  ileostomy  fluids,  and  this  may  be 
augmented  in  different  disease  states,  further  affecting  drug  solubility.  The  solubility 
measurements in human and simulated fluids showed that solubility-dependent pH and bile 
salt concentration may have a strong impact on dipyridamole solubility, and consequently its 
absorption, whereas furosemide solubility demonstrates high correlation with buffer capacity 
and pH. Based on these results alone, it might be that dipyridamole solubility in vivo will be 
controlled  by  bile  salts  concentration  and  variable  pH  between  individuals.  Furosemide 
solubility will vary between subjects with different buffer capacity and pH, especially in the 
lower parts of the gut where low volume of fluids is available for dissolution. 
 
 Our understanding of the GI environment has enormously increased, and significant progress 
has been made to create bio-relevant dissolution media to establish IVIVC. With regard to 
dipyridamole, the results from the dissolution tests confirmed the result from the solubility 
study and it is safe to conclude that dissolution and solubility are rate-limiting steps for its 
absorption,  and  are  highly  affected  by  pH  and  bile  salts  concentration  in  the  intestine. 
Therefore, changes in pH and bile salts between individuals in vivo can help to explain the 
erratic  absorption  of  dipyridamole.  In  the  case  of  furosemide,  although  the  saturated 
solubility  was  affected  by bile salts  and pH, it seems  that  dissolution  tests  alone  cannot 
explain the variability in vivo. It can be concluded that dissolution is not the limiting step in 
furosemide absorption. These findings were striking, considering the fact that furosemide is 
classified  as  BCS  IV  and  the  results  from  the  solubility  study.  Consequently,  the 
classification  of  furosemide  as  BCS  IV  in  the  given  dose  (40mg)  should  ideally  be 
reconsidered.  The  apparent  contradiction  in  the  results  of  the  solubility  study  can  be 
explained  by  the  fact  that  in  the  solubility  study  the  saturated  solubility  was  measured.  
However,  in  the  clinical  dose,  furosemide  dissolved  completely  and  did  not  reach  its 
saturated solubility.  
 
Permeation  studies  are  routinely  carried  out  to  predict  drug  absorption  through  the  gut. 
However, dissolution and permeation are continuous processes and the permeation of the 
drug  is  highly  dependent  on  the  amount  dissolved  in  the  GI  lumen.  The  dissolution 
permeation  system  developed  by  Professor  Yamashita  was  utilised  in  this  investigation. 
Using  the  D\P  system,  it  was  found  that  bile  salt  concentration  was  irrelevant  for  the General Discussion & Future Work 
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dipyridamole permeation through the membrane. Moreover, it was found that pH plays an 
important role in the permeation of ionised drugs such as dipyridamole. This might suggest 
that in vivo, subjects with variations in pH along the GI tract will have considerable changes 
in  the  absorption  of  drugs  with  pka  close  to  the  GI  fluids  pH.  For  furosemide,  a  low 
permeable drug, no differences in the permeation profiles were observed, probably due to the 
lack of sensitivity of Caco-2 monolayer to detect small changes in the permeation of low 
permeable drugs. It is important to note that when interpreting the in vitro results from the 
D/P system to the in vivo situation there is a need to consider the small surface area available 
for permeation compared to the gut membrane surface area. It will be highly interesting to 
evaluate  other  cell  monolayers  such  as  MDCK  in  the  case  of  low  permeable  drugs.  In 
addition, investigation other physiological factors other than bile salt and pH in these systems 
will  add  more  information  on  possible  factors  causing  changes  between  individuals.  For 
furosemide in particular, it may be that gastric emptying time and intestinal motility could 
shed further light on our understanding of variability in drug absorption.   
 
The results presented herein, emphasise the complexity of the GI tract environment and the 
difficulties of capturing it based on only single in vitro method. It is highly important to 
attempt  to  simplify  the  situation  in  vivo  and  work  stepwise  in  order  to  gain  a  better 
understanding of the gastrointestinal tract complexity by assessing each factor separately. 
Combining  the  results  from  different  experiments  will  enable  capturing  of  the  gut 
complexity. With that, it is important to remember that the different stages in absorption are 
dependent on each-other and the extrapolation to the in vivo situation must be carried out 
based on this assumption, as it has been demonstrated herein by the use of the D\P system.  
Future work may include investigating in vitro GI models to predict inter-subject variability. 
This can be implemented by developing simulated gastric/intestinal fluids to mimic not only 
the average person, but also range of conditions of the fed and fasted gut. Moreover, the use 
of  systems  that  can  evaluate  variation  in  gastric  emptying  or  transit  time  like  the  TNO 
systems can be utilised.  
 
Many attempts have been made by the pharmaceutical industry to overcome low and erratic 
absorption,  in  particular,  by  formulating  the  drug  to  increase  the  drug  solubility  and 
dissolution.  Comparing  three  different  formulation  approaches  to  increase  solubility  and 
dissolution have shown that solid dispersion formulation results in the simplest design and 
evaluation followed by the reduction of the particle size to nano size and eventually SMEDD General Discussion & Future Work 
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formulation.  There  is  no  doubt  that  better  understanding  and  evaluation  of  SMEDDS 
formulation  in  vitro  will  be  needed  in  order  to  predict  the  formulation  performance  and 
mechanism in vivo. Further on, an early consideration of the API properties needs to be taken 
into account when choosing the excipients in the formulation. Solid dispersion and SMEDDS 
increased the drug dissolution to a similar extent and minimised the effect of bile salt or pH 
on the dissolution in the case of dipyridamole. On the contrary, when the formulations were 
tested in the in vivo in rat model, only nano-particles formulation has shown to increase 
dipyridamole bioavailability. Similarly, lack of correlation between the  in vitro results of 
furosemide formulations in the D/P system to the in vivo results in rats was observed.  It 
again emphasises the complexity of the GI tract and the difficulties in predicting from in vitro 
results or in vivo in animals to the in vivo in humans. 
 
Future work of this thesis will include evaluation of different formulations of poorly soluble 
drugs using in vitro test (i.e. the D\P system) linking it to in vivo studies in animal models and 
in vivo clinical studies in humans. This can be implemented by establishing guidelines for 
applying different formulation approaches in the case of poorly soluble drugs. This could 
result in reducing development costs and efforts. To this purpose, it will be highly desirable 
to obtain a large dataset of poorly soluble/permeable compounds in different formulations 
with their physicochemical properties and in vitro evaluation.  For the animal models, it will 
be preferable to generate absorption data instead of bioavailability (by measuring the drug 
concentration  from  the  portal  vein  or  in  the  animal  gastrointestinal  tract).  Further  on, 
comparing different formulation approaches in different animal models is needed, to better 
define  the  relationships  between  the  physicochemical  properties  of  a  compound  to 
formulation, and effectiveness as screening tool and predictability for humans. In human, 
utilising clinical trials from phase 1 using population approaches to calculate absorption as 
demonstrated in this research will enable an accurate measurement of absorption and inter- 
subject variability in absorption. Combining all these tools together will enable validation of 
existing in vitro and in vivo methods to understand absorption.  
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1.1. Data for Compound AZD0865  
AZD0865       
Study objective(s)  Study design  Subjects  Dosing regimen 
ADME of AZD0865   Phase I, randomized, open, 
crossover study 
9 
healthy males 
age 38-50 
years 
Single doses of 14C-
labelled or non-
labelled AZD0865 
20 mg IV solution 
(as a single  60-
minute infusion) 
40 mg oral solution 
Ascending dose- oral 
solution   
Phase I study: Tolerability 
part with randomized, 
parallel, single-blind, 
placebo-controlled dose 
escalating design and  
efficacy part with 
non-randomized, 
single-blind design 
 
27 
healthy males  
age 22-39 
years 
 
Single doses of 
oral solution 
0.08-4 mg/kg 
Single oral doses given 
as mesylate salt tablets,   
a base form tablet and 
an oral solution 
Phase I, randomized, open, 
crossover study 
14  
healthy males 
age 21-29 
years 
Single oral doses of 
100 mg as 
micronised base 
tablet 
mesylate salt tablet 
micronised mesylate 
salt tablet 
oral solution 
 
Single oral doses given 
mesylate salt tablets 
and a base form tablet 
at an elevated 
intragastric pH 
 
Phase I, randomized, open, 
crossover, study  
The intragastric pH was 
raised by intravenous 
administration of 
omeprazole 
14 
healthy males 
age 21-37 
years 
Single oral doses of 
100 mg as 
micronised base 
tablet 
mesylate salt tablet 
micronised mesylate 
salt tablet 
effect of clarithromycin   Phase I, randomized, open, 
crossover, study 
18  
healthy males 
age 20-33 
years 
 
Single oral doses of 
an oral solution 
40 mg  
alone and 
concomitantly with 
clarithromycin 
tablets 500 mg bid at 
steady state 
Table A 1: AZD0865 phase 1 clinical trials included in the analysis 
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Figure A 1: Goodness of fit plots for compound AZD0865; Run 47 - IV model; Run 48 – oral solution; Run 49 -IR in the 
base form; Run 60– IR in the salt form; Run 69 – IR in the base form  at elevated pH, Run 85 – IR in the salt form  at 
elevated pH 
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Figure A 2: Visual Predictive Checks for compound AZD0865; Run 47 - IV model; Run 48 – oral solution; Run 49 -IR in 
the base form; Run 60– IR in the salt form; Run 69 – IR in the base form at elevated pH, Run 85 – IR in the salt form  at 
elevated pH Appendix 
- 223 - 
 
 
1.2. Data for Compound AZD242 
AZD242       
Study objective(s)  Study design  Subjects  Dosing regimen 
Single oral dose to healthy 
male subjects 
Single dose, 
double blind, 
randomised, 
placebo-
controlled, dose-
escalation study 
16 Healthy 
male subjects 
age 23-40 
years 
0.5 to 12 mg p.o.  
ADME study   Single dose, 
open label, 
randomised, two-
way crossover 
8 Healthy male 
subjects 
age 30-50 
years 
 
 
1 mg p.o.   
1 mg i.v.   
Single oral dose   Single dose, 
single blind, 
randomised, 
placebo-
controlled; 
Japanese 
bridging study 
56 Healthy 
male 
Caucasians and 
Japanese 
subjects 
age 19-32 
years 
0.5, 2, 4, and 8 mg 
p.o. 
Table A 2: AZD242 phase 1 clinical trials included in the analysis 
 
   
Figure A 3: Goodness of fit plots for compound AZD242; Run 2 - IV model; Run 74 – oral solution Appendix 
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Figure A 4: Visual Predictive Checks for compound AZD242; Run 2 - IV model; Run 74 – oral solution; Appendix 
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1.3. Data for compound AZD1305 
AZD1305       
Study objective(s)  Study design  Subjects  Dosing regimen 
ADME study  A Phase I, Open, 
Randomised, 
Single-Centre, 
Crossover 
10 Healthy 
Male 
Volunteers 
35 to 55years 
Oral solution 180mg 
Iv infusion 70mg  
Extended-release 
Formulations during fasting 
and fed condition. 
A Phase I, Two-
part, 
Randomised, 
Open, Single-
Centre, 
Crossover Study 
Healthy Male 
Volunteers 
50 healthy 
male 
volunteers 
aged 20 to 45 
years. 
125 mg ER  
formulation and 125 
mg oral solution 
Single ascending oral and 
intravenous doses  
 
A single-centre, 
single-blind, 
randomised, 
placebo-
controlled, 
single-dose 
phase I study 
30 healthy, 
male subjects  
 Age 20 to 37 
years 
Oral solution of 
single ascending 
doses; 10 mg, 30 mg, 
90 mg, 180 mg, 360 
mg, 430 mg and 500 
mg 
Table A 3: AZD1305 phase 1 clinical trials included in the analysis Appendix 
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Figure A 5: Goodness of fit plots for compound azd1305; Run 4-IV model; Run 7 - oral solution fasted state; Run 10 -oral 
solution fed  state; Run 16– ER in fasted state; Run 28– ER in fed  state Appendix 
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Figure A 6: Visual Predictive Checks for compound AZD1305; Run 4-IV model; Run 7 - oral solution fasted state; Run 10 -
oral solution fed  state; Run 16– ER in fasted state; Run 28– ER in fed  state Appendix 
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1.4. Data for Compound AZD7009 
AZD7009       
Study objective(s)  Study design  Subjects  Dosing regimen 
ADME study  A phase I, 
randomised, 
open, single-
centre study 
10 healthy 
male subjects 
aged between 
35 and 55 
years. 
 
Single doses of oral 
solution (500mg) and 
iv infusion for 60 
min (100mg) 
Ascending single oral doses  
 
A randomised, 
single-blind, 
placebo-
controlled, 
single centre 
Phase I study 
19 healthy, 
Japanese male 
subjects 
 Age 20 to 40 
years 
Single oral solutions 
(50 – 600 mg) 
Oral solution   A single-centre, 
single-blind, 
randomised, 
placebo-
controlled 
45  healthy 
male subjects 
aged between 
20 and 40 
years 
Solution in escalating 
doses (5-1000 mg) 
Prolonged-release 
formulations and an 
immediate-release formulation  
A phase I, 
randomised, 
open, single-
centre study 
36 healthy 
male 
volunteers  
250 mg prolonged-
release formulations 
or as one immediate-
release (IR) 
formulation. 
Prolonged release 
formulations  
An open, 
randomised, 
single-centre 
study (phase I) 
30 healthy 
male subjects, 
aged between 
20 and 45 
years 
Prolonged-release 
tablet, 250 mg 
Table A 4: AZD7009 phase 1 clinical trials included in the analysis Appendix 
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Figure A 7: Goodness of fit plots for compound AZD7009; Run 5- IV model; Run 17-oral solution; Run 10 – PR tablet Appendix 
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Figure A 8: Visual Predictive Checks for compound AZD7009; Run 5- IV model; Run 17-oral solution; Run 10 – PR tablet   
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Figure A 9: NONMEM script  
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